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Hydrophobic membrane proteins perform a variety of important functions in the 
cell, but their structures are notoriously difficult to solve.  Thus, new strategies to obtain 
crystals of membrane proteins for structure determination are critical. We aim to develop 
a toolbox of peptide specific single-chain antibody fragment chaperones engineered for 
hyper-crystallizability.  These peptide sequences can be introduced into various regions 
of membrane proteins without interfering with protein function. The resulting protein-
chaperone complex is expected to form a crystal lattice mediated by chaperone 
interactions. 
We have developed candidate scFv chaperone proteins binding hexa-histidine 
(His6) and EYMPME (EE) tags with improved biophysical features influencing 
crystallization propensity, including peptide affinity, stability and solubility.    The scFv 
libraries were generated using a novel ligation-free technique, MegAnneal, allowing us to 
rapidly generate large libraries based on 3D5 scFv.  We identified two candidate 
 vii 
chaperones, 3D5/His_683, specific for His6 and 3D5/EE_48, specific for EE tags.  
Variants exhibit high solubility (up to 16.6 mg/ml) and nanomolar peptide affinities; 
complexes of 3D5/EE_48 with EE-tagged proteins were isolated by gel filtration. We 
have developed design rules for EE peptide placement at terminal, inter-domain or 
internal loop regions of the target protein to balance peptide accessibility for chaperone 
binding while retaining rigid protein-chaperone complexes suitable for crystallization.   
The 3D5/ His_683 crystallized in four different conditions, utilizing multiple 
space groups. The 3D5/EE_48 scFv was crystallized (3.1 Å), revealing a ~52 Å channel 
in the crystal lattice, which may accommodate a small peptide-tagged target protein.  Our 
evolution experiments altered scFv surface residues, resulting in use of different 
crystallization contacts. Analysis of these crystal contacts and those used by crystallized 
14B7 scFv variants, led us to postulate that lattice formation is driven by strong crystal 
contacts. To test this hypothesis, we introduced amino acid changes expected to reduce 
the affinity of the 3D5/EE_48 energetically dominant crystal contacts.  This approach to 
crystal contact engineering may allow semi-rational control over lattice networks 
preferred by scFv chaperones.  Co-crystallization trials with model proteins are on-going.  
These engineered scFvs represent a new class of chaperones that may eliminate the need 
for de novo identification of candidate chaperones from large antibody libraries. 
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CHAPTER ONE: Introduction & Background 
 
1.1   PROTEIN CRYSTALLIZATION  
1.1.1  The value & applications of crystallization 
Crystallization of proteins has three major applications:  i) bioseparation 
processes; ii) controlled drug delivery systems and most importantly; and iii) structural 
determination.  The first two applications are driven primarily by the Pharmaceutics 
industry.  In bioseparation processes, crystallization is commonly employed for purifying 
a product from the other biomass during downstream production (ex. Lysozyme, Insulin).  
This form of separation is advantageous because it does not cause unfolding or loss of 
activity [1].  Controlling the crystallization process and improving current crystallization 
unit designs are the major challenges involved.  The potential use of crystals as a drug 
delivery system (such as crystalline lysozyme [2, 3]) focuses largely on producing 
crystals of uniform size to allow administering controlled doses over extended periods of 
time.  While both of these first two applications are critical and have driven the research 
for improved protein crystallization, structural determination has played a major role in 
advancing our knowledge of protein functionality.  
 Structural determination of proteins at the atomic level is important for providing 
insight into the mechanisms of protein function, which guide the fields of protein 
engineering, vaccine development and drug design.  Currently the optimal method for 
obtaining three‐dimensional, atomic resolution structural models for large proteins is 
through crystallization with x-ray crystallography.  Obtaining structural models of 
integral membrane proteins are of the highest priority with the NIH announcing a new 
structural genomics initiative in conjunction with Protein Structure Initiative Structural 
 2 
Genomics Knowledgebase [4].  Accounting for approximately one third of the proteins in 
a cell, integral membrane proteins are vital to maintaining cell function with a myriad of 
responsibilities.  These include, but are not limited to, i) transport molecules such as ions, 
water peptides and drugs across electrochemical gradients; ii) receive and relay signals 
from the extra- to the intra-cellular domains (or between cells); iii) provide openings (via 
channels) for molecules to move across membranes by means of diffusion.  Their various 
roles make membrane proteins potential targets for drug delivery.  Currently the largest 
category of drug targets (~50%) is directed at one particular class of membrane proteins: 
G-protein-coupled receptors (GPCRs) [5, 6].  The little structural information for these 
proteins has limited drug design to approaches guided primarily by protein mechanism.  
Incorporating a three-dimensional visualization of drug targets (including conformational 
intermediates) can clarify the role of protein structure in health and disease resulting in a 
organized and systematic approach to drug design.  Establishing a general engineering 
approach to producing crystalline proteins [7, 8] can help to expand the limited structure 
we have.  The ability to attain these visualizations has guided the motivation for 
improved crystallization processes. Understanding of the crystallization process will aid 
in the structural genomics project as well as expand its reach into bioseparation processes 
and controlled drug delivery.    
 
1.1.2  The current challenges of protein crystallization  
Although advances in NMR have achieved structural visualization of small 
protein molecules [9], in order to acquire atomic resolution images of large molecules (up 
to 150kDa) a crystal form is required.  To obtain these crystal forms, several challenges 
need to be overcome, including i) production and purification of adequate amounts of 
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soluble homogenous proteins; ii) biophysical characteristics – soluble with limited 
hydrophilic or polar surfaces; and iii) determination and optimization of crystallization 
conditions [10-12].  Not only do crystals have to be produced, but they must be of high 
quality suitable for single crystal x-ray diffraction.  Based on the number of targets 
deposited by worldwide contributing centers in TargetDB, of the 269,056 successfully 
cloned proteins, only 9.1% have currently been crystallized, 4.6% produced crystals large 
enough and suitable for x-ray of neutron diffraction studies with 3.6% producing three-
dimensional crystal structures from the diffraction data (Table 1).   The low yields are the 
result of difficulties that arise in part to the structural flexibility of proteins in solution 
and its ability to form many different intermolecular contacts based on slight changes in 
pH, ionic strength, temperature, protein concentration or specific additives in the 
crystallizing solution.  While crystallization technique have successfully been used to 
determine ~60,000 protein structures, only ~100 of these are membrane proteins [Protein 
Data Bank].  Membrane proteins in particular are especially challenging due to their 
hydrophobic/amphiphilic characteristics, requiring additional detergents to prevent 
aggregation and aid in crystallization [13].   
Table 1.1  Success rate of protein crystallization based on TargetDB status statistics for 
SG Centers submissions 
Status Total Number of Proteins (%) Relative to “Cloned” Proteins 
Cloned 128675 100.0 
Expressed 86134 66.9 
Soluble 33652 26.2 
Purified 29954 23.3 
Crystallized 10853 8.4 
Diffraction-quality Crystals 5471 4.3 
Diffraction 4932 3.8 
Crystal Structure 4002 3.1 
NMR Structure 1690 1.3 
Work Stopped 33638 - 
Reference: http://targetdb.pdb.org/statistics/TargetStatistics.html  




1.1.3  The mechanics of crystallization: the kinetics and thermodynamics 
High diffraction quality crystals are formed when the proteins are immobilized 
within the lattice in a consistent formation (repeating units of identical orientation).  
Crystal growth rate is dependent on both kinetics and thermodynamics with three stages 
of growth: i) nucleation ii) post‐nucleation and iii) cessation of growth [14] (Fig 1A).  
The growth of the crystal is dependent on the nucleation stage, because the quality of the 
critical nucleus typically drives the entire crystallization process.  The initial driving 
force is thermodynamic in nature with an energy barrier and entropic in origin, which 
must be surpassed to form the initial nucleus.  Crystal growth is driven by changes in 
Gibb‟s free energy, which is dependent on the entropies of the protein and the solution 
[15].  The equations below define the thermodynamic drive involved in protein 
crystallization, where        
    is a thermodynamically favored process.  
       
         
          
 , 
       
         
             
           
  
     
 
             





         
   is dependent on both the loss of the molecular degrees of freedom in 
addition to the loss of conformational freedom from the amino acids at the intermolecular 
contact interfaces.  The extent of supersaturation (i.e. maintained thermodynamic 
equilibrium) is the driving force behind the phase transitions of a protein, which includes 
crystallization. During the post nucleation stage, crystal growth is driven largely by 
diffusion of molecules to the nucleus and surface kinetics at the edges of the crystal. 
   
(Eq  1.1) 
(Eq  1.2) 
(Eq  1.3) 
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Figure 1.1  Protein Crystallization Diagrams 
(a) Free energy diagram involved with the three stages of protein crystallization i) 
nucleation, ii) post-nucleation and iii) cessation of growth.   
 (b) An example of a solubility phase diagram for a protein.   




The extent of supersaturation (i.e. maintained thermodynamic equilibrium) is the 
driving force behind the phase transitions of a protein which includes crystallization (Fig. 
1.1B).  During the post nucleation stage, crystal growth is driven largely by diffusion of 
molecules to the nucleus and surface kinetics at the edges of the crystal.   While focus of 
protein crystallization has centered largely on the kinetics and thermodynamics of the 
first two stages, all three stages are necessary in producing diffraction quality crystals.  
As a result different crystal growth optimization approaches are currently in practice 
focus on each stage.    
 
1.1.4  Roles of interactions and intermolecular contacts in protein crystallization 
Although scientists are split on whether kinetics or thermodynamics intiates the 




























































































made to develop a solution to the crystallization dilemma, protein‐protein interactions 
will need to be taken into account.   It has become clear that geometrically precise 
intermolecular contacts formed with surface epitopes are required for lattice stability over 
amorphous aggregation [16, 17].   While there still remains no clear marker of crystalline 
ability that can be inferred from the primary sequence level, there have been numerous 
groups that have attempted to develop software to predict a protein‟s propensity to 
crystallize based on its primary sequence [18, 19].  The major disadvantages to this 
prediction software are that it relies on datasets of previously crystallized protein, and is 
limited to prediction of small/medium sized non-homologous proteins.   
As a result, the nature of the intermolecular interaction of the proteins, as well as 
the mechanisms and assembly kinetics for the protein into an ordered crystal lattice is of 
specific interest.  McPherson aptly puts the dilemma: “The major challenges that remain 
in this area are to understand what kinds of mutation are most valuable in increasing 
solubility, enhancing lattice contacts, and discouraging unfavorable interaction, and then 
to employ this knowledge to predict useful modifications [20].”     Different interactions 
are strongly thought to correlate with protein-protein interaction including surface 
hydrophobicity [21], surface electrostatic potential of the protein [22] and a combination 
of surface electrostatic and hydrophobic interactions [23, 24].  We propose to find 
correlations between the biophysical characteristics of the protein and the resulting 
intermolecular contacts.    
The Young Modulus for protein crystal displays the relative importance of 
intermolecular contacts and its impact on the crystal structure and role in defining the 
properties of the crystals [25, 26].  Here the small areas of weakly bound contact explain 
the lower Young moduli that are seen for protein crystals.  Intermolecular contacts within 
the crystal lattice are shown to consist of patches that cover only a small percentage of 
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the surface of proteins.  The patches combined cover approximately less than half of the 
total protein surface area.  In many cases, the interacting patches consist of 
complimentary polar (H-bonds and salt brides) and charged side chains as well as van der 
waals attractive forces (partial electric charges on amino acids).  While these lattice 
constants are biologically nonspecific, the forces guiding these interactions are similar to 
those for protein folding and protein-protein binding specificity.  The variety of 
intermolecular contacts that encompass the entire surface of the lysozyme confirms that 
any molecular surface of the protein can potentially form lattice contacts depending on 
the conditions of crystal growth [26, 27].  At present, there is no rationale for determining 
conditions that can activate potential molecular patches for intermolecular interactions 
and crystal packing.     
 
1.1.5 Characterization of protein interactions  
Different interactions are strongly thought to correlate with protein‐protein 
interaction including surface hydrophobicity [21], surface electrostatic potential [22] and 
a combination of surface electrostatic and hydrophobic interactions [23, 24].  Each of 
these interactions focuses on the protein and solution that it is immersed in.  The majority 
of proteins have rather complicated non-spherical shapes and in many cases the proteins 
are located loosely in the crystal lattice in order to accommodate water and/or electrolytes 
in the cavity.  Electrolytes surrounding the proteins in solution can induce crystallization 
and other solid-phase formations by controlling the like-charged protein molecules.  A 
theory based of this concept known as the Derjaquin, Landua, Verwey & Overvel 
(DVLO) Theory of Colloid Stability  focuses on electrolytes in the solution mediating 
van der waals attractions and electrostatic repulsions between the protein molecules [28, 
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29].  The hydrophobic attraction during crystallization is further enhanced also by the 
electrolytes while hydration repulsion occurs from a result of hydrate ions built up at the 
protein molecule surface [25, 30].  Analysis of lysozyme in varying concentrations and 
salt conditions, suggest that specific attractive interaction correlated with the 
crystallization/precipitation behavior, which was reflected in the retardation of the protein 
rotational diffusion [31].  
Trying to predict and engineer intermolecular contacts has taken two different 
routes: (i) manipulating the protein and its solution or (ii) modifying the surface 
biophysical characteristics of the protein to improve the intermolecular contact.  
Molecular Interactions within protein solutions have been studied using static and 
dynamic light scattering (DLS) for analysis of the second virial coefficient.  It has been 
found that the lower limit of B2 corresponds to a low average protein-protein attraction in 
solution while a high limit results in aggregation [25].   The second virial coefficient is 
written as: 
 
                 
       









Where U(r) is the interaction potential between the molecules [32] and has been 
shown to have an interrelation with solubility via the interaction energy in the crystal.  
The highly negative values of B2 will guide the selectivity of the crystallization process 
by allowing only specific molecular patches to collide and interact, thereby guiding the 
production of crystals that are oriented in the same direction.  Aside from the osmotic 
virial coefficient mentioned above, other coefficients that have been used to study 
pairwise interactions and predict intermolecular contacts for crystallization include but 
are not limited to coefficients via sedimentation equilibrium [33], kinetic diffusion 
(Eq 1.6) 
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coefficients [34] and optical scattering [35].  In addition to studying the biophysical 
characteristic of the protein surface epitopes, protein-protein interaction energies have 
been a point of interest.  Studies have indicated that total interaction energy is fairly 
consistent between different proteins in their crystal lattice and this range needs to be 
retained for crystallization to continue [36].   
Advances in recombinant techniques for crystallization and surveys of 
experimental results from the Northeast Structural Genomics Consortium, have led to the 
conclusion that surface epitopes drive the propensity for crystallization by providing 
intermolecular interactions [37].  Numerous physical properties were investigated to 
determine their control in protein crystallization including, but not limited to, 
thermodynamic stability and protein surface properties.  The survey suggested that 
protein crystallization is dependent on the well-ordered intermolecular contacts rather 
than influence by its overall thermodynamic stability.  In addition, it provides proof that 
low-entropy, well ordered surface features determine the behavior of the crystallization 
process.  Work is still required to understand the nature of intermolecular interactions, the 
correlations of the biophysical characteristics, the mechanisms and assembly kinetics 
involved in a crystal lattice formation.  
From the literature it appears that successful crystallization requires consistent 
intermolecular contacts, spatial orientation and organization.  The challenge still remains 
of being able to predict a protein that has strong stereo-restricted interactions without 
promoting surface areas that can interact with multiple epitopes resulting in random 
aggregation.  Current work in specific domain-domain interactions has allowed 
examination of interaction pairs and determination of interaction potentials [38].  While 
lattice contacts are less specific than these interprotein interactions, we hope to use our 
 10 
observations to further our knowledge of crystallization initiation and apply it to 
engineering crystal lattice contacts.  
The 14B7 will be utilized as a model protein for understanding the role 
intermolecular contacts play in crystallization.  The antibody binds to a protective antigen 
(PA) of B. Anthracis and has been thoroughly studied for enhanced affinity [39].  The 
14B7 antibody was selected due to its ability to produce large yields of monomers and its 
rapid crystallization (~24 hours).  14B7 is also of interest because of its propensity to 
change crystal space groups with 10 mutations, while retaining the largest crystal contact 
[40, 41].  Utilizing this antibody will allow us to study the contact energetics involved in 
driving lattice formation.   
 
1.2  DIFFERENT APPROACHES TO IMPROVING CRYSTALLIZATION 
Numerous techniques have been used to generate protein crystals that include, but 
are not limited, to drop under oil, microbatch, dialysis, liquid-liquid free interface 
diffusion, capillaries, gels and microfluidics [11, 42].  Vapor diffusion utilizing sitting or 
hanging drops is one of the most popular crystallization techniques due to the small 
volume sample size, simple set-up and ability to vary physical parameters during 
crystallization.  Many of these methods require unique protein crystallization conditions 
found through trial and error.  Advancements in robotic technology have helped to 
facilitate methods like vapor diffusion and drop under oil, however, some finesse is still 
required.  This shotgun approach for crystallization makes this process more of an art 
form.  Scientists are struggling to develop a more systematic approach to this process by 
studying the mechanism that guides a protein on their path to crystallization, thereby 
understanding „The Science of Crystallization.‟  
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1.2.1  Art of crystallization 
The advantages to an empirical method are its ability to determine the initial and 
unique conditions for crystallization.  Historically, crystallography has used a shot-gun 
approach, testing thousands of conditions in parallel to provide a starting point for 
optimizing the production of diffraction-quality crystals.  The first protein crystallized 
using this technique was a sperm whale homolog of the human myoglobin because 
crystallization of the human variant was not successful [43, 44].  Most of the initial 
protein structures were found using this empirical method, with numerous conditions and 
use of homologs (other species variants) with conserved function.  Homologs have been 
used successfully to produce three dimensional structures of proteins that otherwise failed 
to produce diffracting crystals using the shotgun approach.  The use of homologs assumes 
optimal success when functional regions are conserved (sequences main > 70% 
similarity) and diversity occursonly at solvent exposed residues.  However, some 
homolog sequences have < 15% similarity and prediction of surface amino acids is 
difficult without structural information.  In addition, the effort involved in subcloning 
each gene, determining protein production conditions and optimal crystallization 
conditions makes this method tedious and unfavorable.   
The advancements in robotic technology and microfluidics, high throughput 
capable labs can perform approximately 1,000 screens with nanovolume samples per 
protein of interest [10, 20, 45, 46].   The use of screens has now expanded to include 
determining compounds, like ligands, that can help stabilize proteins, creating a bridge 
between the art and science [47].  While these advancements have increased the number 
of crystal trials, it still remains a black box with no guarantee of increased crystal 
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production.  It is unclear whether successful crystal production is dependent on 
understanding the properties of both proteins and reagents to predict the protein‟s 
behavior in crystallization conditions.  From this, two systematic approaches to crystal 
growth are currently being undertaken the technique-based strategy, which focus on the 
crystallization conditions and the protein-based strategy, where the focus is on the 
proteins biophysical characteristics.   
 
1.2.2  Science of crystallization – optimization of crystallization conditions 
As a result of empirical methods, engineers are attempting to understand the 
science involved with crystallization.  Systematic methodologies have been developed to 
assist in more efficiently defining prospective crystallization conditions than the 
empirical shot-gun approach.  These methodologies include: i) light scattering for 
determination of second viral coefficients [48, 49], ii) neutron, x-ray and light scattering 
for presence of pre-nuclear aggregates; ii) atomic force microscopy for kinetic studies of 
surface crystal growth and determination of kinetic based coefficient [50]; iv) phase 
diagram for optimization of crystallization conditions; and v) interferometry for 
delineation of crystallization mechanism [8, 20, 46, 51, 52].   
One technique-based systematic approaches utilizes microfluidics to analyze a 
protein‟s phase diagram under several different conditions to determine an optimal 
crystallization condition (salt:protein concentration ratio, temperature, etc.).  These 
devices use liq-liq free interface diffusion to provide kinetic optimization of 
crystallization reactions [45] or phase diagram visualizations [51, 53].  Protein 
nanocrystallography a new emerging field uses a combination of advances 
nanotechnologies to improve the crystal initiation conditions.  Pechkova and Nicolini 
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have developed the Langmuir-Blodgett (LB) and Langmuir-Shafer (LS) technology, two 
innovative approaches to creating a protein thin-film nano-template as initial nucleation 
sites for further crystal growth [54, 55].  The motivation for optimizing crystal conditions 
is centered on determining the fundamentals of inducing and controlling the nucleation 
stage, ideally finding a „universal‟ nucleant to drive the entire crystallization process [10, 
56]. 
 
1.2.3  Science of crystallization – optimization of the proteins of interest 
Recombinant techniques and the homology method have displayed there is a fine 
line between specific and nonspecific interactions that drive protein crystallization.  
Observations from these methods indicate a relationship between amino acid sequence 
and biophysical parameters, which suggests that proteins should be considered a variable 
in crystallography [57].  The successful use of homologs indicates the importance of 
surface morphology as a driving force in crystallization.  Homology has paved the way 
for approaching the challenges of protein crystallization by addressing protein 
modification with recombinant techniques.  The use of recombinant technique has helped 
address many of the bottlenecks at each level of the crystallization process (Table 1.1).  
The use of recombinant proteins has assisted in advancing crystallization with dramatic 
increases in protein yield (via various vectors); solubility and stability (via critical 
mutations) and facilitation of purification (via peptide tags) [58-60].  Additionally, the 
use of recombinant techniques can facilitate overcoming the final hurtle of solving the 
diffraction pattern with techniques such as protein labeling with SeMet.  Recombinant 
proteins are now engineered with the intention that their improved biophysical 
characteristics play a critical role during the crystallization process.  Numerous 
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recombinant techniques have aimed at reducing flexible regions [61, 62], truncating the 
protein into sections that are stable [58] and even removing glycosylation sites or 
unpaired cysteines, which have tendency to promote aggregation [60].  Modifications at 
intermolecular interactions of water soluble and membrane proteins indicate the 
sensitivity of surface residues substitutions to the integrity of the crystal contact [62, 63].   
Use of molecular engineering, using both directed and random techniques, has provided a 
new direction for protein crystallization and has established that modifying the protein is 
a viable path. 
 
1.3  MOLECULAR ENGINEERING VIA DIRECTED RECOMBINANT TECHNIQUES FOR 
IMPROVED CRYSTALLIZATION 
1.3.1  Recombinant work with intermolecular contacts at the amino acid level 
(mutagenesis at known/suspected intermolecular contacts) 
Experimental work with hypercrystallizable lysozyme has supported the 
importance of intermolecular contacts as the driving force in crystallization.  Lysozyme 
has been crystallized under numerous conditions resulting in varying lattice contacts that 
span the entire surface area of the protein.  Different molecular surface areas are activated 
as lattice contacts by varying pH, temperature and crystallization conditions.  The 
activation of these distinct interaction areas result in different polymorphs of lysozyme.  
Recombinant work with T4 lysozyme has yielded various mutants crystallized in 25 
different crystal lattice forms and growth kinetics, where even a single surface residue 
mutation can yield different space group [64].  Recent developments in recombinant 
work have now focused on analyzing specific intermolecular contacts, where the contacts 
are manipulated to explore its impact on protein crystallization.  A modified 14B7 
antibody, M18, with 10 mutations resulted in a drastic change in lattice formation and 
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growth kinetics, requiring a longer time for crystal formation than the wildtype [40, 41, 
64].  Site‐directed mutagenesis techniques have shown impact on protein solubility by 
removing large hydrophobic patches with neutral electrostatic potential, reducing the 
random aggregation and creating more ordered protein‐protein interaction [58, 59, 65].   
Through these studies the effects of surface residues substitutions have been 
shown to impact the integrity of the crystal contact and crystal packing.  Mutations of 
surface residues on the Thermus thermophilus aspartyl-tRNA synthetase-1 were shown to 
influence crystal growth, packing arrangement and crystal quality [63].  The amino acids 
selected for modification were involved in lattice packing contacts and resulted in a 
correlation between protein crystallizability and manipulated packing interactions. From 
this study, it was observed that disruption of lattice contacts leads to poor or no crystal 
production while addition of potential contacts produced better crystals.  This was further 
supported by a study with five single site mutants of Rhodobacter sphaeroides, where 
modified residues resided in contact regions that formed the tetragonal lattice.  Results 
from the crystallization studies indicated that the mutations were significant for 
maintaining the stability of the tetragonal form.  In addition, the loss of diffraction quality 
crystals indicated that the selected mutants carried specific interactions with neighboring 
residues within the contact [62].   
 
1.3.2  Protein modification to reduce surface entropy 
Site-directed mutagenesis on surface residues for rational protein crystallization 
has become well established in protein crystallography [66, 67].  Current work using site-
directed mutagenesis has effectively improved protein crystallization by removing large 
hydrophobic patches with neutral electrostatic potential, reducing the random aggregation 
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and creating more ordered protein-protein interaction [58, 59, 65].  One site directed 
mutagenesis approach, surface entropy reduction (SER), focuses on utilizing mutations to 
reduce the protein‟s conformational surface entropy, allowing for thermodynamically 
favorable crystal contacts.  Removal of amino acids with high conformational entropies 
produces the homogeneous, contact forming surface patches [15, 68] that are beneficial 
for crystallization.  The thermodynamic cost of immobilizing high-entropy side chains 
tends to inhibit their participation in crystal packing contacts, by removing these side 
chains we reduce the cost involved [60].  The generation of these „low-entropy‟ patches 
will reduce the cost requirement for burying surface regions into the crystal contact.  This 
can be accomplished through removal of residues with high conformational energy and 
substitution with smaller amino acids.  It has been shown that amino acids lysine, 
arginine and glutamate do not frequently appear in lattice contacts for this reason [69].  
Further analysis supports the idea that successful utilization of this technique requires 
alanines substitutions in pairs or triplets to improve intermolecular contacts for 
crystallization.  Variants of RhoGDI using these clustered mutations, successfully yielded 
higher order and diffraction quality crystals with this method [60], leading to the release 
of a SER web server for the design of crystallizable variants with clustered mutations to 
reduce amino acids with high conformational entropy [70].   
While manipulating select residues is one of the more popular ways of reducing 
surface entropy, this concept has been extended to include strings of amino acids.  
Flexible termini of proteins as well as large flexible loops have also been targeted to 
reduce entropic impediment to crystallization [71].  Removal of these regions will 
minimize the heterogeneity of the protein as well as reduce the multiple varying 
interactions that can occur.  Successful crystallization of the HIV gp120 envelope 
glycoprotein, shows the impact the replacement of two flexible loops with Gly-Ala-Gly 
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linkages can contribute [72, 73].  This strategy is especially beneficial for membrane 
proteins that characteristically contain large flexible intracellular loops.  The replacement 
of these large loops with smaller linkers can produce crystals with higher resolution [74].  
Considering that many membrane proteins contain at least one region of amino acids with 
no rigid secondary structure, removal of these regions will be the first step towards 
achieving improved membrane protein crystallization.   
 
1.3.3  Introduction of contact forming regions  
SER improves the thermodynamic state of the crystallization process, while other 
site directed mutagenesis approaches are even more systematic for generating crystal 
contacts.  Modulations of intermolecular interactions indicate that crystallization is 
sensitive to surface residues substitutions [62, 63].  Novel methods have proposed to 
facilitate particular lattice formation with the creation of intentional interprotein contacts 
(Fig. 1.2).  This is accomplished by introducing a small modified region on the target 
protein that will guide and possibly control the extent of crystallization.  Banatao 
proposed the implementation of single unpaired cysteines into the protein so that 
intentional dimmers can be generated for more uniform crystallization units [75].  The 
cysteines are strategically placed on the surface of the protein to create symmetric 
proteins upon dimeration with a second protein (Fig. 1.2a).  This creates a more uniform 
molecule, which will facilitate the ease of ordered crystal packing.  The introduction of a 
leucine zipper-like hydrophobic interface (4 Leucines) into human RNase1 resulted in a 
designed hydrophobic packing crystal contact (Fig. 1.2b) [76].  The leucine incorporation 
has shown potential use for promoting intermolecular symmetry for crystallization and 
controlled crystal packing.   
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While small regions of manipulations are the most common method for utilizing 
this approach, a novel approach has been to fuse an additional whole protein to the 
protein of interest to assist in creating contact forming regions.  Fused normally at the n- 
or c-terminal region, the ability to create these fused proteins is fairly straight forward.  
Fusion proteins have successfully been used for protein purification purposes with many 
well established vectors (pMal, NEB).  The successful crystallization of the fused maltose 
binding protein (MBP)-target protein shows the potential of this strategy as a general 
approach to crystallization [77].  The additional MBP provides the lattice contacts 
necessary for crystal growth and serves as a chaperone, assisting in the crystal scaffold 
development (Fig. 1.2c).  Recent work has advanced the use of fused proteins from 
insertion at the termini to engineering the “hyper-crystallizable” proteins in place of a 
flexible region on the membrane protein [61].  The ability of these proteins to remove the 
entropic cost contributed by the flexible loops as well as generate additional polar regions 
for lattice contacts is of particular interest in membrane protein crystallization.  The 
GPCR membrane protein was successfully crystallized using this approach by inserting 
the hypercrystallizable T4 Lysozyme in place of one of the GPCR‟s flexible loops (Fig. 
1.2d).  The additional surface topography contributed by the T4 lysozyme provided the 
intermolecular contacts that drove its crystallization.  While this method was successful, 
insertion of a second protein into an internal region of an existing protein without 
disturbing its structure or function can be especially challenging and time-consuming.  
Appropriate regions for insertion need to be selected to maintain proper folding of both 
the inserted chaperone protein as well as the protein of interest.  For these reasons, this 
method‟s utility as a general approach to protein crystallization is questionable and may 





Figure 1.2  Different strategies to introducing intermolecular contacts for crystal lattice 
formation  
(a) Directed cysteine insertions to create different symmetric units for crystallization [75]  
(b) Insertion of Leucine zipper to create specific interactsion [76]   
(c) Fusion of chaperone protein at terminal end  of target protein (Chaperone: MBP in 
red, Target protein: RACK1 in green) [77]  
(d) Fusion chaperone protein at internal loop of target protein (Chaperone: T4 Lysozyme 
in grey, Target Protein: β2-adrenergic receptor in blue) [61] 
 
1.4  MOLECULAR ENGINEERING VIA RANDOMIZED EVOLUTION - USES IN 
CRYSTALLIZATION 
1.4.1  Gene shuffling between various homologs to improve 
Besides site-directed mutagenesis, studies have indicated the potential of DNA 
shuffling [78].  Little rationale is involved and the diversity produced from shuffling 
homologs, modifies the surface properties enough to produce crystals.  Another technique 
known as co-crystallization has been especially useful for crystallizing membranes 
proteins with large hydrophobic characteristics [79].   
 
1.4.2  Co-crystallization: chaperone assisted scaffold   
As we have mentioned above, there are numerous strategies to generate 
crystallizable proteins however, there still remains no generalizable approach.  The use of 
A B C D 
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fused proteins (like MBP and T4 Lysozyme) as co-crystallizable chaperone serves 
primarily to introduce additional lattice contact regions.  This technique has expanded to 
include protein specific recombinant proteins as chaperones that create stable complexes 
with improved crystallization properties [80].  The first case of co-crystallization was the 
successful use of an antibody chaperone in assisting crystallization [81].  Since then, this 
technique has assisted the crystallization of difficult proteins, in particular the membrane 
protein with their large hydrophobic regions.    A significant portion of a membrane 
protein‟s surface is hydrophobic due to their integration within lipid bilayers.  This 
characteristic poses a major dilemma as, once these proteins are removed from the 
bilayer, their tendency is toward nonspecific aggregation making them not readily soluble 
in aqueous solutions.  The removal of these proteins can also compromise its physical 
stability leading to reduced or lost activity.   
A number of approaches have previously been taken to overcome the 
hydrophobic characteristics dilemma and create the isotropic, monodisperse solutions 
necessary for protein crystallization.  The most common method for improved 
crystallization involves tailoring the surfactant/detergent environment [79, 82].  
Detergent monomers, serve as chaperone-like bodies and associate with the hydrophobic 
surfaces creating a “micelle-like” protein detergent aggregate.  The resulting micelle-
micelle interactions create additional phase transitions that can impact crystal nucleation 
and growth, which enhance nucleation and assist protein crystallization [82].  While more 
traditional methods of solubilized protein-surfactant complexes are more popular in 
membrane protein crystallization, a new and emerging areas involves the in meso 
approach.   This technique employs a bicontinuous lipidic mesophase which attempts to 
build a lipid bilayer reservoir to assist in former crystal packing [13] and includes the in 
cubo approach, that employs lipidic cubic phases [83].  bicelle methods [84].   
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The use of recombinant proteins as an additional aid or chaperone for membrane 
protein crystallization works similarly to the prior detergent based methods.  Both 
methods focus on countering the hydrophobic surfaces, however the protein specificity of 
the chaperone during complex formation allows for additional control.  The chaperone 
protein recognizes and binds a membrane protein to form a stable complex.  The resulting 
complex provides improved crystallization properties (i.e. more homogenous monomeric 
solution) by protecting the hydrophobic regions of the membrane protein and preventing 
numerous protein-protein interactions.  These chaperones or co-crystallization proteins 
(CCP) can provide better probability for ordered crystals in two other mechanisms: (i) 
“lock downing” flexible regions to reduce heterogeneity and (ii) presenting additional 
polar surfaces available for crystal contact formation [7, 80, 85].  The polar regions 
provided by the chaperones produce lattice-forming crystal contacts that allow the POI to 
be suspended within the lattice, particularly beneficial for use with detergent solubilized 
proteins [79, 86].  Because the three-dimensional molecular structure of the chaperone is 
usually predetermined, this provides an added advantage as a molecular replacement 
model for solving the crystallographic phase and diffraction data of the complex.   
Antibody fragments, Fab and Fv antibodies in particular, are currently the 
dominant chaperone in use for successful co-crystallization of membrane proteins, 
primarily due to their well characterized binding interactions [87] [86, 88, 89].  With the 
advancements of recombinant techniques however, efforts to generate alternative protein-
binding chaperones are also in progress.  Developments in this field have led to CCP 
protein options for co-crystallization which include but are not limited to affibodies [90], 
VHH Camelid Domains [85], and designed ankyrin repeat proteins (DARPins) [91, 92].   
Below, we have shown the proteins that have been used successfully to co-crystallize 
target proteins (Fig. 1.3). 
 22 
 
Figure 1.3  Structural images of successful co-crystallization proteins in complex with the 
target protein they helped crystallize  
(a) Antibody Fv fragment – COX from P. denitrificans in complex [89].  i) crystal lattice 
of two-subunit, ii) crystal lattice of four-subunit;   
(b) antibody Fab fragment - KcsA K+ channel [86]. i) view down four-fold axis of the I4 
cell, ii) view perpendicular to the 4-fold axis;  
(c) crystallization of gPCR using two different chaperones [61].  top: Fab5 – gPCR, 
bottom: T4L – gPCR;   
(d) affibody – protein Z [92];   
(e) VhH – RnaseA [85];  
(f)  co-crystallization of DARpins with AcrB, MBP and APH [92]. 
 
The recent chaperone-assisted breakthrough utilizing both Fab and Lysozyme 
chaperones independently to solve only the second known crystal structure of a GPCR 
(Fig. 1.3c) shows the effectiveness of co-crystallization [61, 93, 94].  The hydrophobic 
characteristics and the structural flexibility in one of its intracellular loops makes GPCRs 
unfavorable for crystallization and particularly challenging.  The additional surface 
topography provided by both the T4 Lysozyme and the Fab assisted in mediating crystal 















highlights its negligible impact on the target proteins structure and the systematic 
approach for the protein-specific chaperone strategy for assisting crystallization.  CCP 
antibodies have potential as a general application for protein crystallization if they can 
bind strongly and forming a rigid complex without affecting the native structure of the 
target tproteins.  The in vitro selection of the Fab from a large library, shows a more 
direct approach to screening chaperones for assisted crystallization.  However the search 
of a highly specific chaperone remains time-consuming.  Not only does the chaperone 
need to be specific to the target protein it also must be characterized for crystallization 
propensity before it can become a successful chaperone.  We propose the concept of a 
chaperone highly specific for a peptide tag, which can be added to any protein of interest.  
This peptide specific chaperone can provide a platform system that can reduce the time 
and effort that is currently invested in the present co-crystallization system.   
 
1.5.  ANTIBODIES FOR CHAPERONE ASSISTED CO-CRYSTALLIZATION 
1.5.1  Structures and recombinant versions 
To date, the leading CCPs in the field are antigen binding fragments (primarily 
Fabs-50kDa and Fv-25kDa).  When complexed to proteins with aggregation properties, 
the biophysically favorable characteristics of the CCPs allow the resulting complex to 
become more soluble and monodisperse in solution [88].  One such antibody Fv fragment 
complexed with cytochrome c oxidase (COX), showed the antibody‟s ability to 
crystallize the complex into two different lattice conformations [89] (Fig. 1.3a).  
Examples of some natural and recombinant antibodies used in co-crystallization are 




Figure 1.4  Natural and recombinant antibodies used in co-crystallization 
Schematic drawing of different classes of antibodies and certain antigen binding 
fragments have been proteolytically cleaved and recombinantly developed from these 
classes.  
 
Fabs contain a single constant chain (both light and heavy chain, CL and CH 
respectively) and a variable chain (VL and VH).  The variable domain (VL+VH) consist of 
six hypervariable loops known as complementary determining regions (CDR) that bind 
the antigen with a specifity.  Fab and Fv CCPs currently in use are produced via 
proteolytic cleavage from monoclonal antibodies [79], however advances in recombinant 
techniques have allowed for efficient production of these and even smaller antibodies.  
One particular small recombinant antibody commonly produced is the single chain 
variable fragment (scFv-27kDa) and is created by connecting the VL and VH domains 
with a flexible polypeptide linker [95].  Another single chain antibody variation involves 
attaching the light chain kappa constant domain to the scFv (scAb-43kDa) [96].  While 
some work has indicated the potential of scFv and scAb as co-crystal chaperone, more 
work is needed to determine the full extent of its capabilities [97].  The ability of these 
proteins to generate additional lattice contacts and provide a scaffold system is of 
particular interest and will guide the development of a crystallizable chaperone antibody.   
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1.5.2  Single chain antibody fragments for co-crystallization scaffold 
The major limitation in current co-crystallization methods is the identification of a 
new chaperone with targeted affinity for each unique protein intended for crystallization.  
This challenge extends to selecting a chaperone that binds the “ideal” location on the 
protein without disturbing the native conformation [98].  Additionally, each new 
chaperone selected will have completely different biophysical characteristics.  This 
results in screening of crystallization conditions for the new chaperone complexed with 
the target protein.  To overcome the limitations of the current methods, a single chain 
fragment (scFv) antibody was engineered using established phage display technology for 
high affinity and specificity to a tag that could readily be attached to any protein of 
interest (via internal loop, or at either the c- or n-terminal ends).  The scFv recombinant 
antibody is preferred for our objectives due to its compact nature, comprising a minimal 
binding unit: the variable light (VL) chain domain and the variable heavy chain (VH) 
linked together by a flexible (Gly4Ser)4 linker [95].  Hexahistidine-specific 3D5 scFv 
antibody [99-101] was selected as a candidate for use as the framework of the engineered 
antibody.   Its selection was driven by its similar VL homology (>85%) to a family of 
well-characterized antibodies that crystallize under various crystallization conditions 
(Fig. 1.5).   In the 3D5 P3221crystal lattice, the location of the crystal contacts on the 




Figure 1.5.  Crystalline Lattice Structure of Select Antibodies with similar VL Homology 
to 3D5 scFv 
(a) 3D5 scFv (Space Group: P42121) [99]  
(b) Anti-2-Phenyl-5-oxazolone NQ16-113.8 scFv (Space Group: I212121) [102]   
(c) Anti-dansyl IgG Fv fragment crystallized at pH 5.25 (Space Group: P212121) [103]  
(d) Anti-dansyl IgG Fv fragment crystallized at pH 6.75 (Space Group: P212121) [103] 
 
 
3D5 scFv is an anti-His antibody and currently the only one available in scFv 
form.   A construct created by Kaufman consisting of nine mutations from the wildtype 
expressed extremely well and was capable of crystallizing with contacts along the 
framework as mentioned previously [99].  This allows for the manipulation or 
replacement of the CDRs for switched affinity for peptide tag while retaining the crystal 
contact.  In addition to its other favored characteristics, 3D5 scFv was also selected for its 
large protein yield, crystallization at low protein concentrations and its crystal contacts 
are located on the frameworks.  The 3D5 antibody interacts with only three c-terminal 






pH, binding only between the range of 6 - 7.4, and poor solubility (<2.2mg/mL) requires 
that improvements need to be made to the antibody before it can be considered as a 
crystallization chaperone.   
We propose to switch the affinity of the His-tag to an EYPME (EE)-tag.  This tag 
was favored because of its improved chemical diversity in the peptide sequence, with a 
number of attractive residues i) a tyrosine, which frequently occur in protein-protein 
interactions and known for its hydrophobic interactions and hydrogen bond formation 
[104, 105] ii) a glutamate, negatively charged to form electrostatic interactions and iii) a 
proline that reduces the conformational entropy.  A major proponent for selecting this 
peptide tag was that antibodies with specificity for the EE tag instead of the His tag have 
previously been established [106].   In addition, there are well behaved commercially 
available mAbs that have higher affinity and specificity for the EE peptide tag [Covance].  
Further background and details on all of these antibodies and tags will be discussed in 
their respective chapters.   
 
1.6  ANTIBODY ENGINEERING 
1.6.1  Rational design 
Directed evolution is a robust tool for understanding the relationship between 
protein structure and function.  By introducing mutations into the gene that encodes the 
target protein, we can expand our limited understanding of protein mechanism and 
functionality.  When structural information of the protein is present, Site directed 
mutagenesis (SDM) can be utilized to understand and improve protein activity.  Use of 
targeted mutations at critical interaction, binding or active sites can increase the chances 
of obtaining an improved protein much more rapidly than with random mutagenesis (Fig. 
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1.6b).  Although site directed mutagenesis (SDM) has gained in popularity, random and 
extensive mutagenesis (REM) is an effective tool for altering proteins for enhanced 
stability and improved activity [107, 108].  Two of the more commonly used REM 
techniques are gene shuffling and random insertion (Fig 1.6a).  Some of the most popular 
applications for random mutagenesis involve improving antibody affinity to ligands [109-





Figure 1.6  Two most frequently used methods for generation of protein libraries.   
(a) Multiple genes used for gene shuffling (path 2) and random mutagenesis (path 3).   
(b) Site directed mutagenesis utilizing switched amino acids (path 2) and inserted amino 
acids (path 3) 
 
 
1.6.2  Methods for generating libraries to obtain appropriate chaperones 
Recently, mutagenesis is more frequently accomplished with polymerase chain 
reaction (PCR)-based methods due primarily to the simplicity of these protocols.  The 
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Stratagene QuikChange SDM Protocol (QCM) [115], one of the most widely used PCR-
based methods for site directed mutagenesis, uses plasmid template and complementary 
synthetic oligonucleotides. The synthetic oligonucleotides contain the desired mutations 
and serve as primers to synthesize double stranded PCR product.  Originally used for 
single mutations, recent variations of PCR methods sought to address and improve 
problems related to primer design and length.  Some of these improved protocols include 
servers predicting successful amplifying oligonucleotides [116], partially overlapped 
oligonucleotides [117], overlap extensions with random mutations [118] or the 
production of megaprimers using non overlapped primers with an additional PCR cycle 
to complete whole plasmid double stranded synthesis [119-121].  The QuikChange 
method has also been expanded for application in REM by inducing random mutations 
during the around the plasmid PCR amplification step [122].  Stratagene‟s own variation: 
EZClone Domain Mutagenesis kit produces megaprimers using low fidelity polymerase 
(mutazyme) to initiate the around the plasmid PCR amplification.   While the simplicity 
of the PCR methods is favorable, the exponential amplification of whole plasmid DNA 
allows for increased chances in errors at other locations on the plasmid (i.e. ori, promoter 
and antibiotic resistance) even with high fidelity polymerases such as pfu.   
To avoid the potential errors introduced outside of the target area due to whole 
plasmid PCR, other protocols use error prone polymerase to amplify the regions for 
randomized mutations [123].   The randomized regions are then inserted into the vector 
of choice via ligation.  With the ligation method, major challenges include i) efficient 
digestion of both the vector and insert ii) optimization of the ratio of insert to vector for 
successful ligation and iii) effective transformation into cells.  Kunkel Mutagenesis with 
improvements from Weiss is another SDM technology that avoids PCR amplification and 
ligation limitations using template ss-DNA containing Uracils (U-DNA) [124].  Location 
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specific mutagenic primers anneal to the ss-DNA to covalently closed circular dna 
(heteroduplex).  The U-DNA wildtype template becomes inactivated once transferred 
into ung
+
 E. Coli, which allows for the strand containing the mutagenic megaprimer to be 
replicated.  An inexpensive technique, the major advantage of this protocol is its ability to 
simultaneously anneal multiple independent primers at various regions for rapid library 
generation.   
Other techniques avoid recombinant DNA work completely, using E. Coli 
mutator strains like DM2516 and XL1-Red (Stratagene).  This method is extremely 
limited as the rate of mutations is extremely low and the mutations are uniformly inserted 
throughout the plasmid, impacting areas such as the promoter and antibiotic resistance 
[125].  Previous work in our lab with the XL1-red (deficient in mutS,  mutD  and mutT),  
has indicated the slow rate of mutation insertions into the plasmid (~10 – 6  
mutations/kb/generation).  After 15 rounds of cell growth, still no mutations were seen in 
our region of interest and confirmed previous work where few mutations were seen after 
100 generations [125].   
It is obvious from the current technologies in place that an improved protocol is 
needed for randomization.  Pressure for better technologies involves overcoming the 
major bottlenecks from current SDM and REM protocols which include no longer relying 
on restrictions sites or ligase effectiveness, as well as reducing the amount of errors 
introduced outside the region of interest.    Utilizing a combination of megaprimers and 
Weiss‟ improved Kunkel mutagenesis, we will present a novel method for random 
mutagenesis that can overcome the limitations of the current protocols currently in place 
for directed evolution.    
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1.6.3  In vitro selecion using phage display 
In order to rapidly screen a library, an effective selection platform must be used.  
All library work in this thesis was performed using phage display selection techniques, a 
powerful and highly efficient technology for selecting proteins with desirable biological 
characteristics [126].  In the last 20 years, phage display systems have successfully been 
used to screen antibodies, ligands and other peptide-based molecules [127].  Known 
primarily for high affinity selection, phage display applications are wide-ranging and 
include selection for stabilized proteins [128], as well as improved structural folding and 
enzymatic activity [129].  The phage system in this thesis utilizes phagemid vectors with 
the gene inserted into the vector.  Cells carrying this vector can be super-infected with 
helper phage to produce protein-presenting phage.  These protein-presenting phage are 
incubated over bound target protein to find high binders (Fig. 1.7) eluted and the entire 
process repeated to improve specificity.   
 
 
Figure 1.7  Affinity Selection for Phage Display 
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1.7  OBJECTIVES AND WORK 
The thesis focuses on whether a hyper-crystallizable antibody could be engineered 
for potential use as a peptide specific chaperone.  The objective is to create a hyper-
crystallizable protein able to crystallize in multiple space groups and/or conditions with 
the intention of using it to nucleate crystal growth of more difficult protein.  The 
development of a chaperone specific for a peptide tag would facilitate the path for a 
general approach by adding the cognate peptide to any membrane protein of interest at 
either terminal end or in place of a flexible loop.  Use of this chaperone will simplify 
molecular replacement and increase the hydrophilic surface area available for forming 
lattice constants.  By expanding this idea and applying it to other peptide tags, a more 
organized and systematic approach to protein crystallization is potentially viable (Fig. 
1.8).   
Here we report engineered 3D5 variants with switched peptide binding specificity 
and high affinity to the EE tag while retaining all the critical residues that driving 
crystallization.  Variants were developed based on libraries with both directed and 
randomized evolution and resulted in a potential candidate for use as a crystal chaperone.  
While engineering this antibody, it was important to understand the correlation between 
its intermolecular contacts and crystallization propensity.  This involves understanding 
the driving force behind lattice formation and if it can be controlled as we design our 
chaperone antibody.  The impact of surface mutagenesis at each intermolecular contact is 






Figure 1.8  Chaperone-Assisted Protein Crystallization Systems 
A general platform for a more organized and systematic approach to protein 
crystallization using peptide specific crystal chaperones in place of the currently existing 





CHAPTER TWO: Restriction enzyme-free construction of random gene 
mutagenesis libraries in E. coli 
 
2.1  CHAPTER SUMMARY 
Directed evolution relies on both random and site-directed mutagenesis of 
individual genes and regulatory elements to probe the biochemical basis of protein 
activity and modify activity to meet engineering specifications. Central to these 
experiments is construction of large, unbiased libraries of related molecules; however, a 
number of technical hurdles continue to limit routine library construction. While 
technologies have been developed to avoid some or all of these challenges in yeast and 
for site-directed mutagenesis libraries in E. coli, no such methods exist for development 
of random mutagenesis libraries in E. coli. Here, we report a novel ligation-free library 
approach, based on error-prone PCR amplification of the DNA region of interest and use 
of this product to generate a library of randomly mutated 3‟ megaprimers, followed by 
megaprimer annealing to dUTP-containing, single-stranded template plasmid DNA. The 
T7 DNA polymerase then seamlessly integrates the modified DNA into the vector 
backbone in a modified Kunkel procedure. Using this approach, we were able to reliably 
generate libraries of ~10
7
 cfu/ug PCR product per transformation in a single day. We 
have successfully employed this method to generate libraries for three different single-
chain antibodies and, in conjunction with phage display, have identified variants with 
enhanced function from these libraries. The key advantages of this technology includes 
facile amplification, restriction enzyme-free library generation, and due to the single 
annealing step with linear amplification, a significantly reduced risk of unintended base 
pair changes at unintended sites within the plasmid.  
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2.2  INTRODUCTION 
Directed evolution, the in vitro generation of mutants followed by function-based 
selection of variants, is a standard tool for many protein engineering, synthetic biology 
and metabolic engineering applications [130, 131]. Due to the limited ability to predict 
the effects of amino acid changes on protein structure and function, a variety of 
approaches to protein-based directed evolution have been developed, including site 
directed and random mutagenesis as well as recombination-based methods, such as DNA 
shuffling. These methods are widely used for epitope mapping of protein interactions, 
[112, 132, 133], analysis of protein function [113, 114], optimization of metabolic 
pathways through promoter engineering [134, 135], and enzyme engineering 
applications, including modulation of co-factor use [136, 137]. In particular, random 
mutagenesis is an effective tool for modulating protein activity and stability as long as a 
robust function-based screen is available [107, 108] and can be used to enhance nearly 
any biochemical or biophysical parameter, including antibody affinity for ligands [109-
111].  
The goal of a directed evolution experiment is to identify clones with enhanced 
function; the probability of success is enhanced by generation of large, productive 
libraries, encoding few wild-type variants, stop codons or frame shifted variants. 
Standard generation of libraries in E. coli proceeds with three steps: (1) amplification of 
the region of interest under error-prone conditions, (2) restriction enzyme digestion and 
ligation into a plasmid and (3) transformation into competent cells. Each of these steps 
can be time consuming and inefficient, limiting the final library size [123].  In particular, 
the cloning steps, involving digestion of the plasmid, amplification of insert and 
subsequent ligation of these two fragments, present bottlenecks during library generation. 
These difficulties have stimulated development of recombineering approaches which 
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avoid traditional cloning steps.  Other techniques avoid direct DNA manipulation 
completely, using E. coli mutator strains such as DM2516 and XL1-Red (deficient in 
mutS, mutD and mutt; Stratagene). This method suffers from a low mutation rate (~6–10 
mutations/kb/generation in our hands or a few mutations per 100 generations [125]. In 
addition, mutations are uniformly distributed across the plasmid, potentially impacting 
the promoter and antibiotic resistance gene. 
Random mutagenesis procedures typically employ the polymerase chain reaction 
(PCR) due to its simplicity and ease of mutant generation [138-140].  In particular, 
Stratagene‟s QuikChange site-directed mutagenesis Protocol (QCM; [115]) is one of the 
most widely used PCR-based methods, utilizing methylated plasmid template and two 
complementary, synthetic oligonucleotides. The oligonucleotides both encode the desired 
mutations and serve as primers to synthesize the entire plasmid during a PCR-based 
linear amplification step.  Originally developed to introduce single mutations into a gene, 
variations have (1) increased the plasmid PCR yield via partially overlapping 
oligonucleotides and exponential amplification [117], (2) introduced targeted random 
mutations with degenerate oligonucleotides [118], and (3) use of non-overlapping 
primers to introduce site-directed mutations, and generate megaprimers for PCR-
amplification of the entire plasmid [119-121].  QCM has been employed for random 
mutations by amplifying the plasmid under error-prone conditions, although these 
mutations are not restricted to an area of interest [119, 122].   While the simplicity of 
these methods is appealing, exponential amplification of the whole plasmid increases the 
risk of introducing errors at essential or undesirable locations (e.g. origin of replication, 
promoter and antibiotic resistance genes) even with a high fidelity polymerase.   
Alternatives to QCM, such as recombineering and ligation-independent cloning 
approaches avoid the difficulties of whole plasmid PCR [134, 139] but are not optimized 
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for generation of large libraries. Modified Kunkel mutagenesis procedures avoid 
exponential PCR amplification and restriction enzyme digestion/ ligation bottlenecks by 
utilizing template DNA containing uracils (dU-ssDNA) to form heteroduplex DNA with 
primers containing the desired mutations [104], which are extended to create a dTTP-
containing complementary strand by T7 DNA polymerase in a linear amplification 
process.  Upon transformation into into dut+ung
+
 E. coli, the template dU-ssDNA is 
inactivated, allowing only the mutated strand to be propagated.  An inexpensive and rapid 
technique, a key advantage to this protocol allows for simultaneous annealing of multiple 
independent primers to different locations on the plasmid.  With targeted mutagenesis 
libraries, in which sequential codons are randomized with degenerate primers, libraries 
with over 10
11
 individual clones and eight randomized position have been constructed 
using this method [132]. 
Utilizing a combination of randomly mutated megaprimers and Kunkel 
mutagenesis, we propose a novel method for library generation to overcome the 
limitations of the current protocols.  First, the region of interest is amplified under error-
prone conditions. Next, an asymmetric PCR step generates a library of 3‟ megaprimers 
from the error-prone product. Last, the megaprimers are used in conjunction with dUTP-
containing, single-stranded template plasmid to generate a dTTP- and megaprimer-
containing complementary strand (Figure 2.1). Upon transformation, this method reliably 
and rapidly creates large libraries (~10
7
/ ug DNA/ transformation) and can be scaled-up 
for larger libraries. We have successfully employed this method, termed MegAnneal, to 
generate libraries for three different single-chain antibodies (scFv) and, in conjunction 
with phage display, have identified variants with enhanced function from these libraries. 
The key advantages of this technology includes facile amplification, restriction enzyme-
free library generation, and due to the single annealing step and linear amplification, a 
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Figure 2.1  Generation of ligation-free error-prone libraries with megaprimers.   
Schematic diagram of the process includes  PCR mutagenic amplification of PCR in the 
reverse reading frame.  Followed by annealing of megaprimers to uracil containing single 
stranded DNA (dU-ssDNA) and generation of heteroduplex double stranded DNA (ccc-
dsDNA).   
 
2.3  MATERIALS AND METHODS 
2.3.1  Plasmid preparation  
The scFv genes (750 bp) was inserted via SfiI-SfiI ligation into the phagemid 
vector pMoPac24 (~4800bp), which contains an amipicillin resistance cassette and an 
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M13 origin of replication [141].  Three scFv genes were used: the 3D5/EE scFv, with 
initially poor expression and weak affinity for the EE peptide (sequence: EYMPME); the 
M2 scFv, with poor expression and affinity for the FLAG peptide (sequence: 
DYKDDDDK) and the hu1B7 scFv, with poor expression and moderate affinity for the 
pertussis toxin [142].  To minimize the presence of wild-type peptide specific scFv in 
randomly mutated libraries, three tandem stop codons (TAA TGA TAA) were inserted 
into the gene in the CDR H3 region using overlapping oligonucleotides and standard 
QuickChange mutagenesis.  An additional three tandem stop codons (TAA TAA TAG) 
were inserted into the gene at CDR H2, to create the template for the combined HCDR2 
and HCDR3 control library to ensure the successful annealing of both primers.  Stop 
codons were inserted near the 3‟ end of the scFv, so that even short megaprimers will 
generate in frame scFv sequence upon annealing and extension. For the hu1B7, mutations 
were expected across the entire gene length, therefore stop codons were inserted at the 
beginning of the heavy chain of hu1B7, so that only megaprimers of full length would 
anneal.  After confirmation of stop codon insertion by sequencing, pMoPac24 plasmid 




 E. coli strain CJ236 
(NEB). Clones were grown in liquid culture to mid-log phase at 37 C, infected with 
M13KO7 phage (NEB) at a multiplicity of infection (MOI) of 10 to package uracil-
containing, single-stranded plasmid DNA (dU-ssDNA) within the phage particles [104]. 
The phage were concentrated via precipitation with ¼-volume 20% PEG-1.5 M NaCl 
[124] and the dU-ssDNA extracted using Qiagen‟s Qiaprep Spin M13 Kit for use as 
template DNA during the subsequent mutagenesis and library generation steps.    
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2.3.2  Generation of randomly mutated megaprimers 
Randomly mutated megaprimers were produced via two sequential PCR steps: (1) 
amplification of the region of interest under error-prone conditions and (2) an asymmetric 
PCR step to generate 3‟ megaprimers. First, the entire scFv gene (10 ng) was amplified 
using the low fidelity Mutazyme II DNA Polymerase (Stratagene, La Jolla, CA) and two 
flanking primers (set 1: 5‟ scback and 3‟ scforlong; set 2: 5‟pakpel and 3‟hucK; see Table 
3) according to commercial instructions. The 50 uL reactions were initially heated at 
95
o
C for 4min, followed by 25 cycles of incubation at 94
o
C for 30sec, 58
o
C for 30 sec 
and 72
o
C for 1min. After amplification, PCR product (~750 bp) was purified from a 1% 
TAE agarose gel using QIAquick gel extraction kit (Qiagen).  To calculate the mutation 
rate from this initial step, purified PCR products were cloned into pTopo (Invitrogen), 
transformed into Top10 E. coli cells and the scFv gene sequenced from 10 independent 
colonies to provide an initial estimate of mutation frequency.  
A second PCR step was performed using only the anti-sense primer (3‟scforlong) 
and 32 cycles to generate a library of randomly mutated anti-sense megaprimers. 
Megaprimers were gel purified and phosphorylated in 20uL reactions containing ~2ug 
megaprimer, TM Buffer (0.05M Tris, 0.01MgCl2, pH 7.5), 1 mM ATP, 5 mM DTT and 5 
units of T4 polynucleotide kinase incubated at 37
o
C for 1 hour.  One gene (hu1B7) was 
recalcitrant to a second amplification, producing only PCR products of the incorrect size. 
In this case, the initial Mutazyme reaction was omitted and the megaprimers produced 




2.3.3  Library Construction 
To generate error-prone libraries for directed evolution, randomly mutated 
megaprimers were annealed to dU-ssDNA containing the scFv-stop gene and extended in 
a modified Kunkel procedure.  The dU-ssDNA template plasmid (20 ug) was combined 
with a three-fold molar excess of phosphorylated megaprimer into TM buffer for a final 
volume of 250uL. The mixture was heated to 90
o
C for 2 min to disrupt secondary 
structure, followed by cooling at 50
o
C for 3 min, then 20
o
C for 5 min to facilitate 
annealing of megaprimer to dU-ssDNA template plasmid. Next, extension of the 
annealed megaprimer via T7 DNA polymerase and repair of nicked ends by T4 DNA 
ligase created covalent, closed circular double-stranded plasmid (ccc-DNA) comprised of 
a dU template strand and an anti-sense dTTP strand. The annealed DNA mixture was 
adjusted to contain 0.34 mM ATP, 0.85 mM dNTPs, 5.10 mM DTT, 240 U T4 DNA 
ligase and 3 U T7 DNA polymerase and the reaction allowed to proceed overnight at 
room temperature.  
The resulting double stranded DNA was desalted using QIAquick gel extraction 
columns (Qiagen) and quantified by absorbance (1 OD260nm = 50ug/mL).   Successful 
generation of ccc-DNA was confirmed by comparison with template dU-ssDNA (500 ng 
each) on a 2% agarose gel. Desalted polymerase reaction (~10ug) was combined with 
electrocompetent XL1-Blue E. coli cells (500uL, 10
8
 cfu/ug competency), electroporated 
in a 2-mm gap electrocuvette (Biorad, Hercules, CA) at 2.5kV, 25μF, 200Ω and 
immediately recovered in 2mL of TB media at 37
o
C for 45 minutes with shaking before 
transfer to 500mL TB with 200ug/mL ampicillin. To determine library size, aliquots were 
plated on selective agar plates. Three scFv libraries using the 3D5/EE gene were 
produced using megaprimers of varying lengths (250bp, 750bp and a pool >150 bp) to 
focus mutagenesis to different regions of the scFv gene as well as determine the effect of 
 42 
megaprimer length on final library size and diversity.  In addition, two control libraries 
were created using either one or two 50 bp oligonucleotides in place of megaprimers (see 
Table 3). These oligonucleotides introduce 12 and 7 randomized codons in the CDR H2 
and H3 regions, respectively, and provide a calibration point for library size with respect 
to standard Kunkel mutagenesis.  
 
2.3.4  Analysis of library diversity and quality 
After library generation, 30-50 clones per library were sequenced with primer 
5‟pakpel to measure the expected scFv mutation rate, percent of clones incorporating 
megaprimer, and rates of mis-priming and frameshifting. To assess the rate of unintended 
mutations introduced by T7 polymerase-mediated linear amplification of the entire 
plasmid, a region of the backbone plasmid (skp region using primer 5‟skp) was 
sequenced from 10 clones.    
Following library generation, production and panning of recombinant scFv-
displaying M13 phage was employed to identify clones with enhanced solubility and EE-
peptide binding affinity, as well as demonstrate the quality and richness of the 
megaprimer-based library. After transformation, the pooled library was grown with 
shaking at 37
o
C to mid-log phase. ScFv expression was induced with 1mM IPTG and the 
temperature shifted to 25
o
C for 3 hours. Next, M13K07 helper phage were added (MOI 
of 10) and allowed to rest for 30 minutes, followed by two hours of growth and addition 
of kanamycin (25ug/mL) prior to overnight growth to produce scFv-displaying phage 
particles (~12 hours).  Phage were purified by double-precipitation with a ¼ volume of 
20% PEG, 2.5 M NaCl, resuspension in PBS and quantification by absorbance at 260 nm. 
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Phage panning was performed in ELISA (Costar) wells coated with 4 ug/ml anti-
c-myc antibody (9E10, Sigma) or target ligand (maltose binding protein, MBP, with a 
terminal EE tag) and blocked with 5% non-fat milk in PBS. Panning consisted of three 
selection rounds: one with immobilized anti-c-myc antibody to enrich for full-length scFv 
and remove variants with stop codons or frameshifts, followed by two rounds with 
peptide-tagged ligands or pertussis toxin. For each round, 10
12
 plaque forming units (pfu) 
were added to a coated, blocked ELISA well. After equilibration for 1 hour at 37
o
C, and 
washing 10 times with PBS-0.05% Tween, bound phage were eluted with 0.1 M glycine-
HCl pH 2.2, transferred to a new tube and neutralized with 2 M Tris, pH ~10.7. Next, 2 
ml of E. coli (ER2738) were infected with the eluted phage to amplify selected clones. A 
fraction of this volume was plated to estimate the number of pfu recovered and to isolate 
single clones.  
To characterize individual clones selected during panning, single colonies were 
inoculated into 150uL of TB with ampicillin (200ug/mL) in a sterile 96 well plate and 
phage produced as above. Plates were centrifuged and 50uL of phage-containing 
supernatant used in activity assays. Two ELISA assays were used to characterize clones 
selected during panning. First, incorporation of full-length scFv protein into phage 
particles was monitored via binding of a c-terminally encoded c-myc peptide tag to 
immobilized anti-c-myc antibody (4 ug/mL). Next, phage presenting active scFv was 
captured by immobilized MBP-EE ligand (10 ug/ml). In each assay, bound phage were 
detected using anti-M13-HRP (1:5000, GE Healthcare) and signal developed with TMB 
substrate, quenched with 1N HCl for absorbance measurements at 450 nm. Since phage 
displayed scFv variants can be selected based on enhanced expression as well as affinity, 
the specific activity (the ratio of MBP-EE to anti-c-myc binding activity) was used to 
normalize for expression differences and facilitate comparison between clones. Negative 
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controls included uncoated, blocked ELISA wells and plasmid containing the scFv-stop 
gene, while positive controls included scFvs known to present well on phage.   
 
2.4  RESULTS 
2.4.1  Error-prone scFv gene amplification  
As a first test of megaprimer-based generation of random mutagenesis libraries, 
we started with the 3D5/EE scFv, aiming to identify variants with improved EE-peptide 
affinity, expression and solubility. Our ultimate goal is that well-behaved scFvs with EE 
peptide binding specificity could be used as crystallization chaperones for hard-to-
crystallize proteins presenting with EE peptide.  In principle, any PCR-based method for 
introducing errors into a gene, such as biased nucleotides and error-prone polymerases, 
would be compatible with the megaprimer method. We initially selected the error-prone 
Mutazyme thermophilic polymerase, as yields of amplified, randomly mutated DNA 
were ~10-fold higher than with other methods. In addition, the mutagenesis rate, based on 
amount of template DNA in the PCR reaction, was easier to control than with biased 
nucleotides or plasmid amplification in mutS deficient XL1-Red, which yielded few 
mutations after 15 rounds of cell growth.    
Amplification of the scFv gene with either set 1 or set 2 primers and mutazyme 
polymerase produced a sharp band of the expected size (~750 bp) and ~2ug total DNA.  
After gel purification, the DNA was ligated into pTopoTA (Invitrogen), transformed into 
Top10 cells and 10 clones sequenced with M13 Forward primer. Using the error-prone 
Mutazyme polymerase, mutation rates are controlled by the quantity of plasmid 
introduced into the reaction, with 10-100ng expected to result in 3-4 mutations per 
1000bp (Stratagene). Up to 10 mutations were observed in select colonies, with an 
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average of three mutations per scFv gene.  While the mutations were present in both the 
heavy and light chains of the scFv, the mutations were more frequently observed in the 
heavy chain.   
 
2.4.2  Generation of error-prone megaprimers  
Purified product from the mutagenic PCR reaction (~400 ng) was used as 
template DNA in a second, asymmetric PCR reaction with only the 3‟ scforlong primer 
and Vent polymerase. In the presence of a single primer, PCR linearly amplifies the 
template DNA during each cycle. Under these conditions, incorrect primer annealing or 
enzyme processivity can result in premature termination of the growing DNA strand; as a 
result the PCR product can exhibit a range of sizes. Utilizing the same 3‟ huCk primer as 
used in the mutagenic reaction produced poor yields with multiple products, while use of 
a nested primer, 3‟ scfor, which anneals 46 base pairs internal to the original 3‟ huCk, 
resulted in strong bands of a single size corresponding to the full-length scFv gene 
(Figure 2.2).  In the case of hu1B7 gene, products of the expected size were never 
obtained upon amplification of Mutazyme product. In this case, we used an alternative 
approach: direct production of error-prone megaprimers in a 3‟ asymmetric PCR reaction 
performed with biased nucleotides to introduce random nucleotide base pair changes. 
Products generated from this second reaction were separated on an agarose gel, 
excised and purified to generate megaprimers for use in the library generation step. PCR 
products using the nested set 2 primers (Figure 2.2) produced a single band at 750 which 
was excised and purified. For PCR products using the non-nested set 1 primers, which 
resulted in a range of product sizes (Figure 2.2), the megaprimers were separated into 
three different primer sets of varying lengths: i) 250 only, ii) 750 only, iii) a pool >150 
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bp. Each discrete megaprimer size was used to generate a different library, as indicated in 
Table 2.1. For hu1B7, in which error-prone megaprimers were produced in a single PCR 
step, megaprimer size was controlled by extension time and produced discrete bands at 
~750 and 1500 bp, which were combined to produce library VI. 
 
 
Figure 2.2  Megaprimer production.  
PCR product produced by asymmetric amplification of randomly mutated scFv genes 
with the primer 3‟ scfor. Yield and quality of the megaprimers varies with the annealing 
position of the 3‟ primer used: lane 1, identical primer used in the initial error-prone 
amplification reaction and lane 2, use of a nested primer.    
 
2.4.3  Generation of megaprimer-containing ccc-DNA 
Five separate libraries were constructed to examine the effect of megaprimer 
length on the resulting library size and diversity. Three libraries used megaprimers with 
different lengths: (i) 250bp; (ii) 750bp; (iii) mixture of lengths over 150 bp. Two libraries 
were control libraries using (iv) a single 50bp oligonucleotide (primer 3‟ HCDR3) and v) 
two 50 bp primers used simultaneously (3‟ HCDR2 and 3‟ HCDR3), constructed via 
standard Kunkel mutagenesis. The final library was constructed using biased nucleotide 
mutagenesis to compare 3‟megaprimer generation methods and the impact on size and 
diversity.  The megaprimers were annealed to dU-ssDNA plasmid containing the gene of 
interest with three tandem stop codons near the 3‟ end of the gene. Next, reactions with 
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T7 DNA polymerase extended the megaprimer to generate a heteroduplex, consisting of a 
dUTP-containing strand and a complementary dTTP-containing strand. Finally, T4 DNA 
ligase repaired the nicked ends, prior to desalting and transformation into competent 
cells. Once within dut+ ung+ bacteria, the dUTP-containing DNA strand is degraded and 
only the dTTP- and megaprimer-containing stand retained and propagated as a plasmid. 
Each megaprimer preparation was able to prime T7 polymerase for whole plasmid 
amplification, as monitored by agarose gel analysis of the product (Figure 2.3). The ccc-
DNA runs as three bands (open-circular, supercoiled and nicked) which migrate more 
slowly than the dU-ssDNA.   The yield and quality of the ccc-DNA were predictive of 
final library size and quality and serves as check during library development. 
 





Cfu/ ug DNA/ 
transformation 
%  clones 
encoding full-
length scFv 
scFv error rate 
(%)* 
I 1 250 1.0 x 10
7 
 79.2 1-2bp (0.1-0.2%) 
II 1 750 9.3 x 10
6
 41.3 4-7bp (0.5-0.9%) 
III 1 >150 1.1 x 10
6
  54.9 1-4bp (0.1-0.5%) 
IV 1 50 4.1 x 10
7
  50.0 - 
V 2 50 1.1 x 10
7
 37.0 - 
VI 1 750 and 1500 10
6
 62.5 2-5 (0.2-0.67%) 





Figure 2.3  Generation of ccc-DNA by megaprimers.   
(a) Control libraries using 50 bp primers and randomizing 7 or 12 codons within scFv 
3D5/EE. Lane 1: dU-ssDNA with stop codons in the HCDR2 region, lane 2: blank, 
lane 3: ccc-DNA product from primer HCDR2 (50bp), lane 4: ccc-DNA product with 
primer HCDR3 (50bp); and lane 5: ccc-DNA production with HCDR2 and HCDR3.  
(b) Effect of the megaprimer length on ccc-DNA production for scFv 3D5/EE. Lane 1: 
750bp; lane 2, >150 bp and lane 3: 250bp megaprimers.   
(c) Megaprimer and ccc-DNA production for scFv M2. Lane 1: mutazyme reaction 
product with set 1 primers; lane 2: megaprimer production with nested 3‟ primer; lane 
3: dU-ssDNA, lane 4: ccc-DNA with site-directed oligonucleotides; lane 5: ccc-DNA 
produced with error-prone megaprimers.  
(d)  Single-step production of error-prone ccc-DNA for scFv hu1B7. Lane 1: megaprimer 
produced with Taq and biased nucleotides (700 bp); lane 2: megaprimer produced 
with Taq and biased nucleotides (1500 bp); lane 3: megaprimer produced with Vent 
and biased nucleotides (700 bp); lane 4: hu1B7 dU-ssDNA; lane 5: ccc-DNA 
produced with 700 bp Taq megaprimers; lane 6: ccc-DNA produced with 1500 bp 
Taq megaprimer; lane 7: ccc-DNA produced with 700 bp Vent megaprimers. Arrow 
indicates the 3000 bp molecular weight marker, * dU-ssDNA and ** ccc-DNA 
expected sizes.  
 
2.4.4  Rapid generation of large, rich error-prone libraries without restriction 
enzymes 
After confirmation of successful generation of ccc-DNA production, DNA (~10 
ug) was transformed into electrocompetent E. coli cells with a single transformation (100 
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uL of cells with a competency of 10
8
 cfu/ug/uL) to generate a library. Aliquots of the 
transformation were plated to estimate library size, while the remainder was use to 
produce recombinant scFv-displaying phage for panning experiments. In general, a single 
transformation produces >10
7
 transformants/ ug DNA (0.2 cfu/ ug PCR product/ cell), 
which can be readily scaled up to produce very large libraries. Sequencing confirmed the 
presence of a full-length scFv in about half the transformants (range, 37-79%), consistent 
with standard Kunkel results and a similar error rate within the scFv gene as expected 
from sequencing of the Mutazyme reaction (0.1-0.9%; Table 1). Increasing the 
megaprimer:DNA ratio from 3:1 to 5:1 doubled the final library size for library II, but 
further increases did not yield any additional gains.  
Library size was impacted by megaprimer length using this method, with shorter 
megaprimers being more efficiently incorporated (Table 1).  Libraries generated with 
megaprimers smaller than 300bp (I, IV and V) produced libraries with 10-fold higher 
cfus than those using larger megaprimers (II, III, VI). Analysis of the quality of our ccc-
DNA derived from each megaprimer (Figure 2.3b) shows stronger and more distinct 
product bands for smaller megaprimer.  This suggests that shorter primers anneal more 
efficiently to the dU-ssDNA, while larger megaprimers take longer to find the cognate 
sequence and may partially anneal.  The variable length megaprimer library (III) is about 
10-fold smaller than the others, which may result from competition between primers of 
different length for template plasmid, with shorter primers annealing faster to the ssDNA. 
Sequences from library III revealed mutations primarily in the heavy chain region (~430 
bp region), supporting the idea that short megaprimers outcompete longer ones.   
To determine the actual library mutation rate and assess whether the Kunkel 
mutagenesis step introduces additional mutations within the plasmid, 30-50 clones per 
library were sequenced at two separate locations. Sequencing was performed with primer 
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5‟ pAKpEL which sits upstream of the scFv gene and with primer 5‟ skp, which sits in a 
region of the plasmid distal from that targeted for mutation (Table 2.1). Sequencing of 30 
clones from Library II with 5-pakpel primer revealed an average error rate of 0.73% (4-7 
base pair changes per gene), with mutations distributed across the heavy and light scFv 
chains and expected levels of transitions and transversions as described by manufacturer. 
Final library mutations will be constrained to the region of the gene covered by the 
megaprimer; thus while 250 and 750 bp megaprimers may each encode 1% errors, the 
shorter megaprimer will confer a lower overall mutation rate to the gene since only one-
third of the scFv gene is targeted. Taking this into account, the number mutations 
observed within megaprimer-encoded regions are statistically similar to that observed 
after the mutazyme reaction. Furthermore, no mutations were observed in the skp gene, a 
region of the plasmid not targeted for mutagenesis.  Megaprimer mispriming was 
observed exclusively in library III, in which several colonies (4 of 51 sequenced), 
encoded reading frame shifts and one non-target gene insertion.  This may be a result of 
the size variation of these megaprimers, which also constrained library size or mis-
priming during megaprimer generation.  
For generation of optimal libraries, megaprimers must be clear strong bands with 
DNA only in the 3‟ direction.  The intended megaprimers should not include PCR 
product that is the result of primer misannealing (i.e. smears, indistinct bands).  
Additionally the megaprimers should not be larger than the expected size of your gene, as 
this leads to mis-priming. From our data, it is suggested that megaprimers of 250bp and 
less are more effective at generating large libraries (10-fold higher) than those with 
similar quality megaprimers at a length of 750bp. Should multiple sized megaprimers 
bands occur that fall within the range of your gene length, the recommendation is to 
anneal each megaprimer size independently to avoid competition issues between the 
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range of primers.  After transformation, these colonies can be combined into one library 
before proceeding to the selection/screening phase.    
After two rounds phage panning and selection, pooled clones from library i-iii 
were screened for scFv expression and EE-peptide binding ability.  Selected colonies 
were grown in 96 well plates, infected with M13 phage to produce scFv-displaying phage 
and the phage used in two ELISA binding assays. Binding to anti-c-myc antibody 
indicates the presence of a full-length scFv protein incorporated into the phage coat, as 
the c-myc epitope is encoded at the c-terminus of the scFv. Binding to the target EE 
peptide reflects the scFv activity, while the c-myc/ EE ratio provides a measure of 
specific binding activity. Of the 96 colonies screened, 15 bound anti-c-myc and showed 
successful expression of full length and completely folded proteins (Figure 2.4). Of these 
15 clones, 11 exhibited varying degrees of affinity for the EE peptide (Figure 2.4).  In 
contrast, the WT gene (A12) produced low-level signal for binding to anti-c-myc and was 
undetectable on the EE screen. Notably, clone A2 exhibited remarkably high specific 
activity (c-myc: EE ratio of 6), indicating the presence of high-quality variants in the 
mega-primer-produced library.  Further analysis of soluble protein a variants selected 
from this library characterized variants with 38-fold higher affinity, six-fold greater 
solubility (2.3 vs 12.8 mg/ml) and enhanced monomeric expression levels (50% vs 81%; 
Pai et al, submitted, Chapter 3). 
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Figure 2.4 Functional analysis of clones selected from 3D5/EE MegAnneal libraries.  
Individual clones were grown and recombinant scFv-displaying phage produced in 96-
well plates, prior to use of supernatant in phage ELISAs. Shown is the specific activity of 
each clone, calculated as the ratio of absorbances from EE and anti-c-myc ELISAs. (a) 
library I (b) library II.  Controls: WT 3D5/EE (clone A12), plasmid with scFv-stop gene 
(clone B3). 
 
2.5  DISCUSSION  
Overview Kunkel mutagenesis was developed as an early method to introduce 
site-directed mutations in genes [145] and has been used to produce site-directed libraries 
as large as 10
11
 independent clones randomizing eight sequential amino acid residues 
[132]. We have adapted Kunkel mutagenesis to generate error-prone libraries for directed 
evolution of select regions or an entire gene (Figure 2.1).  First, template plasmid is 
prepared by introducing three stop codons at the 3‟ end of the original gene using point 
mutagenesis to prevent wild-type contamination of the final library (step 1a). This 




 E. coli cells followed by M13 phage 
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super-infection to produce dU-ssDNA template plasmid containing an inactive scFv gene 
(step 2a). Simultaneously, random mutations are incorporated into the gene-of-interest by 
exponential amplification with a low-fidelity polymerase, biased nucleotides, or other 
method (step 1b).  The resulting PCR product is purified and linearly amplified with a 
nested 3‟ primer to enrich for antisense strands capable of annealing to the dU-ssDNA 
(step 2b). Megaprimers anneal to the template DNA, priming T7 polymerase to 
synthesize a dTTP- and megaprimer- containing copy of the template plasmid, with the 
ends covalently joined by T4 DNA ligase (step 3). While we show use of a single 
megaprimer here, two could be used to simultaneously randomize multiple regions of the 
gene or plasmid. Complementary base pairing between template and copied strands 
results in covalent-closed-circular double-stranded DNA (ccc-dsDNA), whose presence 
can be readily monitored by gel electrophoresis (step 4).  Upon transformation into ung
+
 
E. coli cells, such as XL1-Blue, the uracil containing strand is efficiently restricted by 
native nucleases while the mutant plasmid strand is replicated and propagated (step 5), 
providing a second level of background template elimination.  
 
2.5.1  Megaprimer amplification versus competing technologies 
MegAnneal allows for rapid production of large and diverse error-prone libraries 
with mutagenesis targeted to one or more locations on a plasmid and covering regions 
150 to 1500 bp in size. Constraints of the method include the requirement for an M13 
origin of replication on the plasmid, introduction of stop codons within the template DNA 
and production of dU-ssDNA template plasmid. These steps require three days of 
advance work, but are crucial for minimizing the wild-type contamination of the library.  




/ug ccc-DNA with 50uL of 10
8
 electrocompetent cells or 0.2 cfu/ ug ccc-DNA/ 
competent cell) within 24 hours. Importantly, the ccc-DNA can be stored indefinitely, 
and simply re-transformed to produce a fresh library for screening, reducing the effect of 
growth differences among clones upon repeated growth of frozen libraries.   
A comparison of MegAnneal and competing methods such as QuikChange, 
Megawhop and standard Kunkel Method (Table 2.2) underscore the advantages of this 
technique in terms of (1) uniform error via megaprimer production with a low fidelity 
polymerase or error prone conditions; (2) minimized mispriming as a result of the slow 
megaprimer annealing process; (3) reduction in unintended mutations outside the region 
of interest with the use of linear amplification and (4) library contamination by wild-type 
genes is limited by the use of two orthogonal mechanisms. Importantly, the limitations of 
Kunkel mutagenesis also apply to MegAnneal.  The vector chosen must be compatible 
with not only the method of screening but also the method of dU-ssDNA generation, and 
thus require an M13 origin of replication in order to package dU-ssDNA. Since strain 
CJ236, used to produce du-ssDNA, encodes chlorampenicol resistance, this should not be 





















































While error-prone amplification with Mutazyme was the primary method for 
random mutagenesis used here, any ranodom mutagenesis procedure is compatible with 
MegAnneal. Mutazyme II DNA polymerase was selected for the insertion of randomized 
mutations due to its ability to produce more uniform mutations without apparent bias for 
any particular nucleotide or amino acid which is commonly seen in other error-prone 
PCR methods, unlike Taq polymerase (which restricts mutations to nucleotides A and T) 
or weighted concentrations of dNTPs to introduce randomization [119, 138].  However, 
random mutagenesis is inherently limited by the unequal distribution of codons to amino 
acids and their natural frequency in protein sequences [130].  Mutazyme‟s ability to 
construct low to medium rate mutation libraries dependant on the initial amount of target 
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DNA make it an extremely powerful tool to compare with other error-prone PCR 
protocols [108].  By varying the initial concentration of DNA template in the reaction 
(0.1-1000ng), a large range of mutation frequencies (1-16 mutations/kb) can be achieved 
allowing for nearly complete control over the mutation rate per gene while maintaining 
high PCR product yields with varying fold amplification (1-10,000x).  While this 
particular polymerase is more costly than standard PCR polymerases, the reaction 
conditions have been optimized by Stratagene and only small (50 ul) reactions are 
required.   
We directly compared the reaction products from QuikChange and MegAnneal 
(Figure 2.5).  There are two major disadvantages to Quikchange: primer dimer formation 
and mispriming during whole plasmid amplification.  Both of these problems are a 
function of the primer design and length. Primer dimer formation occurs frequently in 
Quikchange and kinetically competes with the desired product during primer annealing.  
In MegAnneal, the use of a single primer initiating megaprimer amplification largely 
eliminates the risk of intermolecular dimer formation.  The coincidental match in DNA 
sequences at these primer lengths (250-950bp) is relatively small and chances of 
mispriming are unlikely.  The slow cooling during annealing allows for megaprimer-
template hybridization; nicontrast, rapid temperature changes potentially cause non-
specific and mismatched hybrids [148].  Not only does it benefit hybridrization and 
reduced mispriming, it reduces the need to optimize the Ta value for this reaction which 
is why multiple primers can be annealed simultaneously.  Finally, the single annealing 
and amplification cycle prevents an inexact pairing of megaprimer and dU-ssDNA to be 




Figure 2.5  Quick change vs meganneal for targeted mutagenesis.   
(a)  (standard quick change eg for stop codons insertion) PCR Product using 
QuickChange method with overlapped oligos at varying annealing temperatures 
from 47 to 52
o
C.   
(b)  Our polymerase product after control primers (50bp) were annealed to dU-ssDNA 
and complementary synthesis of Lane 1: ccc-DNA product from primer HCDR2 
(50bp), lane 2: ccc-DNA product with primer HCDR3 (50bp); and lane 3: ccc-DNA 
production with HCDR2 and HCDR3, desired band is indicated. 
 
The linear whole plasmid amplification provides additional benefits due to the 
reduced risk of unintended mutations at extraneous sites.  For exponential PCR-based 
methods, amplified copies of plasmid are used as template in subsequent steps, thus any 
error will be propagated by daughter copies. Unintended mutations, for instance in the 
origin of replication, the promoter or the antibiotic resistance gene, may result in loss of a 
clone from the library or diminished ability to compete due to reduced protein expression.  
The amplification in this protocol has even less relative risk of DNA base pair changes 
outside the intended region because T7 polymerase error rate is fairly low (error rate: 1.5 
x 10
-5 
per base incorporated, NEB) and each template plasmid is amplified at most once.  
This results in easy quality control during library construction, allowing the investigator 
to readily monitor the quantity and quality of CCC DNA.  In comparison, thermophillic 
polymerases used in exponential whole-plasmid amplification protocols such as Taq 
(error rate: 2.28×10
-5
 per base, NEB) or even high fidelity Pfu (error rate: 4.4×10
-7
 per 
base, NEB) can introduce mutations that are propagated exponentially with each 
additional cycle.   
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Many site-directed and random mutagenesis only have one mechanism to limit 
contaminating template genes in the library.  Many methods, including QuickChange, use 
methylated template DNA produced from dam
+
 E. coli strains or in vitro methylation 
with CpG SssI enzyme. In either case, methylated template DNA is digested in vitro with 
methyl-specific DpnI restriction enzyme (target sequence: 5‟G
m6
ATC-3‟) prior to 
transformation (QuikChange). In our hands, this results in recovery of 25% wild-type 
template. Our process uses a comparable method with uracil containing dU-ssDNA 
which is inactivated by E. coli ung
+
 strains, where literature has shown that similar 
amounts of wildtype template or eliminated, reported here as 20-50% template recovered 
from a library.  However, the additional step of inserting stop codons into our template 
plasmid eliminates the risk of wildtype phenotype controlling the library.    
 
2.5.2  Megaprimer considerations   
Our results demonstrate that megaprimers are a key component to this method 
with DNA fragments up to 750bp successfully annealed.   This particular parameter can 
be optimized to impact the size of the resulting library: i) primer design –at both the 
randomization step and the megaprimer; ii) megaprimer length and number  iii) 
megaprimer to template dU-ssDNA plasmid.  Significant consideration needs to be taken 
into account when designing the flanking primers used during randomization in addition 
to the antisense primers required to produce the 3‟ megaprimers.  When designing the 3‟ 
end primers it is important that the 3‟ primer used during the random mutagenesis sets 
down further away from the gene than the 3‟ primer used during the anti-sense 
amplification.  As we mentioned previously, the use of the identical primers in both steps 
produces the DNA fragment of interest in addition to other PCR products (Figure 2).   
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Using a distinct second 3‟ primer during the anti-sense amplification that sits slightly 
further down on the randomized fragments, better annealing is achieved and higher 
quantities of the intended DNA fragments are produced.   Limiting the amount of 
complementary 5‟megaprimer present during the annealing step will facilitate the 
successful annealing of the megaprimer to the ss-DNA, as DNA kinetics tend to favor 
smaller DNA fragments.   
Megaprimer length can largely impact the library size that can be generated.  
From our three random libraries (I-III), using megaprimers <250bp produced a library 
(~10
7 
cfu) that successfully annealed twice as well as those utilizing larger megaprimers.  
Libraries utilizing single megaprimers <100bp produced large libraries (~10
8
 cfu when 
used with 10
9
 electrocompetent cells).  The correlation between the length of the 
randomly amplified insert and the transformation yield is most likely a result of the 
kinetic ability for smaller oligonucleotides to anneal more quickly and efficiently.  This is 
firmly supported by the results from both library ii and iii indicating that the library with 
mixed lengths of primer yielded a higher percentage of successfully annealed clones 
(55% versus 41%).  Although the maximum primer length used here was 750bp, other 
literature has indicated the effective use of megaprimers as large as 1.3kb (EZClone, 
[119]) for annealing to plasmids.  Using oligonucleotides of 50bp in length, showed no 
notable impact on transformation yields when annealed independently or simultaneously.  
Careful consideration needs to be taken when determining regions of randomization so 
that nucleotide sequences are not similar enough to induce non-specific annealing (i.e. 
high GC content, hairpins, repetitive sequences, etc).  This non-specific annealing was 
prevalent during our library generation when truncated scFvs emerged with Vh domains 
only.   
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The ratio of phosphorylated oligonucleotide to dU-ssDNA present in the 
annealing reaction plays a critical role in the resulting library size.  From our results, we 
have shown that increasing the original ratio from 3:1 to 6:1 (oligonucleotide:template) 
doubled the library size unless the original 3:1 ratio had reached the maximum library 
transformant size of 10
7
 cfu.  It was shown that attempts to increase the ratio up to 9:1 
actually reduced the number of transformants produced.  Given the significant single 
stranded DNA present following the complementary synthesis reaction (Figure 4) the 
megaprimer to template ratio can still be improved. Like previous literature [116], we 
believe that this ratio must be optimized in the range we have studied to produce even 
larger libraries than those presented here.   
 
2.6  CONCLUSIONS 
Directed evolution experiments follows one of two paths: site directed 
mutagenesis and random mutagenesis. Site-directed mutagenesis is historically more 
labor intensive, but modern high-throughput screening technologies are facilitating rapid 
generation and analysis of large numbers of altered genes. Here, we present a novel 
restriction enzyme-free method for generating large diverse libraries with random 
mutations distributed across all or part of a gene of interest. Use of an in vitro generated 
megaprimer allows us to easily and inexpensively create large primers, while linear 
amplification of a single cycle to synthesize complementary DNA also allows reduced 
unintended mutations in regions outside of our intended target.  Meganneal has a wide 
range of applications that extend to DNA shuffling and simultaneous mutations at 
multiple sites.      
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Table 2.3  Oligonucleotides used in this study 
Primer 
name 
Use Primer sequence (5’3’) 
5’pAKpel  sequencing 5’-ATGAAATACCTATTGCCTAC-3’ 
















































3’hucK  Megaprimer, 
sequencing 
5’-GGCGGGAAGATGAAGACAGATG-3’ 






CHAPTER THREE:  Conversion of scFv Peptide-binding Specificity 
for Crystal Chaperone Development 
3.1  CHAPTER SUMMARY 
In spite of advances in protein expression and purification over the last decade, 
many proteins remain recalcitrant to structure determination by X-ray crystallography.  
One emerging tactic to obtain high-quality protein crystals for structure determination, 
particularly in the case of membrane proteins, involves co-crystallization with a protein-
specific antibody fragment.  Here, we report the development of new recombinant single 
chain antibody fragments (scFv) capable of binding a specific epitope that can be 
introduced into internal loops of client proteins.  The previously crystallized hexa-
histidine specific 3D5 scFv antibody was modified in the complementary determining 
region and by random mutagenesis, in conjunction with phage display, to yield scFvs 
with new biochemical characteristics and binding specificity.  Selected variants include 
those specific for the hexa-histidine peptide with increased expression, solubility (up to 
16.6 mg/ml) and micromolar affinity, and those with new specificity for the EE hexa-
peptide (EYMPME) and nanomolar affinity.  Complexes of one such chaperone with 
model proteins harboring either an internal or terminal EE tag were isolated by gel 
filtration.  The 3.1 Å resolution structure of this chaperone reveals a binding surface 
complementary to the EE peptide and a ~52 Å channel in the crystal lattice. Notably, in 
spite of 85% sequence identity, and nearly identical crystallization conditions, the 
engineered scFv crystallizes in a different space group than the parent 3D5 scFv, and 
utilizes two new crystal contacts. These engineered scFvs represent a new class of 
chaperones that may eliminate the need for de novo identification of candidate 
chaperones from large antibody libraries.  
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3.2  INTRODUCTION 
Even though the numbers of protein databank entries continue to increase, 
numerous proteins are rejected from the pipeline leading to structure determination.  
Specifically, there is a need for strategies to overcome the crystallization limitation, 
especially for membrane proteins and proteins with inherent conformational variability.  
A number of strategies to improve the likelihood of growing crystals of so-called 
“difficult” proteins have emerged over the last decade.  Beyond improvements in 
recombinant expression and protein purification that enable more expansive 
crystallization trials, these techniques either involve modifying the protein to be 
crystallized in a way that improves its properties for crystallization, or introducing a 
second protein, a crystallization chaperone, to provide the crystal lattice.  The former 
category includes random mutagenesis and homolog shuffling [78, 149, 150], limited 
proteolysis to generate a compact, stable protein entity [151], the identification of ligands 
to optimally stabilize a particular conformation of the protein [47], modification of the 
protein surface to reduce entropy [67, 68, 70], and protein symmetrization by 
crosslinking [75], among others.   
The chaperone category involves the formation of a specific complex between a 
client protein and a soluble protein that provides hydrophilic residues to form crystal 
contacts and thus increases the chances of growing well-ordered, highly diffracting 
crystals of the complex. Since the first report of a crystallization chaperone used to 
determine the HIV capsid protein structure [81], efforts have focused on generating 
complexes between membrane proteins, which suffer from particularly unfavorable 
surface properties for crystal formation.  Noncovalent complexes of target membrane 
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proteins with tailored antibody fragments [7, 86, 88, 89, 94, 98, 152], affibodies [80], 
VHH camelid domains [85] and designed ankyrin repeat proteins (DARPins, [91, 92, 
153]) have been reported. In general, crystallization chaperones recognize native 
membrane protein sequence, and require identification of a new chaperone for each 
protein of interest. Fusion to or insertion of a chaperone into a flexible loop has also been 
described [61, 93, 94, 152, 154, 155]. The location of the fusion protein is key, as long 
linkers confer flexibility typically detrimental to crystallization [154]. Ideally, the 
chaperone should not interfere with activity or function of the client protein of interest. 
Nevertheless, in principle, any stable soluble protein tethered to or with high affinity for 
the membrane protein of interest could be used in cocrystallization experiments. 
Here, we describe the first steps in development of a generalizable approach to 
chaperoning crystal growth: antibody fragments that can be used as a co-crystallization 
chaperone for any protein in which a short peptide sequence, the EYMPME epitope (EE), 
is inserted.  We selected the hexa-histidine (His6)-specific 3D5 scFv as the framework for 
protein engineering because it does not employ complementary determining region 
(CDR) residues in major crystal contacts and the CDRs face a wide channel that could 
accommodate a client protein [99-101].  We hypothesized that these CDRs could be 
modified to recognize a new peptide epitope, and a peptide or client protein could bind, 
without compromising existing crystal contacts.  Nevertheless, 3D5 possesses several 
short-comings that require optimization for use as a crystallization chaperone including 
low affinity (Kd ~1 μM) for only extreme c-terminal histidines [99], pH sensitive binding 
[101], relatively poor expression in E. coli, and limited solubility [99].  Lastly, terminal 
His6 tags, which are commonly used for protein purification, are not always removed 
before crystallization and can degrade over time due to low-level protease contamination.   
These features limit the broader application of the His6 tag as a receptor for a 
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crystallization chaperone and motivate conversion of 3D5 to new peptide specificity.  
The EE peptide (EYMPME) was chosen for (1) its short length, (2) the presence of 
tyrosines to form hydrophobic interactions and hydrogen bonds that commonly dominate 
protein-protein binding energetics [156], (3) charged residues to form electrostatic 
interactions, (4) the presence of a proline to restrict conformational diversity, and (5) the 
availability of high affinity commercial antibodies binding these peptides [106, 157] 
(Covance, Sigma).  Indeed, our optimized scFv exhibits enhanced crystallization 
propensity, including elevated solubility, stability, affinity and the ability to bind internal 
peptide sequences.  This engineered, peptide-binding scFv represents a new class of 
crystallization chaperones that may eliminate the need for de novo identification of 
candidate chaperones from large antibody libraries. 
 
3.3  MATERIAL AND METHODS 
3.3.1  Molecular biology and expression of proteins presenting EE and His6 peptides  
Antibody binding sites (peptide sequences) were incorporated into proteins of 
interest via site-directed mutagenesis with mutagenic oligonucleotides (Integrated DNA 
Technologies). To generate a ligand with a c-terminal EE tag, maltose binding protein 
(MBP) was amplified from the E. coli genome, appended with an EE tag and cloned into 
the pAK400 vector [158], with or without a stop codon before the vector encoded His6 
tag to generate the MBP-EE and MBP-EE-His6 ligands. The variant without a His6 tag 
was used during phage screening and panning, both variants as well as a third in which 
MBP was cloned directly into pAK400 (MBP-His6), were used in Western analysis.  To 
account for steric accessibility, we generated ligands with varying numbers of internal EE 
tags by introducing tandem repeats of the EE coding sequence into the flexible linker 
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connecting the heavy and light chains of unrelated scFv proteins.  A single repeat was 
introduced into the DO11.10 scFv gene to generate scFv-EE1, two repeats into the 14B7 
scFv gene to generate scFv-EE2 [39] and three repeats into a non-native scFv consisting 
of the 3D5 light chain and 14B7 heavy chain to generate scFv-EE3.  These proteins also 
contain c-terminal, vector encoded His6 tags to facilitate purification.  The original 14B7 
scFv with only a c-terminal His6 tag was used as a hexa-histidine tagged ligand. All 
ligand proteins were expressed from pAK400 in E. coli BL21 in 250 ml cultures of TB 
media, induced with 1 mM IPTG for 3-5 hours at 25°C before cell harvesting and 
periplasmic fractionation via osmotic shock as previously described (Maynard et al., 
2005). Recombinant antibody-based ligands were purified via sequential immobilized 
Ni
2+
 affinity chromatography and SEC, using HEPES-buffered saline (HBS; 10 mM 
HEPES, 150 mM NaCl, pH 7.4). The MBP-based ligands were purified using an amylose 
affinity column and eluted with maltose containing buffer (200 mM HEPES, 150 mM 
NaCl, 10 mM maltose, pH 7.4), prior to SEC. 
 
3.3.2  Library generation by CDR and random mutagenesis 
The 3D5 gene was generated by total gene synthesis from published amino acid 
sequence (Genscript), including previously identified solubilizing mutations (referred to 
here as 3D5) [99] and cloned via SfiI-SfiI ligation into the pMoPac24 phage display 
vector [141], which introduces a c-myc tag at the c-terminus of the displayed protein.  To 
identify clones with desired peptide specificity, two CDR libraries were generated by 
modified Kunkel mutagenesis under error-prone conditions: HCDR3 only and 
HCDR2+HCDR3 simultaneously.  Randomized codons were selected to retain anti-
peptide binding capabilities as described previously [159]. For generation of EE-specific 
 67 
antibodies, amino acid sequencing by Edman degradation (ICMB Protein Microanalysis 
Facility, University of Texas at Austin) of proteolytic fragments of the commercially 
available GluGlu antibody (Covance), identified a candidate HCDR1 sequence.  The 
HCDR2 loop included 13 amino acid modifications (theoretical size, 9 x 10
14
), while 
HCDR3 loop length was set at seven residues to reflect observed diversity in anti-peptide 
antibodies (theoretical diversity, 6.4 x 10
8
). The 3‟ H2 oligonucleotide sequence is 
CACGGTGAGTGTGGCCCTSNNCTTVNHMNYSBNGTTATASNNSNNSNNSNNA
YYSNNARDMYDAATSNNTCCGATCCACTCCAGACC, while the 3‟ H3 
oligonucleotide sequence is CCTTGACCCCAGTAATCCATAGCSNNSNNSNNGCTS 
NNSNNSNNSNNABNTGCACAGTAGTATACG. 
A third library was generated to introduce random mutations into a pool of scFvs 
selected for EE-specificity. Here, 3D5 variants with desired epitope specificity were 
subjected to error prone PCR with Mutazyme II DNA Polymerase (Stratagene) using 
flanking primers (5‟ scback and 3‟ scforlong, IDT [158]) and exponential amplification 
according to manufacturer‟s instructions.  Briefly, reaction mixtures were heated at 95°C 
for 4 min, followed by 25 cycles of incubation at 95°C for 30 sec, 52°C for 30 sec and 
72°C for 1 min to introduce a predicted 3-4 mutations per 1000 bp.  Gel purified PCR 
products (Qiagen) were used in a modified Kunkel mutagenesis step to produce two 
libraries.  Library mutation rate and diversity was assessed by plasmid DNA sequencing 
at the University of Texas Core Facility using primer 5‟ pAKpel [158] (IDT). 
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3.3.3  Selection and screening by phage display 
M13 phage monovalently displaying scFv-gpIII fusions were prepared as 
previously described [158]. After precipitation with ¼-volume PEG-2.5 M NaCl and 
resuspension in PBS, the phage concentration was quantified by absorbance: 
 
     virions/ ml = [(A269-A320)*6*10
16




 plaque forming units (pfu) were added to blocked ELISA wells 
(Costar) coated with either anti-c-myc antibody (9E10, Sigma), His6 or EE presenting 
ligand.  After equilibration, and washing with PBS-0.05% Tween, bound phage were 
eluted with 0.1 M glycine-HCl pH 2.2, transferred to a new tube and neutralized with 2 
M Tris, pH 7.0.  Phage were then amplified in E. coli in preparation for the next panning 
round or used to infect E. coli and plated to isolate single clones.  Panning involved two 
cycles, each consisting of three selection rounds: one with immobilized anti-c-myc 
antibody to enrich for full-length scFv and remove variants with primer encoded stop 
codons or frameshifts, followed by two rounds with peptide-tagged ligands. 
Individual phage clones were analyzed by phage ELISA to confirm enrichment of 
peptide-specific clones and to screen candidates for biophysical characterization. Phage 
from single clones were produced in 200 μl in sterile 96-well plates (Costar). The plates 
were centrifuged and supernatant transferred to coated and blocked ELISA wells 
(Costar). After washing with PBS-0.05% Tween, bound phage were detected by anti-
M13-HRP (1:2500, GE Healthcare) with tetramethylbenzidine (TMB, Sigma) substrate 
and the resulting absorbance at 450 nm recorded.  Binding of each clone to immobilized 
anti-c-myc antibody (1 μg/mL), peptide ligand (MBP-EE or 14B7-His6 at 4 μg/mL) and 
blocked wells (5% milk) was monitored. Clones with a high ratio of peptide ligand to 
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anti-c-myc signal, indicating high peptide-binding specific activity, were further 
characterized. To rank the relative affinities of these high-activity variants, phage were 
produced from 100 ml cultures and the concentration of phage particles quantified by 
absorbance prior to ELISA analysis. The phage concentration resulting in 50% of the 
maximum ELISA signal (EC50) were compared to select final candidates for expression 
and characterization as soluble scFv protein. 
To confirm conversion of specificity, phage displaying the 3D5/EE_48 or 
commercial anti-His-HRP (Invitrogen) were used to probe a Western blot containing host 
proteins presenting the EE (MBP-EE, scFv-EE), His6 (scFv-His6) or both peptides (scFv-
EE2). Phage displaying 3D5 were not used as divalent display is required, due to low 
affinity His6 recognition [99]. A 15% SDS-PAGE gel was loaded with 10 ul cellular 
lysate from cells expressing ligand, and electrophoresed prior to transfer to PVDF 
membrane. After blocking with 5% non-fat milk in PBS, the blot was incubated with 8 x 
10
10
 virions/ml fresh 3D5/EE_48 scFv displaying phage for 1 hour at room temperature, 
washed three times with HBS-0.05% Tween and incubated with anti-M13-HRP 
secondary antibody (1:5000). Signal was developed with SuperSignal West Extended 
Duration substrate (Pierce), and the resulting image captured on Kodak film. The blot 
was stripped with mild stripping buffer (200 mM glycine pH2.2 with 0.1% w/v SDS and 
1% Tween-20), re-blocked and re-probed with commercial anti-His-HRP (1:5000, 
Invitrogen) to detect His6-containing ligands.  The blot was stripped a second time, 




3.3.4  Chaperone protein expression, purification, and complexation 
The parent 3D5 and scFv genes selected from phage display experiments were 
subcloned into the SfiI-SfiI site of pAK400 for scFv expression [158], or pMoPac54, to 
produce an scAb (an scFv appended with a human kappa constant domain as a 
convenient detection handle [141]).  Protein was secreted into the bacterial periplasm of 
E. coli strain BL21, isolated by osmotic shock and purified by immobilized Ni
2+
 affinity 
chromatography and SEC using a Superdex S75 column (GE Healthcare), as previously 
described [160]. The Superdex S75 column was calibrated using a Low Molecular Mass 
gel filtration calibration kit (GE Healthcare). 
Protein purity and size were characterized by SDS-PAGE under reducing or non-
reducing conditions [161]. Protein solubility was determined by concentrating the protein 
to ~20 mg/mL, incubating for four days at 4°C, centrifuging for 10 min at high speed to 
pellet insoluble particles and quantifying the concentration of protein remaining soluble. 
Stability was assessed as the mid-point for thermal unfolding, using a fluorescence assay 
[162].  Purified protein (20 μl at 280 μg/mL) or buffer blank and Sypro Orange (1 μl of a 
1:1000 dilution; Molecular Probes) were heated in a Real Time PCR instrument (7900HT 
Fast Real-Time PCR System (Applied Biosystems) from 20 – 85°C in increments of 0.5 
°C and analyzed with SDS.2 (Applied Biosciences).  The scFv monomer-to-dimer ratio 
was determined from SEC traces by calculating the area under the curve for each peak 
with Unicorn software (GE Healthcare).  Protein concentration was assessed by micro-
BCA assay with a BSA standard curve and buffer blank (Pierce).  To facilitate direct 
comparisons, all 3D5 and variant characterization values reported here were performed 
with these methods and specific values may differ slightly from those previously reported 
[99]. 
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Complex formation between 3D5/EE_48 and two ligands, scFv-EE3 and MBP-
EE (see above), was assessed by SEC. Equimolar volumes of purified 3D5/EE_48 and 
either scFv-EE3 or MB-PEE (~1 μM each) were combined and allowed to incubate on 
ice for six min followed by separation using an analytical Superdex S75 column (GE 
Healthcare) equilibrated with 10 mM HEPES, 150 mM NaCl, pH 7.4.  Fractions of 
interest were concentrated and characterized by SDS-PAGE. Control experiments applied 
the same quantity of each species alone as used in complexation experiments.  The 
Superdex 75 column was calibrated using a Low Molecular Mass gel filtration calibration 
kit (GE Healthcare) supplemented with cross-linked albumin (Sigma). 
 
3.3.5  Determination of chaperone-peptide binding affinity 
Direct ELISA with purified scFv protein was performed in two orientations: scFv 
as an immobilized capture molecule or scAb detection of immobilized EE-tagged protein.  
For the former, wells were coated overnight at 4°C with 50 μg/mL scFv variant in PBS, 
prior to blocking with 5% milk in PBS. MBP-EE was serially diluted (1:2) from an initial 
concentration of 100 μg/mL, followed by washing and detection with anti-MBP-HRP 
(1:2500).  For the inverse configuration, plates were coated with EE-tagged proteins (4 
μg/mL) followed by 1:2 serial dilutions of scAb protein from 200 μg/mL.  In this case, 
detection was achieved with anti-human-kappa-HRP (1:2500; Sigma) and TMB 
substrate.  To assess the pH sensitivity of the binding interaction, ELISAs were 
performed in which the scFv-ligand interaction proceeds at pHs ranging from 6.0 to 8.0, 
in 0.5 increments.  To rank the relative affinities, the EC50 concentrations were compared. 
Kinetic binding assays were performed with proteins bearing c-terminal His6 or 
EE-tags and internal EE-tags to quantify scFv peptide selectivity using a BIAcore 3000 
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(GE Healthcare).  Peptide-binding scFv or protein ligands were coupled to CM5 chips 
using NHS-EDC chemistry to a level of ~500 RU. The signal from a flow cell coupled 
with a control scFv (14B7-His6 [39]) was used to correct for non-specific binding to the 
matrix, while control scFv injections corrected for changes in sample refractive index.  
Soluble protein ligands were injected in a duplicate dilution series from 8 to 0.1875 μM 
at a flow rate of 50 μl/min to minimize mass transport effects. The association rate 
constant (kon), dissociation rate constant (koff), and equilibrium dissociation constant (Kd; 
Kd = koff/kon) were calculated assuming a Langmuir 1:1 binding model with 
BIAevaluation software. Only data sets with χ
2
 < 0.5 were used. 
 
3.3.6  Protein crystallization  
3D5/EE_48 was crystallized by the sitting drop vapor diffusion method at 4 °C. 
Conditions were optimized based on those reported for 3D5 [99]. 1-2 μL of protein 
solution in HBS buffer at 3.8 mg/mL chilled on ice was mixed with 1 μL sample of 
reservoir solution containing 0.1 M Mes (pH 6.4), 0.1 M magnesium acetate, and 20-24% 
(w/v) PEG 8000.  Crystals of rectangular or triangular shape appeared in four days and 
grew to a maximal size of 40-60 μm within 4 weeks. The largest crystals grew when the 
reservoir to protein ratio was 1:1.33-1.66. 
 
3.3.7  Data collection, structure determination and refinement  
Crystals were harvested at 4°C and cryocooled using a solution consisting of 
85.5% (v/v) reservoir solution and 14.5% (v/v) ethylene glycol. Crystallographic data 
were collected using a wavelength of 1 Å at the GM/CACAT beamline (Darien, IL) 
equipped with a 5 μm mini-beam setup. Data were processed with XDS [163] and Scala 
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[164]. The structure of 3D5/EE_48 was solved by molecular replacement with Molrep 
[164] using a polyalanine search model derived from parent 3D5 asymmetric unit (PDB 
ID 1KTR) from which all non-protein atoms and loop residues were removed. All four 
3D5/EE_48 scFv monomers present in the asymmetric unit were identified from Molrep. 
The atomic model was fit to the respective electron density map using Coot [165], and 
then iteratively refined with Refmac [164]. After several initial rounds of refinement 
using tight non-crystallographic symmetry restraints, refinement including 
Translation/Libration/Screw motions and medium noncrystallographic restraints was 
conducted. Of the 947 residues present in the asymmetric unit, 99.2 % are in most 
favored and additional allowed regions of the Ramachandran plot.  The final model has 
been deposited in the PDB (PDB ID 3NN8). Figures were generated using Pymol (The 
PyMOL Molecular Graphics System, Version 0.99rc6, Schrödinger, LLC).  Electrostatic 
surface potentials were calculated using APBS [166] and visualized using Python 
Molecular Viewer 1.5.4 [167]. Computational peptide docking was conducted with 
ClusPro [168]. 
 
3.4  RESULTS 
3.4.1  Selection of 3D5 variants 
We identified an scFv scaffold to use as a starting point for engineering peptide-
binding chaperones by examining a family of structurally characterized antibody 
fragments binding small molecules (PDB IDs including 1KTR, 1MAJ, 2CJU, 1DLF, 
2UUD, 1DSF, 1WZ1, 1N4X, 2G60) that share a highly conserved variable light chain 
(VL from the murine Vκ1 germline, >90% identity) and, if crystallized, a major crystal 
contact.  One member of this family, the His6-specific 3D5 scFv, had previously been 
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displayed on M13 bacteriophage [100].  We hypothesized that we could enhance and/or 
convert scFv peptide specificity while retaining the favorable crystallization 
characteristics of 3D5 through CDR and random mutagenesis, coupled with a phage 
display selection strategy in which peptide binding affinity, solubility, stability and 
expression level are used as proxy variables for crystallizability.  Similar scaffolding 
approaches have been effective for antibody humanization and thermodynamic 
stabilization [128, 169].  
To increase the versatility of our crystallization chaperones, we sought to identify 
variants with affinity for either the His6 or EE (sequence: EYMPME) hexa-peptides.  The 
chemical diversity of the EE peptide would be expected to enhance binding interactions 
while the inclusion of a proline would limit conformational entropy [170]. In order to 
engineer scFvs with the desired peptide specificity (His6 or EE), three libraries with 
randomized CDRs were generated by methods previously described [159].  Since the 
heavy chain (VH) typically dominates ligand interactions [171], VH CDRs 2 and 3 
(HCDR2 and HCDR3) were randomized to convert peptide specificity while retaining the 
desirable crystallization properties of 3D5.  The three libraries of scFv HCDR variants 
(actual library size ~10
7
 each) were monovalently displayed on the surface of M13 phage 
via fusion to coat protein gpIII, and scFv variants were selected for ligand binding 
specificity using a series of panning cycles. First, full-length scFvs, which present a c-
terminal c-myc epitope, were enriched from prematurely truncated variants resulting 
from oligonucleotideencoded stop codons via immunoprecipitation.  Next, eluted phage 
were amplified in E. coli, and variants with desired peptide specificity selected via phage 
binding to an immobilized host protein presenting either the His6 or EE peptide.  One 
host protein, the 14B7 scFv with a terminal His6 peptide (scFv-His6), was employed for 
selection of hexa-histidine specific variants.  Two ligand proteins were used to select for 
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EE peptide binders: maltose binding protein (MBP) with a single c-terminal EE tag 
(MBP-EE), and another scFv with two internal tandem EE tags to allow for steric 
accessibility within the Gly-Ser linkage between VH and VL immunoglobulin domains 
(scFv-EE2). 
The amplification and selection procedure was repeated twice, using different 
immobilized host proteins during each cycle to ensure selection for peptide, as opposed to 
host protein, specificity.  Next, weakly peptide-reactive phage were pooled and subjected 
to random mutagenesis to yield the libraries, one based on EE-specific scFv. Sequencing 
of 20 individual clones from each library comprising ~10
7
 unique members confirmed 
library diversity and the anticipated ~0.5% mutagenic rate. An additional three rounds of 
phage selection yielded the pool of EE peptide-specific scFv variants. 
After screening several hundred clones by monoclonal phage ELISA followed by 
phage titration ELISA to rank clones by binding affinity, two His6 (denoted 3D5/His_#) 
and six EE-specific (denoted 3D5/EE_#) scFv variants with unique sequences were 
identified (Table 3.1). Of these, two clones, 3D5/His_683 and 3D5/EE_48, provided the 
highest specific binding activity (measured as the ratio of peptide tag/anti-c-myc ELISA 
signal). Western blot analysis provided a clear verification of peptide specificity: 
3D5/EE_48 displayed on phage bound host proteins with either internal or c-terminal EE 
peptides, but not those with only c-terminal His6 peptides (Fig. 3.1a). These scFv variants 
were then expressed and purified as soluble protein (Fig. 3.1b and 3.1c), and 
characterized for binding activity by ELISA and surface plasmon resonance (SPR; Fig. 
3.2a-f) analysis and for enhanced biophysical properties (see below). 
  
 76 
Table 3.1 Comparison of 3D5 scFv CDR H3 regions 
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3D5 Y Y C E S Q S G              A Y W G Q 
3D5/His_68
3 Y Y C A A S S P Y S M R A A M D Y W G Q 
3D5/His_67 Y Y C E R A R     S P R A A M D Y W G Q 
3D5/EE_48 Y Y C A R R G G S S H Y Y A M D Y W G Q 
 
 
Figure 3.1. Analysis of scFvs described in this study.   
(a) Western blot detection of MBP ligands by anti-His6-HRP, 3D5/EE_48 displayed on M13 phage 
and anti-MBP-HRP on the same blot.  Lanes are 1: MBP, 2: MBP-EE, 3: MBP-EE-His6.  
(b) Size and purity by SDS-PAGE.  
(c) Purification by SEC. Molecular weight standards on S200 elute at 8.6 ml (void volume; blue 
dextran 2000); 15.6 ml (75 kDa conalbumin); 16.5 ml (43 kDa ovalbumin); 18.6 ml (29 kDa 









3.4.2  Characterization of 3D5/His variants  
 
The selected variants 3D5/His_67 and 3D5/His_683 differ from each other and 
3D5 in the HCDR2 (3D5/His_67) and HCDR3 (3D5/His_67 and 683).  These variants 
harbor longer CDR3 lengths with several amino acid differences (Table 3.1).  In our 
hands, 3D5/His_683 expressed nearly three-fold better in E. coli than 3D5 (8.5 vs 3.1 
mg/L culture; Table 3.2), exhibits enhanced scFv solubility (estimated as 16.6 versus 2.3 
mg/ml, respectively) and modestly improved affinity (Kd 808 versus 4700 nM).  At 
concentrations relevant to crystallization (~4 mg/ml) 3D5/His_683 elutes from a gel 
filtration column as a mixture of a monomer and dimer (Fig. 3.1c).  In contrast, 
3D5/His_67 expressed at lower levels, but exhibited similar affinity for His6 (Kd 760nM).  
One of two key residues in HCDR3 that stabilize the bound His6 in the 3D5 crystal 
structure, Glu93 or Ser96, is retained in each variant (Table 3.1), yet these variants and 
others we tested all exhibited micromolar affinity for His6 (Kd 3-4 μM).  Thus, even 
though these variants possess rather different HCDR3s than 3D5 and more favorable 
biochemical properties, their affinity for His6 is not substantially improved over that of 
3D5.  These results suggest that the His6 binding site is well-organized for peptide 
binding, or that HCDR3 may contribute fewer productive interactions than expected.  For 
these reasons, plus concerns regarding the utility of His6 as a peptide ligand, these clones 
were not pursued further. 
 
 78 
Table 3.2. Biophysical characteristics of 3D5 scFv variants 
 3D5 3D5/His_683 3D5/EE_48 
Expression level (mg/L culture) 3.1 8.5 2.1 
Solubility (mg/mL) 2.3 16.6 12.8 
Melting temperature (°C)  46.5 ± 0.5 53.6 ± 0.0 47.2 ± 0.3 
% AA identity 100 96.2 85 
% Monomeric protein
a
 50 62 81 
Kd (nM), 14B7-His6 (
2
) 4700 (0.08) 3200 (0.26) ND
b
 






 767 (0.03) 
a
% Monomer measured upon initial purification
  
b
ND = not detected   
 
3.4.3  Characterization of 3D5/EE_48 
The lead 3D5/EE scFv candidate, 3D5/EE_48, retains 85% amino acid identity 
relative to 3D5.  In addition to novel HCDR sequences (Table 3.1), two key amino acid 
changes in the VH framework identified during random mutagenesis (E6Q and S74T) 
were instrumental in improving scFv expression and affinity.  The impact of Glu versus 
Gln at position six has been previously described [172].   
The 3D5/EE_48 scFv displayed no detectable binding affinity for c-terminal His6 
tags and instead is able to bind both c-terminal and internal EE-tags with similar 
affinities, Kd 389 and 212nM, respectively (Figures 3.1a, 3.2c, d, e; Tables 3.2, 3.3). A 
terminal EE tag followed by a His tag was recognized with higher affinity than a naked 
EE tag (Kd 389 versus 767 nM), perhaps to due protease protection and reduced entropy 
with an additional c-terminal extension. Varying the pH in 0.5 increments from 6.0 to 8.0 
or increasing the number of internal EE tag repeats from two to three had no detectable 
effect on affinity as measured by ELISA (data not shown) and SPR (Kd 25-30 nM; Table 
3). An increase in affinity was observed for ligands harboring multiple E repeats versus 
single repeats, likely due to re-binding effects, as the measured on-rates are similar but 
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the off-rates are slower (Table 3.3). Use of 3D5/EE_48 displaying phage as detection 
reagents in ELISA (data not shown) and Western blot (Fig. 3.1a) demonstrated specific 
binding of EE but not His6-tagged ligands. Expression levels of 3D5/EE_48 (2.1 mg/L 
culture) are similar to that observed for 3D5 (3.1 mg/L culture), but the solubility 
increased from 2.3 mg/ml to >12 mg/ml. In addition, 3D5/EE_48 is initially purified as a 
predominantly monomeric species (~80% of total eluted protein; Table 3.2) and retains 
this monomeric state when concentrated up to at least 3 mg/ml (Fig. 3.1c).  This contrasts 
with the lower initial ratio of monomeric to dimeric protein (Table 3.2) and slow 
conversion of purified monomer to dimer observed for 3D5 and 3D5/His_683 under 
similar conditions (Fig. 3.1c).  The melting temperature of 3D5/EE_48, is almost 
identical to 3D5, indicating similar thermal stabilities (Table 3.2).  Overall, 3D5/EE_48 
exhibits similar or enhanced biophysical properties as compared to 3D5 in terms of 
affinity, expression level, solubility, stability, and homogeneity of oligomerization state. 
 
Table 3.3 Characterization of 3D5/EE_48 scFv binding kinetics by SPR 
ligand kon (1/Ms) SD (%) koff (1/s) SD (%) Kd (nM) 
2
 
MBP-EE  1.5E+05 62 7.3 E-02 24 767 0.030 
scFv-EE2 3.9E+05 30 9.0 E-03 34 25.5 0.586 
scFv-EE3 3.6E+05 37 9.2 E-03 41 29.6 0.598 
 
3.4.4  Complexation of 3D5/EE_48 with EE-tagged proteins 
The ability to isolate complexes of 3D5/EE_48 and client proteins expressing the 
EE tag was assessed next using size exclusion chromatography (SEC).  Equimolar 
concentrations (~1 μM) of 3D5/EE_48 and the client protein were combined and 
fractionated using an analytical gel filtration column.  Fractions corresponding to the 
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eluted peaks were analyzed by SDS-PAGE and compared to control runs with isolated 
binding partners.  One client protein, scFv-EE3 used originally for selections (see above), 
elutes as a dimer, and runs slightly higher than its expected molecular mass by 
SDSPAGE, likely due to an extended conformation of the individual VH and VL domains 
within the monomer (Fig. 3.3a).  Complexation with 3D5/EE_48 results in a single 
elution peak that corresponds to a molecular mass consistent with a heterotetramer, i.e., 
an scFv-EE3 dimer with two bound 3D5/EE_48 monomers (Fig. 3.3a).  The second client 
protein tested was MBP-EE, which harbors only a c-terminal EE tag. Although MBP-EE 
by itself elutes as a monomer, complexation with 3D5/EE_48 yields two higher 
molecular weight complexes with molecular masses consistent with a heterodimer and 
heterotetramer (Fig. 3.3b).  Given the lack of dimerization precedent for MBP, the 
heterotetramer could arise from a domain swapped 3D5/EE_48 dimer in which two 
distinct binding sites for MBP-EE are presented.  Domain swapping has been proposed as 
a mode for 3D5 dimerization [99]. 
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Figure 3.2  Isolation of 3D5/EE_48 complexes with EE-tagged client proteins by Size 
Exclusion Chromatography (SEC).  
(a) 3D5/EE_48 incubated with scFv-EE3. Elution peak 1 corresponds closely to the 
expected retention volume of a heterodimer complex as described in text.  
(b) 3D5/EE_48 incubated with MBP-EE. Elution peaks 1, 2 correspond to heterotetramer 
and heterodimer complexes as described in text.  
For (a) and (b), SDS-PAGE analysis of elution peaks confirms protein and complex 
identities. In addition, individual elution profiles are overlayed. Red: scFv-EE3 or 
MBP-EE. Blue: 3D5/EE_48. Molecular weight standards elute on S75 at 7.4 ml (void 
volume; dextran 2000); 8.9 ml (132 kDa albumin dimer); 9.6 ml (75 kDa 




Figure. 3.3  Peptide-scFv binding kinetics.  
Top row, analysis of 3D5 and 3D5/His_683 binding affinity and specificity His6 by 
SPR. Binding partners were injected in duplicate in concentrations ranging from 
8000 to 125 nM.  
(a) 3D5 scFv recognition of immobilized scFv-His6 ligand;  
(b) binding of scFv-His6 ligand to immobilized 3D5/His_683;  
(c), 3D5 recognition of control MBP-EE ligand. Bottom row, analysis of 3D5/EE_48 
affinity and specificity for EE-tagged proteins by SPR. Binding of  
(d), a single, internal EE peptide presented by scFv-EE1,  
(e), a control scFv lacking an EE tag, scFv-His6 (buffer spikes erased for clarity); and  
(f), a c-terminal tag presented by MBP-EE-His6 to immobilized 3D5/EE_48 scFv 
ligands. Ligands were injected at concentrations ranging from 6000-475 nM for 
MBP-EE, 2000-125 nM for the scFv ligands.  Cartoons illustrate the orientations 
and identity of binding partners. 
 
3.4.5  Structure of 3D5/EE_48 
Crystals of 3D5/EE_48, grown under conditions used to crystallize 3D5 [99], 
appeared within four days and continued to grow over several weeks. The structure of 
3D5/EE_48 was solved by molecular replacement using a search model derived from the 
3D5 coordinates (see Methods, Table 3.4). Although the crystals were grown under 
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similar conditions, and the proteins share a high level of sequence identity, the two scFvs 
do not crystallize in the same manner (Fig. 3.4). First, whereas 3D5 crystals belong to a 
trigonal space group (P3221), crystals of 3D5/EE_48 belong to a cubic space group (F23). 
The asymmetric unit of 3D5/EE_48 contains four molecules whereas 3D5 contains one 
VH-VL pair (Fig. 3.4a). In addition, in spite of the fact that no amino acid changes 
occurred in the major 3D5 crystal contact, the contact is not preserved in the 3D5/EE_48 
lattice. Whereas the crystal lattice of 3D5 is built by alternating VH/VL subunits from 
neighboring molecules, that of 3D5/EE_48 relies primarily on HCDR residues from 
adjacent molecules (see arrows, Fig 3.4b). The second largest contact in the 3D5 crystal 
lattice (305 Å
2
) has become the largest crystal contact (560 Å
2
) in the 3D5/EE_48 lattice 
with several additional hydrogen bonds formed at this interface (see shaded area, Fig. 
3.4b). Finally, as a consequence of lattice changes, 3D5/EE_48 crystals consist of 66% 
solvent with a channel ~52 Å wide while 3D5 crystals consist of 77% solvent and a 




Figure 3.4 Comparison of 3D5/EE_48 (top) and 3D5 (bottom) crystal lattices.  
(a) Asymmetric units.  
(b) Crystal contacts. The preserved contact common to both lattice networks shaded grey. 
New crystal contact comparison depicted in arrows and labeled.  
(c) Lattice structure with size of central cavity indicated. For both structures, lighter hue 
indicates the VL chain while the darker hue indicates VH. CDRs for 3D5/EE_48 are 
depicted in red and those for 3D5 are yellow. 
 
The overall structure of the 3D5/EE_48 scFv remains very similar to that of the 
parent 3D5 (average rmsd ~0.55 Å for main chain atoms in VL and ~1 Å for VH 
domains); however, changes observed in the CDR regions reconfigure the peptide 
binding region to accommodate an EE-tag (Fig. 3.5). In the VL CDR1 loop (LCDR1) of 
3D5/EE_48, slight movement in residues His27d-Asn30 may be influenced by the 
presence of neighboring Leu93 in the VL CDR3 loop (LCDR3), instead of the 
corresponding His residue at this position in 3D5 (Fig. 3.5a). Another substitution in 
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LCDR3 of 3D5/EE_48, introduction of a Pro96 for the Phe in this position in 3D5, 
appears to open up the peptide binding groove to accommodate longer peptides, and in 
particular, may allow internal peptides to be recognized (Fig. 3.5a). Compared to the 
LCDRs, HCDRs are more divergent both in sequence and in structure. In 3D5/EE_48, the 
beta-hairpin in HCDR2 as a whole shifts closer to HCDR1. HCDR3 differs primarily in 
its longer length, which significantly alters the shape of the peptide binding region when 
compared to 3D5. The binding surface near the interface of the heavy and light chains 
forms a pronounced tri-lobed hydrophobic pocket (Fig. 3.5b and 3.5c). The electrostatic 
surface potential reflects a charge distribution complementary to that of the peptide in 
this region (Fig 3.5b). 
 
Table 3.4  Data collection and refinement statistics 
 3D5/EE_48 
Data collection  
Space group F23 
Cell dimensions  
    a=b=c (Å) 266.64 
    α=β= ()  90 
Resolution (Å)
*
 154.3-3.1 (3.18-3.10) 
Rsym  12.4 (34.2) 
I/ I  5.6 (2.1) 
Completeness (%) 99.6 (99.6) 
Redundancy 5.6 
Refinement  
Resolution (Å) 154.3-3.1 




No. molecules  




R.m.s deviations  
    Bond lengths (Å) 0.016 
    Bond angles () 1.871 
a
  Highest resolution shell is shown in parenthesis. 5% of reflections were selected for Rfree. 
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We turned to computational docking to model EE-peptide binding to 3D5/EE_48 
(Fig. 3.5c) because no crystals of adequate size for structure determination containing 
both 3D5/EE_48 and EE-peptide have been grown to date, and soaking with the 
commercial EE-peptide (Covance) has not yielded crystals with bound peptide. The EE 
peptide is predicted to bind in an orientation in which the central proline (Pro4) 
introduces a kink, allowing peptide residues Tyr2 and Met3, to reach into the 
hydrophobic binding pocket. In this working model, VH residue His50 appears to 
stabilize peptide Tyr2 through hydrophobic interactions, while VH residue Arg95 forms 
key polar interactions with multiple peptide side chains (Tyr2, Met3, Glu6). Peptide 
residues Glu1 and Glu6 stabilize this binding mode through surface electrostatic 
interactions, and hydrogen bonding interactions between the peptide backbone amide and 
carbonyl stabilize the peptide conformation.  In the case of a terminal EE tag, the C-
terminus may compete for the Glu6 side chain interactions, and/or more flexibility of the 
tag may destabilize the peptide backbone interactions. In this docked model, peptide 
residue Met5 does not appear to be directly recognized by 3D5/EE_48.  Notably, VL 
residues predicted to form interactions with peptide are conserved between 3D5 and 
3D5/EE_48, while VH residues contributing to peptide interactions, such as Arg95, were 





Figure 3.5  Analysis of 3D5/EE_48 structure.  
(a) Superimposition of 3D5/EE_48 and 3D5 with CDRs labeled. Amino acid changes 
discussed in the text are represented as ball-and-stick. LCDR1, LCDR2, LCDR3 
indicate VL CDR loops 1, 2, and 3 respectively. HCDR1, HCDR2, HCDR3 indicate 
VH CDR loops 1, 2, 3, respectively.  
(b) Calculated electrostatic surface potential of the binding site (-15 kT to +15 kT).  
(c) Modeled peptide binding interaction of EE peptide with 3D5/EE_48. Color scheme 
identical to Fig. 3. 
 
3.5  DISCUSSION 
Crystallization chaperones are proposed to aid co-crystallization by several 
distinct mechanisms, including immobilizing flexible regions, concealing exposed 
hydrophobic regions, and providing polar surfaces capable of forming lattice contacts 
[79, 86].  To date, most co-crystal structures have employed antibody fragments because 
the molecular requirements for ligand binding are well understood and their 
hypervariable regions can be modified to recognize nearly any epitope of interest [159, 
173]. 
Typically, antibodies that recognize specific epitopes on unmodified target 
proteins are identified through traditional hybridoma screening or library selection 
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techniques [91, 98, 174, 175] where there is minimal control over the epitope recognized.  
Moreover, the identification and optimization of a chaperone tailored to each client 
protein of interest is an expensive and time-consuming process.  An attractive alternative 
is the use of commercially available purified monoclonal antibodies for common 
epitopes, such as commercially available anti-His antibodies.  Unfortunately, the 
hybridomas secreting these antibodies are not available and the cost to purchase purified 
antibody sufficient for use in crystallization trials is prohibitive.  Moreover, without the 
gene sequence available, the biophysical properties and format of the antibody (e.g., 
scFv, scAb, Fab) cannot be readily altered.  Finally, even in the case where sequences are 
known and genes for the corresponding antibody fragments can be synthesized for 
recombinant expression, antibody fragments often express with relatively low yield in E. 
coli and lack suitable solubility and stability profiles. 
The engineered scFv chaperone approach complements non-antibody formats that 
have been developed to allow modular recognition of a specific binding partner (e.g., 
DARPin, VHH) [80, 85, 91, 92].  Whereas these alternative frameworks express in very 
high levels (up to 200 mg/L in the bacterial cytoplasm for DARPins) and possess a stable 
structure, a potential disadvantage is their small size ~15 kDa, which limits the 
hydrophilic surface area available for generating protein-protein crystal contacts.  By 
contrast, scFvs are nearly twice as large, and can be readily converted to a ~50 kDa Fab 
format to accommodate larger client proteins with a larger hydrophobic surface area. 
Our engineered scFv chaperones, derived from the previously crystallized 3D5 
scFv framework and binding short His6 or EE peptide sequences, overcome several of the 
aforementioned limitations of antibody fragments and represent a potentially 
generalizable solution to the production of high affinity protein complexes for 
crystallization of difficult proteins.  We overcame the affinity, pH sensitivity and 
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solubility limitations specific to 3D5 by employing a two-step protein engineering 
process of randomizing the HCDR 2 and 3, followed by random mutagenesis of the 
selected scFvs.  This selection scheme does not directly select for the ability to 
crystallize, as there is no clear biophysical correlate of crystallization propensity, but can 
select for “well-behaved” proteins, as evidenced by the increased expression levels, 
solubility and peptide binding affinity of our characterized variants.  The initial library 
design focused on the HCDRs because these can be sufficient to confer high affinity and 
specificity [104, 176] and in the 3D5 family of antibody fragments, the VL domains are 
highly conserved. 
After limited success in improving the biochemical characteristics of His6-
specific scFvs, we converted 3D5 to EE epitope specificity. The 3D5/EE_48 scFv is 
expressed in high yield in E. coli, is highly soluble, is predominantly monomer, and is 
readily crystallized. The affinity of 3D5/EE_48 for internal EE-tags (Kd 212 for single, 
26nM for multiple peptide insertions) likely reflects the combined effects of restricted 
conformational variability due to the presence of a proline in the EE-peptide, as well as 
the ability of the remaining peptide residues to participate in hydrogen bonding, 
electrostatic or hydrophobic interactions. Combined with the general reduced entropic 
costs of binding an internal peptide this scenario represents a desirable binding 
configuration for crystallization chaperone and tagged client protein. Indeed, complexes 
of 3D5/EE_48 with host proteins are sufficiently tight to withstand separation by SEC.  
In the context of a co-crystallization experiment, a modest 5 mg/ml concentration of a 30 
kDa scFv chaperone protein equates to 170 μM, which is nearly 1000-fold above the 
measured equilibrium dissociation constant and will drive complex formation within the 
crystallization drop.   
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3.6  CONCLUSION 
Unexpectedly, the crystal lattice of 3D5, whose open framework and limited use 
of CDRs in crystal contacts was an initial design criterion, was not preserved in 
3D5/EE_48. Although the use of CDR residues in crystal contacts appears to render 
3D5/EE_48 not ideal for cocrystallization, none of the residues participating in the major 
crystal contact of 3D5 have in fact been altered.  Thus, it should be possible for 
3D5/EE_48 to revert back the 3D5 lattice framework when most CDR residues are 
participating in a complex and CDR-based crystal contacts are no longer accessible.  We 
are optimistic about the prospect of the ability 3D5/EE_48 to promote crystallization of 
“difficult” proteins, either by mediating formation of crystal contacts (as observed for 
KcsA [86]) or by immobilizing flexible loops (as observed for GPCRs [94, 153]). Our 
current efforts are focused on further engineering of 3D5/EE_48 to render the CDR 
crystal contact less favorable than those found in 3D5. We are also cocrystallizing 
3D5/EE_48 with MBP and candidate membrane proteins in which the EE peptide has 
been installed into an accessible but functionally silent location. In the long term, we plan 
to extend our approach to generate 3D5-based scFvs or Fabs that recognize other peptide 
sequences, leading to a toolbox of peptide binding crystallization chaperones with 
homotypic crystal contacts that could be used to crystallize any protein of interest. 
 
Accession numbers 
The coordinates of the 3D5/EE_48 structure are deposited in the Protein Data Bank under 
PDB ID 3NN8. 
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CHAPTER FOUR:  Optimization of Peptide Placement in Target 
Proteins for chaperone assisted crystallization. 
 
4.1  CHAPTER SUMMARY 
An innovative and potentially general approach to crystallization of membrane 
and other hard-to-crystallize proteins employs complex formation between a protein of 
interest harboring a short, surface exposed peptide and hyper-crystallizable antibody 
fragments with peptide specificity.  The antibody provides additional hydrophilic surface 
regions to mediate formation of crystal contacts and facilitate crystal growth. Once 
developed, the crystal chaperone can be used without further modification to co-
crystallize multiple proteins with efforts primarily focused on peptide insertion.  In order 
to minimize the subsequent optimization of each construct, we aim here to develop 
general design rules for peptide insertion into target proteins in three locations: (1) 
terminal, (2) inter-domain linkers and (3) internal loops. The EE peptide was introduced 
into three model proteins at these sites to identify constructs meeting the dual goals of 
rigid complex formation and high affinity antibody binding.  Constructs utilizing peptide 
insertion at the c-terminal region are preferred for proteins with no structural information, 
however, a protective tail is required to reduce conformational entropy.  For proteins with 
some structural information, single EE peptide insertion is favored at the start of the 
interdomain linker with four flanking residues preceding the tag resulting in higher 
affinity (KD~200nM) and minimal impact to the structural stability of the target protein.  
Peptide insertion into linker regions connecting two domains conferred higher affinity 
than at protein termini (26 vs. 389 nM).  When the EE peptide was introduced into a 
natural internal loop of maltose binding protein, however the affinity was reduced, even 
when flexible adapters were added to either side of the peptide (KD = 800-1000 vs. 389 
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for terminal peptide). These engineered variants provide us with better guidelines for 
peptide insertion, transferable across multiple target proteins of interest, to facilitate rapid 
construction of clones to assess in complex crystallization trials.   
  
4.2  INTRODUCTION  
4.2.1  The importance of chaperone-assisted crystallization 
Crystallization remains the bottleneck to obtaining structural visualization of 
protein using X-ray Diffraction.  X-ray crystallography is the major technique used to 
establish the three-dimensional structure of large target protein (>30kDa).  The atomic 
resolution image reveals protein mechanism and clarifies the role of protein structure in 
health and disease, resulting in organized and systematic approaches to drug design.  
Currently one successful technique for acquiring high resolution membrane protein 
structure visualization involves co-crystallization with a protein-specific chaperone for 
X-ray diffraction.  Developments in this field have led to chaperone options for co-
crystallization, which include, but are not limited to, fusion proteins like MBP and 
Lysozyme [61, 177], affibodies [90], VHH Camelid Domains [85], designed ankyrin 
repeat proteins (DARPins) [91, 92], in addition to the most popular chaperone - antibody 
fragments [86, 88, 89].   Fabs (fragment antigen binding) and the Fvs (fragment variable) 
are the most successful co-crystallization chaperones to date, having successfully 
crystallized many membrane proteins including, KcsA potassium channel [98, 178], 
Cytochrome c oxidase (COX) [79], cytochrom bc1 complex (QCR) [152], and Na+ -
citrate cymporter CitS [91] just to name a few.  The recent breakthrough of the structural 
determination G-protein coupled receptor with parallel crystallization utilizing two 
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different chaperones: a targeted Fab and a T4 Lysozyme inserted into a flexible loop, 
demonstrates the vital role co-crystallization plays in proteonomics [61, 93].   
Membrane proteins are extremely difficult to crystallize as a result of their 
conformational complexity.  The relatively small polar surfaces available for crystal 
contact formation in addition to flexible intracellular loop regions and extended c-
terminus interfere with homogenous lattice formation.  Long linkers are particularly 
detrimental to crystallization [154], so it is critical that these areas are removed or 
restricted to produce high diffraction quality crystals.  The primary role of a co-
crystallizing chaperone is creating a stable complex to facilitate ordered packing.  The 
chaperones provide improved crystallization properties for the complex by i) protecting 
the hydrophobic regions of the membrane protein – preventing numerous protein-protein 
interactions (i.e. more homogenous monomeric solution) ii) “locking down” flexible 
regions, minimizing conformational entropy  and ii) providing additional polar surfaces 
for crystal contact formation (i.e better probability for ordered crystals) [7, 80, 85].  The 
mediated crystal contacts allow target proteins to remain suspended within the resulting 
lattice scaffold [79, 86].  In addition to facilitating crystallization, the chaperones provide 
an additional benefit by assisting with the crystallographic phase and diffraction data 
analysis since the three-dimensional molecular structure of these helpers is usually 
predetermined.  Key characteristics of a successful chaperone involve the ability to bind 
with high affinity to the native conformation of the target protein, in addition to forming a 
stable and rigid complex.   
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4.2.2  Utility of a generic chaperone: The development of peptide-specific 
chaperones  
With more urgency being placed on obtaining structural analysis of membrane 
proteins, it is critical to create a rapid, efficient and general system for co-crystallization.  
The current technology in co-crystallization utilizes protein-specific chaperones that bind 
random epitopes of the target protein [90, 179].  Recombinant in vitro antibody 
technology has provided tools that have improved the speed in generating binders 
specific for target proteins, which involves proteolysis of monoclonal antibodies [91].  
This technology facilitates the selection of a chaperone, identification and optimization of 
a chaperone tailored to a particular protein by efficiently generating numerous individual 
libraries.  Even with the successful selection of the antibody chaperone with favorable 
biophysical characteristics, the crystallization conditions of these chaperones are 
unknown and can result in thousands of screens that are expensive and time-consuming 
process [91, 174].   
To bypass some of the challenges associated with current protein specific 
chaperones, a hyper-crystallizable peptide-specific antibody chaperone is in development.   
This platform allows us to easily insert our peptide into functionally silent regions of the 
target protein and complex the engineered antibody fragments with high affinity to short 
peptide epitopes and hyper-crystallization qualities for assisted crystallization.   Using 
this process, we eliminate the need to screen large libraries using traditional hybridoma 
screening of library selection techniques as this peptide specific antibody becomes a 
universal chaperone.  Control over epitope recognition is also better established as can 
define the peptide insertion location and are no longer restricted by the outputs of the 
libraries.  The system also reduces the extent of crystallization condition screening 
required by providing a starting crystallization condition based on the non-complexed 
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chaperone‟s crystallization characteristics.  A hyper-crystallizable single chain fragment 
variable (scFv) antibody has been successfully engineered with high affinity for the EE 
tag (EYMPME) [chapter three].  This antibody has shown potential as a co-crystallization 
chaperone with high peptide affinity and a lattice structure that contains central cavities.  
While high affinity has been established (26nM) it has not yet been determined if the 
location of the peptide is optimal for co-crystallization.   Here we explore the insertion of 
various peptide tags at a myriad of locations, with strong focus on the optimization of the 
EE tag, to establish the optimal region for use in co-crystallization.  Additional tags 
included in our studies are the Hexa-histidine (His6) tag, commonly used in purification 
methods, and a substitute Flag tag (MDYKAFDNL), that had 10-fold higher affinity to 
the M2 antibody than the original Flag tag (DYKDDDDK) [180]. 
 
4.2.3  Importance of  peptide optimization 
Ligand engineering plays a critical role in our approach to a general platform for a 
peptide-specific co-crystallization chaperone.  The limiting factor to this technology is 
generating a functional target construct with a presentable peptide tag.  The 
crystallization of the GPCR β2-Adrenergic receptor shows the laborious effort involved 
with properly inserting a T4 Lysozyme into a flexible intracellular loop with minimal 
impact on structure [93, 94].  In order to reduce the effort involved and facilitate the 
process, peptide placement rules need to be defined.  Before optimizing location, 
interaction of the chaperone and the peptide must be well characterized to ensure correct 
conformation for peptide presentation.  The sequence of the peptide not only affects the 
conformational structure of the tag but use of select charged residues with tendency for h-
bonding and electrostatic interactions can improve the affinity.  As previously discussed, 
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the peptide tags in this paper were selected based on its propensity for h-bonding 
(tyrosyine) [104], electrostatic interactions (glutamates, aspartates, lysines) [87] and 
restricted conformation (proline).  These key residues will provide high affinity binding 
complexes needed for successful co-crystallization.   
Peptide location whether at the terminal ends or at internal regions of the protein 
can impact the accessibility and rigidity of the peptide.  Select peptide tags are only 
accessible for interaction at the c-terminal ends [99, 100].  It is therefore important to find 
a ligand with the ability to produce recognition and high affinity in both types of 
locations.  The amount of rigidity contributed by the peptide will play a critical role 
during the formation of homogeneous complex for co-crystallization.  The application of 
this system is widespread and can be extended to other applications including protein 
scaffolds for enzyme assemblies [181], however determining optimal locations in soluble 
regions remote from the active site of the target protein without crystal structures will be 
the major obstacle.    Selecting these regions has always been a major obstacle in protein 
crystallization.  Current crystallization techniques that reduce the conformational entropy 
by removing flexible loops without structural information have started to address these 
challenges.  Previously this has been done with the assistance of surface topology 
experiments, such as Fluorescence resonance energy transfer (FRET) [182] and analysis 
of other proteins in the same protein class [61].   
Utilizing select model proteins (maltose binding protein, scFv, TCRs and a select 
membrane protein-signal peptidase), extensive peptide insertions will be introduced at 
various locations.  Observations involving engineered ligands harboring the cognate 
peptide will provide design rules for peptide insertion in our platform technology.  
Through analysis of interaction kinetics, isolated complexes and co-crystallization trials 
will offer guidelines for effective peptide placement that will provide high affinity and 
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accessibility while retaining functionality and conformational rigidity to provide 
homogeneous complexes for crystallization.   
 
4.3  MATERIAL AND METHODS 
4.3.1  Molecular biology of peptide-presenting proteins  
Peptide sequences were incorporated into target proteins via site-directed 
mutagenesis with mutagenic oligonucleotides (Integrated DNA Technologies). To 
generate ligands with c-terminal peptide tags, maltose binding protein (MBP) was 
amplified from the E. coli genome, appended with either an EE (EYMPME) or 10X 
FLAG tag (MDYKAFDNL) and cloned into the pAK400 vector via SfiI-SfiI sites, 
upstream of a His6 tag [158].  A stop codon was inserted before the vector encoded His6 
tag to generate an MBP-EE ligand without a His6 tag.  To generate ligands with internal 
EE tags, three model proteins were used, MBP, two-domain antibody (scFv) and two-
domain T-Cell Receptor (TCR).  To mimic peptide insertion into an internal loop, the EE 
sequence replaced a naturally occurring loop in MBP between amino acids 171 – 176 
with sequence KYENGKY. Three variants were created to assess requirements for 
flexibility and accessibility. The entire seven amino acid loop sequence was removed and 
replaced with EE tag in different conformations (Table 4.1).  To mimic peptide insertion 
into natural linker regions present in multi-domain proteins, tandem repeats of the EE 
coding sequence were inserted into the flexible linker connecting the two domains of the 
DO11.10 TCR gene (DO11-v1,v2), 14B7 scFv gene[39] (R30A-EE2) or a non-native scFv 
consisting of the 3D5 light chain and 14B7 heavy chain (62-EE3). DO11-e3 was 
engineered with the full original EE peptide (SREEEEYMPME) [106].  The number of 
internal EE repeats was varied from single to triplet repeats to account for steric 
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accessibility (Table 4.2).  All engineered proteins were cloned into pak400 and, unless 
specified, contain a c-terminal, vector encoded His6 tag to facilitate purification.  For the 
MBPs with internalized EE tags, an additional c-terminal 10X FLAG tag 
(MDYKAFDNL) was appended prior to the vector encoded His6 tag.  Three hexa-
histidine tagged ligands were employed: unmodified 14B7 scFv, DO11 TCR and MBP 
each with a c-terminal His6 tag.   
 
Table 4.1 Peptide Insertion in the Interloop of Maltose Binding Protein (171-176)  
EE-tagged protein Sequence starting at 171 in Maltose Binding Protein 
MBP-v1 GGSEYMPMEGGS 
MBP-v2 EYMPMEY 
MBP-v3 KEYMPME  
 





Sequence immediately following the first domain and 
prior to the Glycine Linker [G4S]4 
DO11-e3 TCR SREEEEYMPME 
DO11-v1 TCR GSGSEYMPME 
DO11-v2 TCR GSGSEYMPMEGGGGSEYMPME 
R30A-EE scFv EYMPME 
R30A-EE2 scFv EYMPMEGGGGTKLELKREYMPME  
62-EE3 scFv EYMPMEGGGGTKLELKREYMPMEGGGGTEYMPME  
 
4.3.2  Expression and purification of peptide-presenting proteins 
All ligand proteins were expressed in E. coli strain BL21 in 250 ml cultures of TB 
media, induced with 1 mM IPTG for 5 hours before cell harvesting and periplasmic 
fractionation via osmotic shock as previously described[160].  Recombinant peptide 
tagged proteins were purified via immobilized Ni
2+
 affinity chromatography followed 
immediately by Size Exclusion Chromatography (SEC) on a Superdex 75 column in 
HEPES-buffered saline (HBS; 10 mM HEPES, 150 mM NaCl, pH 7.4). The MBP-based 
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ligand lacking a His6 tag was purified via amylose affinity column and eluted with 
maltose-containing buffer (200 mM HEPES, 150 mM NaCl, 10 mM maltose, pH 7.4). 
The model membrane proteins, signal peptide peptidase (SPP) and a SPP variant with an 
internalized EE tag, with its running buffer were a gift of Dr. Raquel Lieberman (School 
of Chemistry and Biochemistry and Institute for Bioscience and Bioengineering, Georgia 
Institute of Technology).   
 
4.3.3 Expression and purification of the chaperone protein 
Chaperone 3D5/EE_48 was cloned into plasmid pAK400 for scFv expression 
[158], or pMoPac54, to produce a scAb format (an scFv appended with a human kappa 
constant domain as a convenient detection handle [141]).  Protein was expressed, isolated 
and purified by immobilized Ni
2+
 affinity chromatography and SEC using a Superdex 
S75 column (GE Healthcare), as previously described [160].  The Superdex 75 column 
was calibrated using a Low Molecular Mass gel filtration calibration kit (GE Healthcare).  
Commercial M2 IgG (Sigma-Aldrich), Glu-glu Monoclonal IgG (Covance) antibodies 
were utilized for a control chaperone to the flag and EE peptide tags.   
 
4.3.4  Protein biophysical characterization  
A 12% SDS-PAGE (under reducing or non-reducing conditions) was used to 
characterize protein purity and size [161].  Protein solubility was determined by 
quantifying the concentration of protein in solution post-concentration to ~20 mg/mL, 
incubation (four days at 4°C), with centrifugation (10 min, 13Krpm) to pellet insoluble 
particles. Stability was assessed by quantifying the mid-point of thermal unfolding, using 
a fluorescence assay [162].  Purified protein (20 μl at 280 μg/mL) or buffer blank and 
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Sypro Orange (1 μl of a 1:1000 dilution; Molecular Probes) were heated in a Real Time 
PCR instrument (7900HT Fast Real-Time PCR System (Applied Biosystems) from 20 – 
85°C in increments of 0.5°C and analyzed with SDS.2 (Applied Biosciences).  The 
protein monomer-to-dimer ratio was determined by calculating the area under the SEC 
trace curve for each peak with Unicorn software (GE Healthcare). BCA assay with a 
BSA standard curve and buffer blank (Pierce) was used to assess protein concentrations.  
 
4.3.5  Determination of chaperone-peptide binding affinity, kinetic analysis and 
complexation. 
Direct ELISA with the chaperone scFv was performed using two different 
systems: purified scFv as an immobilized capture molecule or scFv presenting phage with 
immobilized EE-tagged protein. For the former, wells were coated overnight at 4°C with 
50 μg/mL 3D5/EE_48 scFv in PBS, prior to blocking with 5% milk in PBS.  MBP EE-
tagged proteins were serially diluted (1:2) from an initial concentration of 200 μg/mL, 
followed by washing and detection with anti- MBP-HRP (1:2500). For the inverse 
configuration, plates were coated with EE-tagged proteins (10 μg/mL) followed by 1:3 
serial dilutions of purified phage at a concentration of 10
12
 pfu/ml.  Phage expression and 
purification was carried out following previous described methods (Chapter 3).  After 
washing with PBS-0.05% Tween, bound phage were detected by anti-M13-HRP (1:2500, 
GE Healthcare) with tetramethylbenzidine (TMB, Sigma) substrate and the resulting 
absorbance at 450 nm recorded.  Relative affinities were then ranked by comparing the 
concentration of EC50.  
Kinetic binding assays were performed with proteins displaying c-terminal His6,  
EE or Flag-tags and internal EE-tags to quantify peptide accessibility and affinity using a 
BIAcore 3000 (GE Healthcare).  Primarily two systems were used:  first the chaperone 
 101 
scFv (3D5/EE_48) was coupled to the chip with ligands flow through, the second coupled 
the MBP with all three tags displayed (internalized EE, sequential c-terminal Flag-His6 
tag.  All proteins were coupled to the CM5 chip using NHS-EDC chemistry to a level of 
~500 RU.  For the first system, the signal from a flow cell coupled with a control scFv 
(14B7-His6 43) was used to correct for responses due to changes in sample refractive 
index while the second utilized a control MBP (no peptide tags). Soluble flow through 
proteins were injected (one minute with a 5 min dissociation) with running buffer (HBS; 
10 mM HEPES, 150 mM NaCl, pH 7.4) in a duplicate dilution series from 3 to 0.1875 
μM at a flow rate of 50 μl/min to minimize mass transport effects.  Surface regeneration 
was performed with a one minute injection of 2M MgCl2.  The association rate constant 
(kon), dissociation rate constant (koff), and equilibrium dissociation constant (Kd; Kd = 
koff/kon) were calculated assuming a Langmuir 1:1 binding model with BIAevaluation 
software (GE Healthcare, Uppsala, Sweden). Only data sets with 
2
 < 0.5, were used.  
During flow through with SPP membrane protein a separate running buffer (50 mM 
Hepes, 150 mM NaCl, 0.1 % detergent, pH 7.5) was used.   
Complex formation between 3D5/EE_48 and three ligands, scFv-EE3, MBP-EE 
and SPP-EE, was assessed by SEC as discussed in Chapter 3.  Equimolar volumes of 
purified 3D5/EE_48 and the peptide-tagged protein were combined and allowed to 
incubate on ice for six min followed by separation using an analytical Superdex 75 gl 
column (GE Healthcare) equilibrated with 10 mM HEPES, 150 mM NaCl, pH 7.4. 
Fractions of interest were concentrated and characterized by SDS-PAGE. Control 
experiments applied the same quantity of each species alone as used in complexation 
experiments. The Superdex 75 gf column was calibrated using a Low Molecular Mass gel 
filtration calibration kit (GE Healthcare) supplemented with cross-linked albumin 
(Sigma).  Wildtype SPP was combined with purified 3D5/48 scFv at a ratio of about 2:1 
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and were allowed to incubate on ice.  Equimolar volumes of purified 3D5/EE_48 and 
SPP-EE with just a slight excess of EE-SPP were combined and allowed to incubate on 
ice before separation using the analyIn followed by separation using an analytical S300 
column.  Calibration of the column was performed as in Chapter 3.   
 
4.3.6  Protein co-crystallization 
3D5/EE_48 complexed with peptide-tagged  proteins were crystallized by the 
sitting drop vapor diffusion method at 4 °C. Conditions were optimized based on those 
reported for 3D5/EE_48 [chapter three]. 1-2 μL of protein solution in HBS buffer at 3.8 
mg/mL chilled on ice was mixed with 1 μL sample of reservoir solution containing 0.1 M 
Mes (pH 6.4), 0.1 M magnesium acetate, and 20-24% (w/v) PEG 8000.  
 
4.4  RESULTS & DISCUSSION 
4.4.1  Analysis of peptide insertion at the C-terminus  
The C-terminus and N-terminus are preferred locations for peptide tag insertion 
when no structural information is available for the target protein.  Placing the short 
sequence at either the front end or tail end of the target protein involves less risk of 
destroying the structural integrity or functionality and requires no structural information.  
Only one terminal peptide insertion was selected for further in depth analysis because it 
was assumed the presentation of the tag at either end of the protein would display similar 
characteristics.  The C-terminal location was chosen because the vectors were already 
designed to incorporate the short sequences in this region.  In the prior chapter, we 
discussed the successful kinetic analysis of 3D5/EE_48 for the MBP with a single EE 
peptide presented at the c-terminal region resulting in a ~767nM affinity.  The same 
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affinity experiment involving a MBP with a sequential c-terminal EE-His6 tag (MBP-EE-
His6), upon expression, purification and immediate kinetic analysis, showed an improved 
affinity of 389 nM (χ
2
 =0.028).   The two-fold increase in affinity observed with the 
protective His6 tag on the MBP-EE-his may be the result of the peptide‟s reduced 
conformational entropy or extended immunity of the peptide tag to random cleavage.  
Studies with this protein following a week at 4
o
C incubation, MBP-EE-His6 showed no 
affinity for anti-his variants on the Biacore.  After a fourth month incubation at 4
o
C, 
complete loss of the EE peptide was observed with direct ELISA.  This rapid loss of the 
His6 tag, followed by the subsequent loss of the EE tag (389 nM to 767nM) indicates this 
tag‟s propensity to cleavage.  Therefore protective measures (including a flanking amino 
acid sequence) must be taken if this location is selected for peptide insertion.  The 
retained affinity of the EE tag suggests that the His6 tag serves a protective role, 
prolonging the length of time before c-terminal EE-tag cleavage.  Kinetic studies with a 
sequential c-terminal 10XFlag-His6 tag showed similar cleavage of the His6 peptide and 
retention of the inner 10XFlag peptide (data not shown).  In addition to protecting from 
random protease clipping, the displacement of the peptide from the c-terminal end 
reduces the conformational entropy.  Minimizing the degrees of freedom allows higher 
probability of binding to occur.     
Even with the chaperone‟s lower affinity to MBP-EE (no His6), the complex form 
of MBP-EE and 3D5/EE_48 scFv was successfully isolated using SEC [chapter three].  
Current co-crystallization attempts with this complex resulted in the lack of crystal 
formations from co-crystallization attempts and can be contributed to the high entropy of 
the peptide tag at the c-terminal region.  The high entropy conformation observed at c-
terminal appears to interfere with the chaperone‟s initial recognition for that peptide tag.  
The flexibility of the peptide can also contribute to a hinge-like conformation resulting in 
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heterogeneous complexes, which are not beneficial during the generation of a crystal 
lattice.  In order for the peptide-specific chaperone to be utilized in a co-crystallization 
platform successfully, a tight and rigid complex needs to be created that can create a 
uniform repetitive unit for lattice formation.  This can be established by limiting the 
number of amino acids located on the tail of the target protein.  For this reason only short 
peptide sequences (6 – 10) amino acids are considered for this platform that contain 
amino acids that restrict the conformation of the peptide, like the proline in the EE tag.  If 
the flexibility of the peptide at the c- or n-terminal ends can be controlled and rigid 
complexes can be formed, this would provide a high-throughput system for creating 
protein crystals.  Like purification tags, the peptide tag can be inserted with minimal 
effort by cloning the protein gene into a vector with the peptide sequence encoded [158, 
183].  The ease of use –– and the fact that no structural information is required, make this 
platform and location extremely advantageous for co-crystallization as long as the 
concerns mentioned above are addressed.    
 
4.4.2  Analysis of peptide insertion into inter-domain linkers 
EE peptide insertion in an internal loop requires some structural information 
about the target protein.  However, the benefit of this location is its ability to provide a 
more rigid conformation of the peptide.  Achieving a successfully presented peptide for 
interaction without impacting the overall structural ability an functionality makes this 
area of insertion challenging.  There are two different types of locations for peptide 
internalization: interdomain regions or within natural loops (interloop).  The degree of 
protein topology information required for each of these models varies from relatively 
minimal (interdomain) to essential (interloop).  The first region studied was the 
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internalization of EE peptide tags between two domains of antibodies: scFv and TCRs.  
The EE peptide was placed prior to the glycine linker ([G4S]4) that connects the two 
domains with variations in the flanking residues to examine and determine effective 
peptide accessibility (Table 4.2).  Peptide tags were inserted either directly following the 
first domain or were flanked with 4-5 additional amino acids prior to the peptide insertion 
to allow for more flexibility in acceptable conformational presentation.  Variants with 
multiple EE tags were initially designed simply to insure binding and accessibility of the 
peptide as well as potential applications in protein scaffolds for enzyme assembly.   
Expression of each of these variants was similar to the original wildtype from 
which it was derived with the exception of R30A-EE (Table 4.3).  R30A-EE, which did 
not have flanking residues prior to the peptide tag, resulted in very little monomeric scFv 
expression following purification via SEC.  The additive impacts of the restricted 
conformation of the peptide tag as a result of the inclusion of the Pro4 and the location of 
the peptide immediately following the first domain appears to have interfered with proper 
protein folding.  The failure to fold into its correct structure results in the scFv‟s inability 
to be transported to the periplasm for extraction using osmotic shock.  This suggests that 
the flanking amino acids help to accommodate the conformation of the peptide tag for 


















MBP-EE-his 26 63.9 ± 0.5 94 389 (0.028) 
DO11 ~20 - 97 ND
a
 
DO11-v1 ~20 - 99 212 (0.092) 
DO11-v2 ~20 - 98 17.1 (0.012) 
DO11-e3 ~20 - 98 236 (0.023) 
14B7  4 69.4 ± 0.4 72 ND
a
 
R30A-EE <0.05 - 30 - 
R30A-EE2 2 51.2 ± 1.6 63 25.5 (0.586) 
62-EE3 2 56.2 ± 0.3 84 29.6 (0.598) 
a
ND = not detected 
 
Kinetic analysis of the expressed proteins indicated that all inserted peptides were 
accessible for interaction to the chaperone scFv (3D5/EE_48).  The variants with multiple 
peptide tags yielded a higher affinity (17-40nM) which can be attributed to:  i) improved 
probability for accessible binding epitope and ii) additional valency for repetitive 
binding.  Linking sequential peptide tags were generated to confirm that at least one tag is 
located in a more accessible area for peptide binding.  However, the drastic difference in 
affinities seems to indicate that all the peptides were accessible in the multiple EE-
ligands, which results in chaperone interaction with several peptide tags.  This leads to a 
valency issue, where the chaperone acts like a zipper releasing one peptide tag and 
immediately setting down on the peptide immediately following.  The ability to bind both 
peptides results in a solution that consists of two different complex formations, which 
produces a heterogeneous solution that is not ideal for crystallization. 
While the high affinity of the multiple EE insertion ligands is not preferred for our 
co-crystallization technology, the application of this peptide insertion for other protein 
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scaffold applications is still being considered.  For crystallization, however, the number 
of EE sequences must be reduced to a single peptide in order to remove valency issues 
that can lead to heterogeneous solutions of complexes.  Two variants with a single EE-
peptide preceded by four random amino acids (D011-e3 and D011-v1) produced a slightly 
improved affinity (KD: 210 – 240nM) than protected EE peptides presented on the c-
terminal tail of MBP (KD: 389nM) (Table 4.4).  The significantly lower affinity compared 
to the multiple EE peptide presenting variants (KD: 17 – 40nM) indicates that additional 
location optimization must be addressed further.  Further analysis is needed to explore if 
the single EE peptide variants can reach the same affinity as those with multiple EE tags 
by using the second peptide location.  Further location optimize can determine if this 
location is an improved location or merely an artifact of the valency addressed above.   
 
Table 4.4 Kinetics of 3D5/EE_48 scFv binding to EE-tagged proteins by SPR 
ligand kon (1/Ms) SD (%) koff (1/s) SD (%) Kd (nM) 
2
 
MBP-EE-his 3.5 E+04 47 1.2 E-02 2 389 0.028 
DO11-e3 4.1 E+05 41 8.08 E-02 16 236 0.023 
DO11-v1 2.4 E+05 32 4.77 E-02 21 212 0.010 
DO11-v2 2.7 E+05 41 3.81 E-03 29 17.1 0.012 
R30A-EE2 (frozen) 2.0 E+05 73 3.69 E-03 58 28.9 0.314 
62-EE3 (frozen) 3.6 E+05 63 8.17 E-03 26 40.2 0.131 
R30A-EE2 3.9 E+05 30 9.0 E-03 34 25.5 0.586 
62-EE3 3.6 E+05 37 9.2 E-03 41 29.6 0.598 
 
4.4.3  Analysis of peptide insertion into internal loops: within natural loop 
The second region for internalized peptide insertion that we focused on was a 
natural loop of maltose binding protein.  Unlike the scFvs and TCRs, where the peptide 
insertions are guided by knowledge of artificial linkers locations, selection of the peptide 
insertion region requires a little more finesse and more detailed structural information.   
Utilizing the MBP PDB (#1YTV and 1A7L) surface accessible natural interloop regions 
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with (~6-8 amino acids in length) were examined.  Careful consideration needed to be 
taken when choosing the kinked loop due to Pro4, which limits the conformational 
entropy.  Amino acids 171 – 176 (sequence KYENGKY) were selected as the ideal 
region due to its conformation and inclusion of amino acids with similar properties to 
those in the EYMPME sequence (Fig. 4.1a).  The initial variant (MBP-v1) was designed 
with flanking linkers to provide steric accessibility of the peptide.  Additional variants 
were modified to reduce the number of flanking linkers and to determine if direct 
replacement of the loop was acceptable (MBP-v2 and MBP-v3).    
 
 














MBP-his 24 63.3 ± 0.3 99 ND
a
 
MBP-EE 8 62.5 ± 0.2 N/A 767 (0.030) 
MBP-EE-his 26 63.9 ± 0.5 94 389 (0.028) 
MBP-v1 14 - 94 NSB
b
 
MBP-v2 32 - 98 1210 (0.224) 
MBP-v3 18 52.8 ± 0.8 96 816 (0.024) 
a
ND = no detection binding 
b










Figure 4.1  Characterization of the MBP peptide presenting variants  
(a) Structural Image of the MBP natural loop (171-176: KYENGKY,) selected for 
peptide insertion with an enlargement of the loop configuration with peptide 
rainbow color coded from n-terminal blue to c-terminal red.   
(b) Size and purity by SDS-PAGE: Lane 1: MBP-his; Lane 2: MBP-EE-his;  Lane 
3: MBP-v2; Lane 4: MBP-v3; Lane 5: MBP-v1.  
(c) Purification by SEC. Molecular weight standards on S75 elute at 7.4 ml (void 
volume; blue dextran 2000); 9.6 ml (75 kDa conalbumin); 10.9 ml (43 kDa 
ovalbumin); 12.7 ml (29 kDa carbonic anhydrase); 15.4 ml (residual peak 
from Ni
2+





Kinetic analysis, using Surface Plasmon Resonance (SPR), established that the 
peptide with the flanking linkers (three amino acids on each side) resulted in non-specific 
binding of the MBP (not shown).  The addition of six flanking amino acids may have 
affected the structural conformation, resulting in improper folding of hydrophobic 
regions.  The binding curves for the maltose binding proteins variants were very similar 
in nature, MBP-v2 and MBP-v3, however the resulting affinities were lower than those for 
the EE c-terminally tagged maltose binding proteins (Fig. 4.2 and Table 4.5).  This shows 
that minor modifications to the loop, where the peptide is directly substitutes the natural 
loop, still allow for successful affinity to the EE-specific scFv chaperone.  The successful 
kinetic analysis of the direct replacement of the loop indicates that peptide insertion in 
either format does provide a somewhat accessible peptide although some structure 
stability is lost.  The drastic change in MBP-v3‟s melting temperature to 52.8
 o
C (± 0.76), 
from the wildtype Tm of 63.9
 o
C (± 0.46), indicates the altered stability of this variant and 
suggests that there was a perturbation in the structural integrity of the maltose binding 
protein (Table 4.5).   The visualization of doublets from SDS-page gel separation across 
all MBP variants appears to confirm the possibility that the structural stability of the all 
the variants were affected during peptide insertion (Fig. 4.1).   
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Figure 4.2  SPR analysis of comparison of different variants of MBP with EE peptide 
insertion at internal loop (171 – 176).   
Coupled on the chip is chaperone 3D5/EE_48 scFv chaperone with wildtype14B7 
scFv couples as the blank. Serial 1:2 Dilutions of soluble proteins were injected 
over the chip from 3uM to 0.1875uM   
(a) MBP with c-terminal Flag-His6 – negative control   
(b) MBP with c-terminal EE-His6  
(c) MBP-v2: EYMPMEY  
(d) MBP-v3:KEYMPME 
 
Table 4.6  Characterization of 3D5/EE_48 scFv binding kinetics with internal loop 
peptide presenting proteins by SPR  
Ligand kon (1/Ms) SD (%) koff (1/s) SD (%) Kd (nM) 
2
 
MBP-EE  1.5 E+05 62 7.3 E-02 24 767 0.030 
MBP-EE-his* 3.5 E+04 47 1.2 E-02 2 389 0.028 
MBP-v2
** 
1.4 E+04 44 1.5 E-02 10 1210 0.024 
MBP-v3 1.2 E+-4 29 9.1 E-03 33 816 0.025 
SPP-EE 3.2 E+04 57 3.1 E-02 12 1283 0.024 
*Highest affinity  
















































































For internalization of the tag at the 171-176 natural loop in MBP, the six flanking 
residues were not preferred.  Direct peptide substitution resulted in chaperone affinities 
that were two-fold lower (KD~800nM) than those for the protected c-terminal tag (KD: 
387nM) and even the unprotected c-terminal tag (KD: 767nM).  The low affinities of the 
MBP EE-tagged variants highlight the challenges involved with optimizing the peptide 
insertion in this natural loop.  The addition of extra amino acids should allow for more 
flexibility in this loop, resulting in improved accessibility of the EE tag.  However, the 
flanking triplet residues in MBP-v1 may have created too much structural perturbation on 
the natural loop conformation.  The current internalized peptide need to be further 
optimized for accessibility and rigidity to establish a favored conformation.  Additional 
variants with varying flanking residues are needed to study the extent of steric 
accessibility these residues can provide without introducing added conformational 
entropy or upsetting natural protein folding.  It should be considered that a minimal 
flanking linker is preferred for this peptide tag because of its tendency to increase the 
rigidity of the resulting complex thereby enhancing its propensity to crystallize.     
 
4.4.4  Application with a membrane protein  
The inherent flexibility of many intracellular loops on membrane proteins can 
limit the crystal formation and even the quality of the crystals [74].  The design of this 
peptide-specific chaperone technology aims to specifically target and replace flexible 
unstable regions with the peptide tag, allowing the chaperone protein to further lock these 
regions in place.  Although structural information is very limited for most membrane 
proteins, solvent-exposed loops have been identified through other sources such as 
homology sequencing analysis or membrane topology studies [184].  The Kobilka group 
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successfully used these methods to systematically remove flexible regions and even insert 
an entire T4 Lysozyme in place of one loop [61, 93, 94].  If a solvent-exposed loop can 
be identified, introduction of a peptide in this region can be done with relative ease.  The 
resulting complex of chaperone with the peptide would rigidify this otherwise flexible 
region and remove a critical region that would previously interfered with crystallization. 
To confirm the ability to apply our platform for membrane proteins, the EE 
peptide tag was inserted into a flexible extra-membranous loop and terminal regions of 
the highly conserved transmembrane enzyme, signal peptide peptidase (SPP).  The 
complex formation, between our chaperone and the SPP with an internal EE peptide, 
simultaneously immobilizes the SPP‟s flexible loop while providing additional 
hydrophilic surfaces for lattice formation.  One particular variant with a single EE tag 
located at an extra-membranous loop produced an affinity for the 3D5/EE_48 chaperone 
of 1283nM (χ
2
=0.024) (Fig. 4.3a), which was similar to the MBP-v2 variant (KD: 
1210nM).  A direct kinetic analysis comparison of these two variants is difficult due to 
the high noise signal contributed by the surfactant buffer that stabilized the membrane 
protein.  The 0.1% detergent in the SPP running buffer may be negatively impacting the 
binding interactions.   
Regardless of the low uM affinity, the peptide was accessible enough for 
complexation with our 3D5/EE_48 chaperone (Fig. 4.3c and Fig. 4.3d).  While the 
chromatograms do not show much difference between the control and the EE-tagged 
SPP, the separation of column flow fractions over SDS-page gels display successful 
complexation of the SPP-EE with our hyper-crystallizable chaperone 3D5/EE_48 scFv 
(Fig. 4.3c and Fig. 4.3d).  The initial peak in the SPP-EE SEC flowthrough now contains 
both SPP-EE and the scFv with the leftover uncomplexed scFv present at the tail-end of 
the separation.  Successful isolation of the complexed chaperone with SPP proved a little 
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more difficult as a result of the surfactants in the running buffer.  A major concern now is 
to efficiently separate the coupled SPP from non-complexed SPP, as the two peaks nearly 
overlap.  Column resolution using gel filtration has always been a challenge in membrane 
protein fractionation; however, other purification methods can be utilized to successfully 
separate the complexed form from the uncomplexed.  Current work is in progress to 
utilize Ni columns, following size exclusion to get the correct complex for co-
crystallization trials.  In addition, current SPP variants now contain two EE tags, one at 
an internal loop, and the other at the n-terminal region of the protein.  The design of this 
protein will further show the utility of our chaperone‟s ability to successfully bind the 
peptide at different locations.  The objective of utilizing multiple peptide locations is to 
simultaneously surround the more hydrophobic regions of the protein with additional 
polar regions to mediate contacts.  Current co-crystallization trials are in progress for 
complexed chaperone with the model membrane protein, as well as many of the EE-
tagged proteins mentioned above.  Successful complex crystallization will allow us to 
ultimately determine if these peptide insertions are acceptable for our co-crystallization 







         
 
Figure 4.3  Characterization of the chaperone and SPP-EE interaction.   
(a) Preliminary kinetic analysis of the SPP-EE protein (internal loop) Serial 1:2 Dilutions of 
sample were injected over the chip from 3uM to 0.1875uM with 14B7 scFv coupled as the 
blank 
(b) Size and purity by 12% SDS-PAGE  
(c) Isolation of 3D5/EE_48 complexes with variants SPP by SEC: 3D5/EE_48 incubated with 
wild-type SPP  
(d) Isolation of 3D5/EE_48 complexes with variants SPP by SEC: 3D5/EE_48 incubated with 
SPP-EE.   For (c) and (d), SDS-PAGE analysis of elution peaks (top right of each respective 
image) confirms protein and complex identities.  The three peaks visualized on the 
chromatograph is first the SPP, followed by the dimeric and monomeric forms of the 






4.5  CONCLUSION: FUTURE POTENTIAL USE FOR CO-CRYSTALLIZATION CHAPERONES 
Peptides were inserted at three locations: terminally, interdomain and interloop.  
All peptide-tagged proteins have shown successful complexation with the 3D5/EE_48 
chaperone even at low affinity (KD~1uM).  Terminal peptide insertions are the preferred 
insertion site if no structural information is required.  For internal peptide insertions, 
consideration for the EE tag‟s restricted conformation required us to address the use of 
additional linkers that provide flexibility and accessibility for the tag.  A single EE tag 
insertion with 4-5 flanking residues prior proved beneficial for insertion in our 
interdomain proteins to create rigid complexes and create a homogenous solution for 
crystallization.  The peptide insertion into the natural loop of MBP and SPP shows the 
difficulties of selecting an acceptable loop and retaining a good peptide conformation.  
The guidelines we have established here for peptide insertion are bringing us a step closer 
to creating the generalized toolbox of co-crystallization peptide-specific chaperones.  
Observations of these EE-tagged protein variants will provide additional information as 
we generate guidelines for preferred insertion that can be successfully transferred for use 
in other target proteins.  The ability to insert the EE tag into different regions of the 
protein and retain successful chaperone complexation shows the broad application of 
system.  This technology is potentially transformative, allowing the incorporation of the 
peptide into any membrane protein loops/tails and no longer requiring the need to re-
engineer chaperones for each new membrane protein target.   
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CHAPTER FIVE:  Control of Protein Crystallization through Tuning 
Intermolecular Contacts 
 
5.1  CHAPTER SUMMARY 
The arrival of protein engineering techniques for improving crystallization, such 
as SER (surface entropy reduction) and chaperone assisted co-crystallization, have 
indicated that a protein‟s intermolecular contacts assist in drawing proteins into an 
ordered lattice.  Analysis within a selection of scFv antibodies (14B7 and 3D5 derived 
variants) revealed that modulating an intermolecular contact‟s energetic contribution can 
guide the crystal lattice formation for the protein.  Critical residues involved in a 
particular intermolecular contact can be determined using PISA and Rosetta Alanine 
Scanning, where the criteria for high affinity interactions can similarly be applied to low 
affinity crystal contact interactions.  Global manipulation of 3D5 scFv‟s surface epitopes 
affected the protein‟s intermolecular contacts resulting in a wide range of crystal lattice 
formations (hexagonal, tetragonal and cubic).  Armed with current protein engineering 
strategies for improved crystallization, we can systematically modulate the energetics of 
the 3D5 based antibodies‟ topology for improved hyper-crystallizability.  The creation of 
co-crystallizable chaperones will potentially transform traditional shotgun crystallization 
screening techniques into a methodology with a more rational approach and higher-
success rate.   
 
5.2  INTRODUCTION 
Co-crystallization is a method that utilizes a chaperone protein to assist the 
crystallization of a target protein.  Frequently used for membrane protein like GPCRs 
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[61, 93, 94], the addition of the second protein assists in crystallization by protecting 
hydrophobic regions, replacing or locking in flexible regions and most importantly 
providing additional polar regions for more potential lattice contacts [79, 85, 88, 92, 98, 
179].  Currently a universal hyper-crystallizable antibody chaperone is in development 
that is specific to a peptide tag [Chapter 3].  This peptide tag can be appended to any 
target protein of interest and will assist in drawing the intended target protein into a 
crystalline structure.  [Chapter 4].  With this platform technology, crystal optimization 
efforts now focus on a well characterized peptide specific chaperone with improved 
biophysical characteristics and higher propensity for crystallization.  Emphasis is placed 
on engineering a chaperone with the ability to mediate crystal contacts utilizing many of 
the protein engineering modification techniques in place.   
Crystallization requires molecules to associate together, mediated by weak 
specific interactions.  Surveys of experimental results from the Northeast Structural 
Genomics Consortium, has led to the conclusion that surface epitopes drive the 
propensity for crystallization by providing intermolecular interactions [37].  Stringent 
statistical analysis indicates that the intermolecular contacts are generated by anisotropic 
interactions that include small hydrophobic residues and exclude high-entropy residues 
with large polar side chains [185, 186].  The many interaction contacts available for 
hyper-crystallizable lysozyme‟s different lattice formations appear stochastic in nature 
[64].  Molecular dynamic simulations of hyper-crystallizable lysozyme, however, 
indicate that the extent of these interactions is dependent on the physical chemistry 
involved at the interface [186].  This suggests that the nucleation of lysozyme into its 
multitude of space groups may be initiated in a systematic fashion contrary to previous 
perceptions that crystallization was generated largely by random interactions [17, 187, 
188].   
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The rise of new recombinant technology produced a drastic increase in material 
for protein crystallization by reducing protein purification efforts with fusion proteins and 
affinity tags [183, 189, 190].  Crystallization is no longer dependant on samples of 
purified native protein, however the preparation of high-diffraction quality crystals still 
remains the limiting factor to structural determination.  Current strategies for 
crystallization primarily focus on extensive shotgun-screening of thousands of 
crystallization conditions, which is a tedious and time-consuming process [191].  While 
these strategies focus on improving the conditions of crystallization, recent progress has 
emphasized the need to modify the protein molecules themselves to enhance 
crystallizability [10].  Progress in protein engineering has improved the chances of 
creating target protein crystals by modifying biophysical characteristics of proteins [37, 
78, 177, 192].  These modifications allow successful crystallization to proceed, which 
had not been attained with the wildtype form.  In addition, proteins that crystallized 
poorly can be modified using these techniques for higher diffraction quality crystals.  
Protein modification techniques such as solubility [149] or surface entropy [37, 74, 185, 
193] impact the intermolecular contacts involved in crystallization.   Improved solubility 
allows for more stable proteins less prone to the random interactions characteristic of 
aggregation [57, 59].  The generation of more symmetric proteins allow for well-ordered 
packing to proceed.  Surface Entropy Reduction (SER) and flexible protein truncation 
both aim to accomplish well-ordered packing by reducing the entropic cost of the protein.  
Truncating flexible regions of the protein can eliminate their propensity to create multiple 
interaction contacts [193] and reduce the conformational heterogeneity, characteristically 
seen in many membrane proteins,  resulting in improved crystals with higher resolution 
[74].    SER is usually intended for proteins that are intrinsically stable, targeting specific 
flexible amino acids (Glu, Gln, Lys) [37, 185] and replacing them with threonines and 
 120 
tyrosines which are known to contribute to protein-protein interfaces [87] or  alanines, a 
minimal residue [68].   
Utilizing the protein engineering modification techniques in place, the improved 
biophysical characteristics mediate novel crystal contacts or improve the preexisting 
protein-protein interactions.  Surface modification of a potential antibody chaperone for 
co-crystallization produced novel intermolecular contacts that impact the propensity for 
new crystal lattice frameworks [Chapter 3].  These crystal contacts are viewed as low 
affinity interactions and their energetic must be studied in order to better understand their 
role in guiding crystallization.  Understanding the energetics of intermolecular contacts 
and their ability to define lattice formation will allow us to use current surface 
modification techniques (SER, optimization of target constructs) and potentially provide 
additional considerations to improve the antibody chaperone‟s crystallizability.  Two 
different murine model family antibodies will be studied to examine the global effects 
modulating crystal contact energetics has on lattice formation in crystallization (anti-
hexahistidine antibody 3D5 scFv, [99]).  Computational modeling program and 
crystallization experiments were used to investigate whether protein crystallization and 
lattice formation can be controlled by fine-tuning the energetics of key intermolecular 
contacts.  The impact of manipulating a particular intermolecular contact on crystal 
formation (anti-protective antigen of anthrax antibody, 14B7 scFv [39, 41]) will 
potentially allow us to better govern crystallization of our antibody chaperone. 
The results presented here highlight the potential role intermolecular contacts play 
in the two-step process of crystallization: first clustering of solute molecules followed by 
reorganization into ordered nuclei is of primary interest.  Our understanding of these 
interprotein interactions and their role in crystal contact formation will allow for rational 
modification of our universal chaperone for enhanced crystallizability.   
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5.3  MATERIALS AND METHODS 
5.3.1  Computational analysis of amino acids selected for mutation 
Experimental structures derived from diffraction data found in the protein data 
bank were used in computational analysis (3D5 family: PDB #1KTR, 3NN8; 14B7 
family: PDB #3ESU, 3ETB).  PDBe Protein Interfaces, Surfaces and Assemblies (PISA) 
was used exclusively to examine the critical amino acids in the crystal contacts that 
compose the 3D5/EE_48 lattice framework.  Amino acids were selected on based on two 
criteria: i) critical H-bond forming amino acids and ii) potential salt bridges (charged 
amino acids).  One final amino acid was selected based on the determination of its role in 
the original 3D5 crystal lattice as a potential electrostatic interaction.  Rosetta’s 
Computational Mutagenesis Alanine Scanning program was also used as an additional 
selection tool to predict energetically important amino acid in each intermolecular 
contact.  The program functions by replacing each amino acid at the crystal contact with 
an alanine and predicting the residues with the highest loss of free energy (ΔΔG ≥ 1.0 
kcal/mol) with respect to the alanine substitution [194, 195].  The Rosetta and PISA 
programs were used in combination to study the energetics involved with protein-protein 
interaction for the 14B7 family of murine antibodies.  The areaimol program from the 
Collaborative Computational Project (CCP4) software for Macromolecular X-Ray 
Crystallography provided the calculations for the solvent accessible surface areas of the 
residues as well as the surface area involved in the crystal contact [196].  Average ΔΔGs 
were calculated for the 14B7 intermolecular contact using Alanine Scanning Robetta 
software by averaging the results from the two separate occurrences of this interaction in 
the asymmetric unit.  Amino acids were selected that showed altered free energy 
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contribution to the complex on alanines substitution based on the Robetta software and 
contribute a significant portion of the surface area without impacting the protein‟s 
stability.  Amino acids identified as critical for loop conformation in literature [197, 198] 
were avoided with the exception of residue L:W33, which was included because the 
amino acid exposed area involved in the crystal contact was greater than 85%.   
 
5.3.2  Molecular biology of scFv proteins  
Each of the scFv variants was created by linking a VL and VH chain with a gly-ser 
linker [(G4S)4].  Targeted amino acids, selected from computational analysis, were 
mutated to preferred amino acids in proteins via site-directed mutagenesis with 
mutagenic oligonucleotides (Integrated DNA Technologies).  For 14B7 scFv, the amino 
acids with ΔΔG ≠ 0 kcal/mol were mutated to alanines (Appendix B.8.1).  Double 
alanines substitutions were selected with one alanines mutation in each chain (one heavy 
and one light) and introduced using two sequential site directed mutagenesis steps 
(Appendix B.8.1).  The amino acids selected in 3D5/EE_48 scFv were mutated to the 
original wildtype scFv (3D5)  amino acid or to an alanine if that location was not 
originally present in the wildetype scFv.  Five variants were engineered to target different 
two different crystal contacts in the 3D5/EE_48 lattice formation:  i) 3D5/EE_48.2 – 
S30T and S32T ii) 3D5/EE_48.2a – S30T and S32A iii) 3D5/EE_48.3 –  D55G, K57T, 
R58S and S62K iv) 3D5/EE_48.23 – combined substitutions of (i) and (iii) v) 
3D5/EE_48.23a – combined substitutions of (ii) and (iii).  Variants utilizing the anti-
hexahistidine 3D5 scFv framework [99] were derived by generating libraries with site-
directed CDR mutagenesis, selected and screened as previously mentioned [Chapter 2 
and 3].   
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5.3.3  Protein expression, purification and characterization  
All engineered proteins were subcloned into the SfiI-SfiI site of pAK400 for scFv 
expression [158] and contain a c-terminal, vector encoded His6 tag to facilitate 
purification. Protein was secreted into the periplasm of E. coli strain BL21, by induction 
of 1mM IPTG (OD600 = 3.0) for 5 hours at room temperature.  The protein was isolated 
by osmotic  shock and purified using immobilized Ni
2+
 affinity affinity chromatography 
(IMAC) followed by size exclusion chromatography (SEC) using a Superdex S75 column 
(GE Healthcare) equilibrated with HBS running buffer (10 mM HEPES, 150 mM NaCl, 
pH 7.4), as previously described [160].  The Superdex S75 column was calibrated using a 
Low Molecular Mass gel filtration calibration kit (GE Healthcare).  Qualitative analysis 
of the distribution of multimers at equilibrium in solution (scFv monomer-to-multimer 
ratio) was determined from SEC traces by calculating the area under the curve for each 
peak using Unicorn software (GE Healthcare).   
Protein purity and size were characterized by 12% SDS-PAGE under reducing 
conditions [161]. Protein concentration was assessed by BCA assay with a BSA standard 
curve and buffer blank (Pierce).  Protein solubility was determined by quantifying the 
concentration of the remaining soluble protein solution following a concentration of the 
protein to ~20 mg/mL and incubation for four days at 4 °C with centrifugation (10min at 
13.2krpm) to pellet insoluble particles.  Maintained structural conformation for each 
mutant was analyzed using two methods: circular dichroism and thermal stability with 
Real Time PCR (RT-PCR).  Circular Dichroism (CD) measurements were performed 
with secondary structure analysis using the yang reference data set [199].  Each protein‟s 
structural stability was assessed as the mid-point for complete thermal unfolding, using a 
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fluorescence assay [162].  Purified protein (20 μl at 280 μg/mL) or buffer blank were 
mixed with Sypro Orange (1 μl of a 1:1000 dilution; Molecular Probes) and heated in a 
RT-PCR instrument (7900HT Fast Real-Time PCR System (Applied Biosystems) at 
increments of 0.5 °C from 20 – 85 °C and analyzed with SDS.2 (Applied Biosciences).  
As we mentioned in chapter three, to facilitate direct comparisons, all 3D5 and variant 
characterization values reported here were performed with these methods and specific 
values may differ slightly from those previously reported [149]. 
Impact of the 3D5/EE_48 amino acid substitutions on its affinity for the EE tag 
was established through kinetic analysis with Surface Plasmon Resonance (SPR).  
Kinetic binding assays were performed with a MBP bearing a c-terminal EE tag protected 
by a His6 tag to quantify the 3D5/EE_48 selectivity using a BIAcore 3000 (GE 
Healthcare).  Protein ligands were coupled to CM5 chips using NHS-EDC chemistry to a 
level of ~500 RU.  Responses due to sample refractive index changes were corrected 
using signal from a flow cell coupled with a control protein (MBP bearing a c-terminal 
10XFlag-His6).  Dilution series from 3 to 0.1875 μM of soluble proteins was injected in 
duplicate at a flow rate of 50 μl/min to minimize mass transport effects.  Surface 
regeneration was performed after each run with a one minute injection of 2M MgCl2.  
 
5.3.4  Protein Crystallization 
All 14B7 scFv variants were crystallized via sitting drop vapor diffusion under the 
same conditions as the wildtype (20% PEG 4000, 0.1M HEPES (~ pH 7.5–8.5), 10% 
IPA) at 20
o
C for up to 6 months.  Crystal trials were prepared with filtered proteins 
(0.25um) concentrated to 14mg/mL using 1uL sitting drops at varying concentrations of 
precipitant to protein (protein to mother liquor ratios of 1:2, 1:1 and 2:1).  Proteins 
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crystals were grown to a minimum size of 20 μm and preliminary confirmed using 
polarized light.  Crystallization rates were determined by studying the crystal size every 
three hours.  3D5/EE_48 and its variants were crystallized as previously discussed in 
chapter 3. Crystals of rectangular or triangular shape grew within 4 weeks to a maximal 
size of 40-60 μm.  3D5/His_683 was crystallized by optimizing the conditions of 
3D5/EE_48, refer to Table 5.1 for the various conditions tested.  Crystals of teardrop or 
rodlike shape grew within 4 days.  Crystallization of 3D5 wildtype scFv has not been 
successfully replicated in our lab and therefore all mention of its crystal contacts is in 
reference to published literature [99]. 
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0.1M MES (pH 6.4) 0.1Mg(OAc)2 20-25% PEG4000 




4 - 10 1:1 0.1M Imidazole  (pH 8.0) 





5.3.5  Data collection, structure determination and refinement   
14B7variant crystals were transferred into a cryoprotectant solution consisting of 
the reservoir solution and 25% (v/v) glycerol.  Each crystal was then mounted in a 
cryoloop (Hampton Research, Laguna Niguel, CA) and dipped into liquid nitrogen for 
placement in the coldstream.  14B7 crystallographic data was collected at the University 
of Texas at Austin‟s beamline.  Structure determination and refinement were performed 
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using diffraction methods imosflm [200] and Molrep [201] from the CCP4 software 
[164].   3D5 family scFv crystals were harvested at 25°C and cryocooled using a solution 
consisting of 85.5% (v/v) reservoir solution and 14.5% (v/v) ethylene glycol. 3D5 family 
scFv crystallographic data were collected using a wavelengths of 1-6 Å at the GM/CA-
CAT beamline (Darien, IL) equipped with a 5 m mini-beam setup. Data were processed 
with XDS [163] and Scala [201]. The structures were solved by molecular replacement 
with Molrep using a polyalanine search model derived from parent 3D5 asymmetric unit 
(PDB ID 1KTR) from which all non-protein atoms and loop residues were removed.  
Translation/Libration/Screw motions and medium non-crystallographic restraints was 
conducted. Figures were generated using Pymol (The PyMOL Molecular Graphics 
System, Version 0.99rc6, Schrödinger, LLC).  
 
5.4  RESULTS AND DISCUSSION  
5.4.1  The role of energetics in crystal contacts: critical amino acid residues 
The intermolecular contacts involved in crystallization are characterized as low 
affinity interactions.  While it has been shown that surface epitope manipulations can 
impact crystallization [57, 68, 177], it has not been established if these low affinity 
interactions can be controlled on the residue level as high affinity interactions are [112, 
194, 195].  Systematic mutations at the crystal contact region will determine if 
modulating the energetic contribution of an protein-protein interaction can guide the 
formation of crystal lattice contacts.  A model scFv with a large interprotein interaction 
(789.3 Å) was used to study the intermolecular contacts role in driving crystallization.  
The 14B7 wildtype (WT) scFv antibody was selected because this large intermolecular 
contact was retained even with 10 mutations (Light: L46F, S56P, S76I, Q78L, L94P; 
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GlinkD; Heavy: S30N, T57S, K64E, T68I) and a change in space groups (M18 scFv, 
Table 5.2).  Both scFv antibodies were crystallized in the same conditions 20% PEG 
4000, 0.1M HEPES (~ pH 7.5–8.5), 10% IPA, however 14B7 crystallized within 24 
hours into a primitive tetragonal space group lattice structure (P42121) [39] while the 
ultra-high affinity 14B7 variant with 10 amino acid changes (M18) required 6 months to 
form crystals and resulted in a P21 space group [41] (Fig. 5.1a and Fig. 5.1b).  Structural 
data for 14B7 wildtype and the affinity matured scFv M18, were used to determine low 
affinity protein-protein interactions (Table 5.3).   
 
Table 5.2  14B7 Survey of Crystal Contacts in the Unit Lattice Cell 





1 VL+VH:VL+VH 789.3 
2 VL:VH 436.7 
3 VH:VH 262.7 
4 VL:VH 158.9 
5 VH:VH 98.8 
a





Figure 5.1.  Crystalline Lattice Structure of 14B7 variants  
(a) 14B7 (Space Group: P42121);   
(b) 14B7 variant M18, with 10 mutations (Space Group: P1)   
 
Within the lattice unit cell for the wildtype 14B7, there are eight scFv molecules 
with 13 contact points, of which five are distinct low affinity protein-protein interactions 
(within 7Å) characteristic of a crystal contact (Fig. 5.1a).  The largest interaction has a 
protein-protein contact, nearly two times larger than any other contact (Table 5.2).  Its 
retention in the M18 variant crystal lattice (primitive P1)  in spite of the different growth 
kinetics [41], emphasizes the need to study its low affinity energetic surface epitopes in 
more detail.  By modulating this specific contact, it will allow us to study the energetics 
involved in the driving crystallization.  Critical intermolecular amino acids were selected 
using PISA, which highlights predicted residues that contribute hydrogen bonds and 
electrostatic interactions (salt bridges).  Rosetta‟s Computational Mutagenesis Alanine 
Scanning program [194, 195] was used to select amino acids predicted as energetically 
important to the major protein-protein interaction (ΔΔG ≥ 1.0 kcal/mol, after substitution 
with alanines) (Table 5.3).  Although Rosetta‟s alanine scanning is commonly used to 
study the energetics involved with high affinity binding, it is believed the energetics 
B A 
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involved are similar to those in low affinity interactions like crystal contacts and can 
therefore be applied for crystal contact determination.  It is unclear if the 1 kcal/mol 
threshold is too high for analysis of crystal contacts, considering that the strength of 
binding interactions are greater than intermolecular contacts involved in the crystal 










Δ ΔG in 
14B7 
(kcal/mol)a 






SA in 14B7 
Crystal 
Contact (Å2)c 
% SA of AA in 
14B7 Crystal 
Contact 
% of 14B7 
Total Crystal 
Contact 
L:28 D -0.20 0.94 - 52.3 64.7 7.4 
L:30 R 2.66 0.26 HS 130.5 82.9 18.6 
L:32 Y 2.17 0.34 H 69.7 94.3 9.9 
L:50 Y 2.06 0.03 H 69.0 90.7 9.8 
L:53 R 0.22 0.53 - 27.7 22.7 3.9 
H:31 S 0.14 -0.17 H 46.7 66.7 6.6 
H:33 W 0.87 - H 15.5 89.6 2.2 
H:54 D 0.65 -0.13 HS 85.0 75.5 12.1 
H:56 D 1.19 -0.34 HS 36.3 49.1 5.2 
H:97 L 1.16/0.66 1.54 - 131.6 81.6 18.7 
H:98 L 2.18 1.29 - 38.9 76.3 5.5 
H:99 R 0.91 - H 62.6 46.8 8.2 
a 
Computational mutagenesis Alanine Scanning Robetta Software (average of all four antibodies involved 
in the two disctinct contacts) 
b
 Predicted using Protein Interfaces, Surfaces and Assemblies (PISA), H- hydrogen bond contribution, S-
Salt Bridge contribution 
c
 SA=Surface Area, calculated using Areimol from the Collaborative Computational Project (CCP4) 





14B7 scFv variants with single alanines mutations were characterized and 
crystallized in order to study and fine-tune the energetics involved in the formation of a 
crystal lattice.  Amino acids were selected for alanine mutagenesis with a wide range of 
altered free energy contribution to the interaction and contribute a large portion of their 
solvent accessible surface areas to the crystal contact surface area [196].  Amino acids 
previously reported as critical for loop conformation residues were eliminated as 
mutagenesis sites [197, 198].  The exception was light chain residue L:W33, which was 
included because more than 85% of the residue‟s exposed area was involved in the 
crystal contact.   
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Biophysical characterization of the variants showed fairly similar expression 
yields however a qualitative analysis showed a wide range of structural stabilities (Table 
5.4).   Size exclusion of antibodies demonstrated that most of the variants maintained 
their monomeric form in equilibrium with little cleavage (Fig. 5.2a and 5.2b), which was 
further confirmed with SDS-Page separation (Fig. 5.2c).  CD measurements confirmed 
little structural perturbation in the variants with the exception of heavy chain variant 
W33A (Fig. 5.2d and 5.2e), corroborating previous literature which suggest this site is a 
structurally conserved residue [32].  Structural breakdown for each variant indicated 
traditional scFv formations of 8.5±3.9% alpha helices and 69.7±14.0% beta sheets 
(W33A not included in data set).    Heavy chain variants R53A and D54A displayed 
unusual deviation in the calculated secondary structure composition, while maintaining 
similar characteristics to the WT in expression and thermal stability).  The deviations are 
most likely the result of experimental error due to contamination from protein cleavage, 

























WT - - 0.934 4.4 73.6 69.36 ± 0.36 200.0 
L:28 D -0.20 0.790 0.0 69.6  666.7 ± 291.7 
L:30 R 2.66 0.897 9.5 87.0 58.27 ± 0.41 - 
L:32 Y 2.17 0.617 7.0 75.7 54.93 ± 0.22 500.0 
L:50 Y 2.06 1.115 9.2 79.3 56.37 ± 0.31 - 
L:53 R 0.22 0.469 13.7 41.4 57.00 ± 0.82 125.0 ± 58.9 
H:31 S 0.14 0.381 10.9 61.5 59.43  ± 0.058 375 ± 58.9 
H:33 W 0.87 0.518 43.6 37.6 54.10 ± 0.44 - 
H:54 D 0.65 0.627 10.2 54.3 59.00 ± 0.283 333.3 
H:56 D 1.19 0.388 - - 52.35 ± 0.64 - 
H:97 L 1.16/0.66 0.655 11.8 74.4 58.53 ± 0.47 308.3 ± 82.5 
H:98 L 2.18 0.572 11.7 88.3 57.60 ± 0.00 - 
H:99 R 0.91 1.101 6.0 62.1 62.37 ± 0.23 358.3 ± 11.8 
a Computational mutagenesis Alanine Scanning Robetta Software (average of all four antibodies involved in the two 
distinct contacts) 
b From 250mL Culture of Terrific Broth and induced with IPTG for 4-5 hours 





Figure 5.2  Biophysical Characterization of 14B7 variants  
Top: Size exclusion purification (FPLC-SEC) of 14B7 and light chain variants (a) and the 
heavy chain variants (b) fractionated using superdex (S200) column.    
Middle: (c) Separation of 14B7 and variants with 12% SDS-PAGE, stained with Pierce 
GelCode Blue.  Single monomer band at expected peak at 28kDa for scFv, indication 
of a little cleavage of the antibodies.   
Bottom: (d) Circular Dichroism (CD) measurements of 14B7 and light chain variants (e) 
CD Measurements of WT and the heavy chain variants.   
Light Chain Mutants of 14B7 scFv - Monomeric Separation (250mL Cultures) 



















Heavy Chain Mutants of 14B7 scFv - Monomeric Separation (250mL Cultures) 
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5.4.2  The role of energetics in crystal contacts: crystallization of 14B7 variants 
14B7 scFv single alanines mutants crystallized under the same conditions as the 
wildtype (20% PEG 4000, 0.1M Hepes (~ pH 7.5–8.5), 10% IPA) with varying crystal 
growth kinetics and produced different diffraction-quality crystal with lengths of 120 to 
670um (Table 5.5 and Fig. 5.3).  With the exception of light chain mutant D28A, crystal 
formations maintained the wildtype rod-like crystal shape, growing in one-dimension.  
Initial X-ray diffraction data indicated that most of the variants were high diffracting 
(~2.7 Å) with an initial index for the wildtype primitive tetragonal group (P4).  Mutation 
at heavy chain D54A resulted in crystals that diffracted at low resolution (~15 Å), 
indicating a lack of long-range order within the crystal.  14B7 with a mutation at heavy 
chain D28A showed improved crystallization characteristics and will be discussed later in 
further depth. 
Mutations at residues indicated by PISA to contribute either a hydrogen bond or 
an electrostatic interaction resulted in an impact on crystallization.  The single alanines 
mutations at these particular residues resulted in either no crystal lattice formation (L: 
R30, Y50; H: W33, D56), modified crystal growth (L: Y32 – 3 month, H: S31 – 1 month) 
or poor diffraction quality (H: D54).  The exception was H: R99, which indicates other 
forces may be involved with maintaining crystallization.   The ability to impact 14B7 
crystallization shows the potential of utilizing PISA to pinpoint critical amino acids that 






Figure 5.3  Crystallization of 14B7 mutants of the largest intermolecular contact  
(a)  Structural representation of the intermolecular contact;  
(b) Location of all the amino acids subjected to experimental alanine scanning 
color-coded by their contribution of free energy;  14B7 and Variant Crystals at 
concentration of 15 mg/mL and a 1:1 concentration of mother liquor to protein 
within the sitting drop.   
(c-k) Crystal Images of 14B7 variants with single alanines mutations at the largest 
contact 
(c)  WT-model image from previous work in the lab;  
(d) WT; (e) L:D28A; (f) L:Y32A; (g) L:R53A; (h) H:S31A; (i) H:D54A; (j) 
H:L97A; and (k) H:R99A. 
 
  
Color Scale for the Amino Acid Residues
• Green > 2.0 kcal/mol
• 2.0 kcal/mol > Yellow >1.0 kcal/mol
• Red < 0 kcal/mol
Y32A Y50A
D56AL98AD28A
Not to scaleNot to scale
Length Scale:
A B 
C D F E 




Table 5.5  Crystallization Characterization of 14B7 variants with alanine subsitutions 
 
Exploring the energetic contribution of these particular variants in more depth 
using Rosetta Alanine Scanning showed that mutations at residues with a free energy 
contribution ≥ 1.0 kcal/mol yielded no crystals following the 24 hours after initiation.  In 
long-term crystallization studies, only variant Y32A managed to crystallize three months 
post-initiation.  Based on the drastic change in growth kinetics indicates the Rosetta 
alanines threshold used for predicting critical amino acids in high affinity binding 
interactions is acceptable for determining residues involved in intermolecular contacts of 
crystallization [194].  Variants with residues that had a free energy contribution of < 1 
kcal/mol showed varying crystallization kinetics. Residues L: R53, H: L97 and L98, 
which were specifically predicted only by the Rosetta program, conformed to the 
energetic criteria of Alanine scanning we have set for manipulating crystallization.   
From the single alanine substitutions, it is apparent that modulating the energetics 












P4 Unit Cell  






WT - - 200.0 24hr 80.18, 67.825 Y 2.0 
L:28 D -0.20 666.7 ± 291.7 2hr 84.31, 199.85 Y 3.2 
L:30 R 2.66 - - - - - 
L:32 Y 2.17 500.0 3 month 80.11, 68.21 Y 2.6 
L:50 Y 2.06 - - - - - 
L:53 R 0.22 125.0 ± 58.9 - - N - 
H:31 S 0.14 375 ± 58.9 1 month - N - 
H:33 W 0.87 - - - - - 
H:54 D 0.65 333.3 24hr N/A N 13.0 
H:56 D 1.19 - - - - - 
H:97 L 1.16/0.66 308.3 ± 82.5 24hr - - - 
H:98 L 2.18 - - - - - 
H:99 R 0.91 358.3 ± 11.8 24hr 74.79, 68.25 Y 3.7 
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were created to establish the extent to which this contact energetic is upheld and 
determine if a free energy contribution limit is needed to maintain the intermolecular 
interaction.  All D28A double mutants (D54A, L97A, L98A, R99A) maintained a similar 
crystal growth rate to the single mutant D28A producing crystals within 2 hours, with the 
exception of variant: D28A + L98A.  The negative free energy contribution of D28A 
appears to stabilize the intermolecular contact enough and allow for crystal initiation of 
the double variants.   The loss of the free energy contributed by the heavy chain L98A, 
however appears to outweigh the stabilizing effect of the D28A mutation and results in 
no crystal formation.   
Analysis of the intermolecular contact energetics established a total free energetic 
modulation of >1 kcal/mol at a protein-protein interaction impacts the crystal lattice 
formation for 14B7.  The potential energy cost requirement for this particular 
intermolecular contact of 13.5kcal/mol must be reached to impact crystallization of 14B7 
scFv.  By fine tuning a key intermolecular contact, we have established a selection 
criterion for surface modification to control protein crystallization.  PISA predicted 
residues that provide hydrogen bonds and electrostatic interactions potentially critical to 
lattice formation.  Additionally, the free energy contribution analysis utilized for high 
binding affinity can be similarly applied to predict critical amino acids involved in low 
affinity intermolecular contacts.  Residues critical to maintaining the interaction have a 
ΔΔG > 1 kcal/mol and residues that stabilize the interaction have a free energy 
contribution < 0 kcal/mol.   Utilizing the criteria for critical residues that impact 
intermolecular contacts, established by studying the 14B7 scFv crystallization kinetics, 
we can apply these to designing and improving the 3D5 based chaperones in 
developemont [Chapter 3].   
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  5.4.3  Manipulation of surface epitopes on lattice formation  
Due to its favorable characteristics, 3D5 scFv (PDB 1KTR) was used as a 
framework while engineering different anti-peptide chaperone variants in house.  
Modifications were introduced at varying locations on the HCDR regions and resulted in 
unique lattice formations for each engineered antibody under the same crystallization 
conditions.  The surface epitope modifications resulted in the introduction of amino acids 
that contributed H-bonds or electrostatic interactions that generated additional driving 
contacts that affected the lattice space group the scFv crystallized into [Chapter 3].  Even 
with the overwhelming homology of these antibodies to the wildtype 3D5 (3D5/His_683 
and 3D5/EE_48, >80%), these antibodies when crystallized under identical conditions 
resulted in their diverse lattice formations (3D5/EE_48: cubic space group, 3D5/His_683: 
hexagonal/tetragonal space group and 3D5: tetragonal space group).  Examination of 
these scFvs will allow us to analyze the impact intermolecular energetics contributed by 
protein region modification can have on lattice formation.   
3D5/His_683 scFv deviates from the wildtype only in the heavy CDR3 region (13 
amino acids).  In addition to crystallizing in the wildtype mother liquor solution, this scFv 
successfully crystallized in a number of other conditions that span a large range of pH  
6.4 - 8.0 with varying buffers and different sizes of PEGs (Table 5.1).  From these 
conditions, crystals were produced much more rapidly than the wildtype (within 4 days, 
compared to 2 weeks) in two different forms: teardrop and rod-like shapes.  These 
crystallization characteristics suggest the potential of this scFv as a hyper-crystallizable 
antibody (Fig. 5.4).  The 3D5/His_683 scFv has effectively been crystallized to lengths of 
60μm with one crystal successfully diffracted to a resolution of 3.5Å.  Preliminary 
diffraction of the crystal resulted in a densely packed space group (P6522, 58% solvent) 
(Fig. 5.5c).  Like the wildtype lattice formation, only one scFv molecule occurs in each 
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asymmetric unit and the preliminary analysis show most of the intermolecular contacts 
involve the framework.  Further refining of this model is in progress to analyze the 
specific intermolecular contacts involved in these lattice contacts.  Lattice comparison for 
each of the three 3D5 variants showed that all maintained a central cavity and the 




Figure 5.4  Images of 3D5/His_683 Crystals grown at different conditions  
(a) rod shaped crystals  





   
Figure 5.5  Comparison of 3D5 derived antibodies (3D5, 3D5/EE_48 and 3D5/His_683) 
(a)  3D5 (purple) crystal lattices with size of central cavity indicated 
(b) 3D5/EE_48 (blue) crystal lattices with size of central cavity indicated  
(c) Preliminary crystal lattice for 3D5/His_683 
For both structures, lighter hue indicates the VL chain while the darker hue 
indicates VH. CDRs for 3D5/EE_48 are depicted in red, 3D5 are yellow.  
 
Further modification of the heavy CDRs in the anti-His6 3D5 scFv resulted in 
crystallization of variant 3D5/EE_48 in the unique lattice space group F23 [Chapter 3] an 
extremely rare occurrence in protein crystals.  A thorough analysis of the new lattice 
structure showed that the largest crystal contact was a retained intermolecular interaction 
from the 3D5 lattice.  The next two largest crystal contacts in the 3D5/EE_48 lattice were 
novel interactions formed as a result of amino acids located at the modified HCDR 
regions.  An energetic analysis using PISA revealed that the second largest contact 
(contact 2) was formed by hydrogen bonds contributed by heavy chain amino acids in 
CDR1: S30 and S32.  The third largest contact (contact 3) involves salt-bridge 
interactions supplied by amino acids in the heavy chain CDR2 region: D55, D56, K57 
and R58.  The inclusion of these two new contacts appears to guide the F23 lattice 
formation.  These contacts however are not beneficial to the design of our 3D5/EE_48 
A B C 
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chaperone as they involve binding regions which should be accessible for peptide 
interaction.   
Six variants were engineered to systematically modulate the energetic 
contribution of two novel intermolecular contacts using a PISA analysis of the energetic 
contribution of critical residues.  These surface residues were modified to determine if 
lattice structure could be reverted to the wildtype‟s crystal formation.  Each contact was 
removed individually as well as in combination to study the impact these had on lattice 
formation (Table 5.6).  A variant designed for removal of contact 2 (3D5/EE_48.2a) 
resulted in crystallization while variants with contact 3 modified resulted in no crystal 
formations.  The modification of contact 2 required two different variant versions 
because Ser32 was an inserted residue to extend the 3D5/EE_48 HCDR2 loop.  As a 
result, two possible mutations were tested to remove this interaction i) alanine – a 
minimal substitution (3D5/EE_48.2a) or ii) threonine – similar characteristics with the -
OH in a different location (3D5/EE_48.2).   Effective modulation of contact 3 was 
accomplished by returning the critical residues (D55, K57 and R58) back to their original 
wildtype amino acids.  Critical residue Asp56 was not included because of its potentially 
critical role in EE peptide tag affinity [Chapter 3].  Ser62 was included to restore a 
critical salt-bridge interaction that was present in the wildtype 3D5 lattice.   
Biophysical characterization of 3D5/EE_48 variants showed proteins maintained 
a pure monomeric form in equilibrium solution, although modification at contact 3 
negatively impacted protein expression and stability (Table 5.7, Fig. 5.6).  Preliminary 
ELISA and Biacore analysis (not shown) showed reduced peptide affinity for variants 
with modified residues from the contact 3 region.  While currently not a major concern, it 
must be taken into consideration as further work is continued development on this 
chaperone variant.  Only variant 3D5/EE_48.2a has successfully been crystallized in the 
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same conditions as the 3D5/EE_48.  Preliminary analysis indicates the crystal shape is 
similar.  Diffraction data will provide more information regarding whether modification 
of this contact guided this lattice formation.     
 
 







SA in Crystal 
Contact (Å2)c 
% SA of AA in 
Crystal Contactc  
% of Total 
Crystal Contact 
S30 2 -0.14 H 54.45 91.2 10.5 
S32 2 -0.17 H 68.72 88.7 13.2 
D55 3 -0.18 S 10.73 13.5 2.2 
K57 3 -0.60 S 47.81 69.6 10.0 
R58 3 -0.68 S 76.07 49.3 15.9 
S62 3 -0.07 - 6.17 10.2 1.3 
aSolvation Energy Effect (PISA) – does not account for free energy contribution from the H-bonds or salt interactions 
bPredicted using PISA, H- hydrogen bond contribution, S- Salt Bridge contribution 
cSA – Surface Area calculated using PISA 
 
 














D55G K57T R58S S62K 
3D5/EE_48 4.5 50.25 ± 0.27 - - - - - - - 
3D5/EE_48.2 3.1 51.67 ± 0.29 0.29 + T - - - - 
3D5/EE_48.2a 4.3 51.08 ± 0.21 0.29 + A - - - - 
3D5/EE_48.3 0.5 58.08 ± 0.20 1.84 - - + + + + 
3D5/EE_48.23 3.5 59.00 ± 0.55 2.13 + T + + + + 
3D5/EE_48.23a 0.9 58.33 ± 0.26 2.13 + A + + + + 
aBased from 1L culture 
bUsing  RT-PCR 









Figure 5.6  Biophysical characterization of 3D5/EE_48 variants  
(a) Purification by Size Exclusion Chromatography on S75 Column.  Molecular 
weight standards on S75 elute at 7.4 ml (void volume; blue dextran 2000); 9.6 
ml (75 kDa conalbumin); 10.9 ml (43 kDa ovalbumin); 12.7 ml (29 kDa 
carbonic anhydrase); 15.4 ml (residual peak from Ni
2+
 affinity column).    
(b) Size and purity of scFv by SDS-Page.  Lanes are 1: 3D5, 2: 3D5/His_683, 3: 
3D5/His_67, 4: 3D5/EE_48, 5: 3D5/EE_51, 6: 3D5/EE_48.2, 7: 
3D5/EE_48.2a, 8: 3D5/EE_48.3, 9: 3D5/EE_48.23, 10: 3D5/EE_48.23a 
 
The surface epitope modification of 3D5 to create or eliminate multiple critical 
intermolecular contacts allows better understanding of its impact on lattice formations. 
From our global study of 3D5 framework antibodies, the overall propensity of a protein 
for crystallization seems to be driven by key intermolecular contacts.  The introduction of 




systematic modification in the HCDR3 suggests a new interaction was created that guides 
the hyper-crystallizability of 3D5/His_683.  Further modification of all the heavy chains 
contributed to multiple protein-protein interactions and resulted in the formation of a 
completely unique space group for 3D5/EE_48, indicating the role multiple 
intermolecular contacts have in affecting lattice construction.  It appears that in this 
family of antibodies the modulation of one intermolecular contact can impact the lattice 
structure of the crystal, indicating that more than one protein-protein interaction is critical 
for initiating crystallization.  Examination of particular driving contacts in 3D5/EE_48, 
allow us to explore the key intermolecular contacts involved in the crystallization 
propensity of this particular antibody.   Other 3D5 framework antibodies that carried 
similar homology (>80% homology, in PDB) can be analyzed for their crystallization 
characteristics for potential contacts.  By characterizing these contacts in detail, we can 
modulate specific low affinity interactions in 3D5/EE_48 without impacting critical high 
affinity peptide binding regions.  This provides the potential to create a hyper-
crystallizable antibody with maintained functionality for potential use as a crystallization 
chaperone.    
 
5.4.4  Application for engineering enhanced chaperones for protein crystallization 
Current protein engineering techniques are used to directly modify and improve 
the particular target protein crystallization propensity.  Numerous proteins have been 
successfully enhanced for protein crystallization by improving different biophysical 
characteristics.  The two most popular methods target improving solubility or reducing 
the surface entropy of the protein through targeted point mutations.  Rational 
enhancement of protein solubility has successfully improved crystallization of other 
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proteins like S1 hydrofolate reductase [202], Leptin [203],  mitogen-activated protein 
(MAP) Kinase [204].  Successful amino acids recommended for improved solubility 
include mutations to Arg and Ser, as well as mutating Asn and Gln to their acids (Asp 
and Glu) [192].   
Effective reduction of the surface entropy of the target protein (SER) has helped 
to crystallize several novel proteins that had been unsuccessfully crystallized in their 
wildtype form [66, 67, 205].  Surface topology of proteins contributed by flexible amino 
acids such as Lys, Glu and Gln can interfere with intermolecular interactions that allow 
molecules to associate together and are necessary for crystallization [67, 177, 205].  
Systematic removal of these high entropy residues with smaller residues like alanines, 
was most effective when multiple amino acids clusters are simultaneously mutated [68].  
This generates a more symmetric unit for crystal packing.  This success of this strategy 
has resulted in the development of servers that currently assist in identifying the critical 
clusters for mutation [70].  Both of these processes are effective at improving 
crystallization.  However, our understanding of the energetics involved at the 
intermolecular contact can provide additional guidance for facilitating the creation of 
improved intermolecular contacts.  This energetic criterion in conjunction with the other 
techniques can provide a more comprehensive targeted modification of the surface 
topology to develop improved energetically stable lattice interactions.   
Like SER, modification of solvent accessible residues utilizing the energetic 
criteria requires structural information, which is especially challenging for proteins not 
successfully crystallized.  This limits the number of proteins that these techniques can 
assist in crystallization.  For our platform peptide specific chaperone technology this is 
not the case as the antibody for modification is characterized with atomic resolution 
maps.  The use of a peptide specific chaperone drastically reduces this number of 
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chaperones need to crystallize the wide range of proteins.  As a result, it directs the focus 
on these particular chaperones to engineer, study and improve the low affinity 
interactions that guide crystalline growth.  These chaperones serve to assist the target 
protein in crystallization by mediating the lattice forming contacts for the complex.  Our 
detailed analysis of the interaction energetics of the 3D5 based antibodies will guide us as 
we fine-tune their intermolecular contacts for improved crystal propensity.  Our energetic 
selection criteria can be utilized to select critical residues in lattice formation on the 3D5, 
3D5/His_683 and 3D5_48 scFvs for improved lattice formation.  The design of this 
hyper-crystallizable chaperone will provide a generalizable approach to enhancing 
crystallization of difficult proteins.   
  
5.5  CONCLUSION 
Engineering a hypercrystallizable peptide specific chaperone is the critical design 
component for a platform chaperone-assisted crystallization technology.  The ability to 
improve the chaperone protein’s propensity to crystallize is of utmost importance.  In 
order to modulate the chaperone for hyper-crystallizable characteristics a better 
understanding of the role of lattice contacts in crystallization is needed.  The two 
different murine model family antibodies were used to examine global effects of crystal 
contacts on lattice formations and the small scale effects of individual residues on a 
specific protein-protein interaction.  The protein surface modifications indicate the role 
intermolecular contacts play in defining crystallization.   
Programs like Rosetta alanine scanning that calculate energetics for high affinity 
interactions can similarly be applied to select residues in low affinity interactions of 
crystal contacts to modulate crystal lattice formation.  Variations in these intermolecular 
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contacts impact the lattice formation that is generated.  Further work is required to fully 
understand the impact of surface modification on intermolecular interactions, crystal 
lattice mechanisms and assembly kinetics.  Utilization of the information will assist in 
improving the crystallization propensity of our 3D5/EE_48 chaperone by engineering 
thermodynamically viable specific interactions.  
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CHAPTER SIX:  Conclusions and Recommendations for Future 
Direction 
 
6.1  CONCLUSION 
The dissertation presented here is composed of the necessary steps towards 
achieving a general platform for crystallizing target proteins.  High quality protein 
crystals have previously been obtained using protein-specific antibodies as a co-
crystallization agent in complex with the protein of interest.  The identification and 
optimization of each protein specific chaperone becomes expensive and time-consuming.  
Even after obtaining a potential chaperone, optimal co-crystallization conditions must be 
determined for the complexed chaperone and target protiein.  Our platform seeks to 
generalize this system with the development of a hyper-crystallizable antibody fragment 
with binding specificity for a short peptide sequence, which can easily be inserted into 
the target protein of interest at functionally silent regions without destroying the 
structural stability.  In order to study the feasibility of this platform we first must: (1) 
engineer a peptide-binding scFv [Chapter 2], (2) characterize the potential scFv 
chaperone [Chapter 3] and (3) optimize the peptide ligand location to enhance 
complexation [Chapter 4] and (4) study the scFv‟s crystallizability for potential co-
crystallization [Chapter 5].   
We developed a novel and efficient method to generate scFv antibody libraries for 
improved solubility, expression and crystallization (MegAnneal).  With this method, we 
bypass a major hurdle in recombinant DNA by circumventing the restricting ligation step 
to produce libraries rapidly and with large population numbers [Chapter 2].  Utilizing this 
technique and the anti-His 3D5 murine framework, the intention was to retain framework 
crystal contacts while modifying the peptide specificity.  From our different 3D5-based 
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phage display libraries, we demonstrated the ability to select a number of antibody 
fragments with specificity for the His6 tag and one scFv with successful conversion to 
EYMPME (EE) tag specificity, while enhancing biophysical characteristics (improved 
stability, solubility and monomeric expression levels).  The resulting anti-EE antibody, 
3D5/EE_48, possessed higher affinity (KD: 26nM) than the variants with His6 tag affinity 
and readily formed complexes with proteins tagged with peptides at various locations 
(terminally and internally) [Chapter 3].  Crystallization of 3D5/EE_48 produced an 
unexpected crystal lattice, resulting in the creation of two new contacts while retaining a 
previous contact from the original antibodies crystal lattice.  Although the lattice is in a 
different space group (F23 vs. 3D5‟s P3221) it still retains a central cavity (~50Å) that 
carries potential for crystal scaffolds.   
Upon establishing 3D5/EE_48 as a viable co-crystallization chaperone candidate, 
the focus shifted to optimizing the location of the peptide: N-terminal, C-terminal and 
internal [Chapter 4].  To effectively create a co-crystallization scaffold, the peptide must 
be optimized for tight chaperone binding resulting in the formation of rigid complexes 
with minimal structural perturbation to the target protein.  Terminal tags linked to a 
protective tail provide a good affinity (KD
:
 389nM) and are a preferred location for 
peptide insertion since no structural information is necessary.  Two internal locations 
were selected to study the impacts EE-internalization has on structural stability, the first 
in natural loops and the second in artificial linkers.  Maltose binding proteins with direct 
EE tag replacement in a natural loop produced an accessible peptide for the chaperone to 
form a rigid complex.  Insertion of a single peptide tag into the interdomain regions of the 
scFv required a lead sequence (~4 amino acids) in order to achieve the correct structural 
stability and flexibility in conformation for chaperone accessibility.   
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Crystallization results from engineered 3D5 derived scFvs indicate the need to 
better understand the forces that guide crystal lattice formation [Chapter 5].  Surface 
modifications of 3D5 resulted in novel and unique lattice formations (3D5: tetragonal, 
3D5/EE_48: cubic, 3D5/His_683), with 3D5/EE_683 scFv variant displaying hyper-
crystallizable characteristics.  The new crystal contacts appear to involve modified amino 
acids in the HCDR regions and are contributing additional protein-protein mediated 
contacts, which is impacting protein crystallization.  Energetic modulation of key 
intermolecular contacts impacted crystal growth.  Systematic modulations allowed us to 
establish the role energetic contribution of intermolecular contacts play in crystal lattice 
formations.  The energetic analysis of high affinity intermolecular contacts with programs 
like Rosetta Alanine Scanning, can be similarly applied to low affinity intermolecular 
crystal contacts.  Understanding the role of intermolecular contacts in crystallization will 
assist in guiding the design our hyper-crystallizable chaperone antibodies and improving 
the diffraction quality of its crystals.  
 
6.2  RECOMMENDATIONS FOR FUTURE DIRECTION 
The successful characterization of the 3D5/EE_48 scFv with tight binding to the 
EE epitope at various regions demonstrates the potential for this antibody as a crystal 
chaperone.  The in depth analysis of its biophysical properties has been explored, 
however, the exact interaction between the ligand and the antibody has not been 
determined.  The generated model of the interaction, using computation docking 
(ClusPro), provides a possible prediction however, high diffraction quality co-crystals of 
3D5/EE_48 scFv with EE-peptide are needed for structural determination.  Additional co-
crystallization studies with peptide-tagged proteins are also needed to effectively study 
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the resulting complex between the chaperone and the POI for rigidity and high affinity.  
Currently co-crystallization trials with 3D5/EE_48 scFv and select EE-tagged proteins 
are underway (R30A-EE2, MBP-EE, MBP-EE-his, SPP-EE), however other proteins 
must be added.  Other proteins to include are the MBP variants with internalized EE tag 
at the interloop region (amino acid 171 – 176) and the TCR with single EE tags at the 
interdomain linker.  Successful assisted crystallization of these EE-tagged proteins will 
provide additional support that this scFv carries the potential to serve as a co-
crystallization chaperone.   
The development of 3D5/EE_48 with high affinity for EE-tagged proteins opens 
the possibility of engineering other peptide specific antibodies for use as crystallization 
chaperones.  This creates a limitless number of future projects, which involves the 
creation of multiple peptide specific hyper-crystallizable chaperones derived from similar 
frameworks.  By switching out the 3D5 CDRs for specificity to other short peptide 
epitopes, will lead to the development of a potentially generalizable toolbox of co-
crystallization chaperones.  3D5/His_683‟s hypercrystallizable characteristics suggests 
it‟s potential as a chaperone and work should be done to improve its His6 affinity.  Efforts 
have also focused on the Flag tag (DYKDDDK) due to the presence of tyrosines and 
charged residues that favor hydrophobic and electrostatic interactions, respectively.  The 
CDRs that bind this tag also display 10-fold higher affinity to another tag 
(MDYKAFDNL) [180].  It is therefore recommended to graft these CDRs onto the 3D5 
framework, generating a new chaperone with the ability to bind these two different short 
peptides.  Ambiguous HCDR3 residues in the PDB, resulted in unsuccessful preliminary 
attempts at producing the graft with high affinity and high yields (courtesy of Kevin 
Entzminger).  It is recommended that engineering this anti-Flag antibody use site directed 
and random mutagenesis simultaneously.  This can be accomplished with the MegAnneal 
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technique by amplifying 3‟ directional megaprimers under error-prone conditions 
utilizing a primer that contains degenerate codons at the H:CDR3 region.  This 
methodology will rapidly select for both a soluble, high expressing and tight binding 
chaperone with 10X flag affinity using a single library.  With the successful selection of 
3D5/EE_48 using this method, there is high expectation that an improved 3D5/Flag 
variant will be found.     
The chaperone assists in protein crystallization by contributing additional polar 
surface for lattice-forming crystal contacts, locking down flexible regions for increased 
overall uniformity and stabilizing the target protein for a homogenous solution.  Our 
studies primarily focused on the scFv chaperone antibody format due to its small uniform 
shape and its ability to produce a more symmetrical and compact complex.  It is 
questionable whether a single scFv (28kDa) will effectively provide enough surface for a 
target protein (50 – 100kDa).  Two ways that we propose to study and address this 
problem involve:  i) using a larger antibody chaperone format or ii) inserting multiple 
peptides at various regions in the POI.  If the hyper-crystallizable trait of our 3D5/EE_48 
scFv can be transferred into this Fab antibody format (50kDa) with similar lattice contact 
formation, this candidate can provide additional polar surface contributions making this a 
more advantageous potential chaperone.  The Fab has successfully been cloned into the 
pFabs plasmid provided by the Georgiou lab with characterization and co-crystallization 
of these antibodies in progress, similar to those previously mentioned for the scFv version 
of the chaperone (Appendix A).   
Another way to provide additional polar surface, is to surround the target protein 
with multiple scFv chaperones.  We hypothesize that the use of multiple peptides and 
multiple chaperones would be advantageous for creating and controlling an intended 
scaffold system.  This can be accomplished utilizing one of two options: i) the same 
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peptide in multiple regions or ii) multiple peptides in different regions (Figure 6.1).  Our 
engineered MBPs displaying internalized EE tags [Chapter 4] have already been designed 
with the second suggestion in mind.  Located at the c-terminal regions of these proteins, 
the ten times higher affinity Flag Tag (MDYKAFDNL) has been inserted prior to the 
His6 tag.  The use of two distinct chaperones will potentially allow for further control in 
the formation of the lattice structure by utilizing their distinct driving contacts.  Once a 
hyper-crystallizable chaperone with affinity for the Flag tag is found we can proceed with 
the complex isolation studies of the correct chaperones and target protein in addition to 
co-crystallization studies.   
The generation of additional 3D5 based chaperone antibodies will also help us to 
further explore the driving forces involved in protein crystallization for this particular 
family.  With the recent successful crystallization of 3D5/His_683, a detailed analysis of 
its crystal contacts in the different crystal shapes will provide understanding of the 
driving force behind this protein‟s propensity for crystallization.  Comparing the 
intermolecular contacts of the other scFvs in the family (i.e. wildtype 3D5 and 
3D5/EE_48) will provide a more detailed analysis of the 3D5 family and further expand 
our knowledge of key intermolecular contacts for our chaperone.  Our current 
understanding of crystallization has focused primarily on only two families of antibodies: 
3D5 and 14B7, and provided some observations of how their intermolecular interactions 
impact lattice formation.  The recommended next step is to expand our survey to analyze 
other families of single chain fragments (>80% homology) in the PDB database.  In 
doing so, we would like to analyze the sequence properties (i.e. mean hydrophobicity, net 
electrostatic charge, side chain entropy, etc.) to determine the role surface epitopes play 
in generating intermolecular contacts.  This data will provide a more thorough and 
detailed understanding for the sensitivity of scFv intermolecular interactions on a 
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protein‟s propensity to crystallize.  The result: a more systematic guideline for designing 
and engineering our chaperones for hyper-crystallizability. 
 
 
Figure 6.1  Depiction of the potential application for the toolbox of multiple scFv 












APPENDIX A:  OTHER PROJECTS IN PROGRESS 
A.1.  Producing Fab version of 3D5/EE_48 
The VL and VH were subcloned into the pFabs plasmid provided by Dr. George 
Georgiou (refer to Appendix B).  A His6 tag is subcloned into the light chain portion of 
the Fab while a Flag tag is located at the end of the heavy chain portion for purification 
purposes.  The protein was expressed with BL21 E. Coli at 37
o
C for 14 hours before 
incubating at 25
o
C with 1mM induction of IPTG for 5 hours.  Periplasm isolation was 
performed as mentioned in Chapter 3 with Ni
2+
 Affinity Chromatography followed by 
Size Exclusion with an S75 Column (Figure A.1a).  The yield produced from a 1L cell 
culture was 1.77mg comparative to the 2.1mg generated from the scFv format of this 
antibody. 
Biophysical characterization using 12% SDS-PAGE of the Fab protein with non-
reducing buffer indicated that the solution maintains a largely monomeric form however 
there are some byproducts (Figure A.1b).  Our purification methods involved using only 
metal affinity, which targets the light chain regions, which may explain the shorter bands 
found as the rentention volume increases.  The shorter bands suggest that only the VL 
region was selected indicating that a second purification step (such as anion exchange 
chromatography) is needed that involves the Flag tag for pure Fab separation.  ELISA 
utilizing protein from the 10.5-11mL (A12) Retention fraction suggest that affinity for 
the EE tag was retained and is comparable to the scFv format.   






Figure A.1  Biophysical Characterization of 3D5/EE_48 Fab  
(a)  Size Exclusion Chromatography Purification comparison of the 3D5/EE_48 Fab 
format and scFv format  
(b) Size separation using 12% SDS-Page with non-reducing buffer.  Samples were 
collected at different flow-throughs off the SEC Lane 1: 9.5-10mL (A10), Lane 2: 10-
10.5mL (A11), Lane 3: 10.5-11mL (A12), Lane 4: 11-11.5mL (B12), Lane 5: 11.5-
12mL (B11), Lane 6: 12-12.5mL (B10), Lane 7: 12.5-13mL (B9), Lane 8: 13-13.5 
(B8)    
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A.2  Engineering humanized 1B7 with improved solubility and expression yields 
Below is a slightly more detailed discussion library generation with MegAnneal 
of humanized 1B7 which has high affinity for the pertussis toxin.  The library (10
6
 
transformants) displayed 1B7 scFvs with on average 3 mutations per gene. Preliminary 
screening using phage-display produced one particular gene of interest, which is currently 
being subcloned into pak400 and pMopac54 for protein expression and characterization. 
As mentioned, 1B7 had some processivity issues and primer annealing issues, 
requiring some modification to the 3‟ megaprimer generation process.  Both mutazyme 
and the 5‟ pakpel primer were ineffective in generating the correct PCR product size 
(750bp), therefore production of the 3‟ megaprimer involved PCR with a biased 
nucleotides, Taq polymerase and only the 3‟Huck primer.  A strong PCR product at 
750bp was excised and purified for use as the 3‟ megaprimer.     A preliminary ELISA 
colony screen showed some potential candidates even with the relatively low growth of 
protein presenting phage (Figure A.3).  Note: ELISAs were read before HCl 
neutralization (i.e. low absorbance signal).  Panning over pertussis toxin (PTX) will be 




Figure A.2  ELISA Colony Screen of select hu1B7 derived from the library generated.   
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APPENDIX B: ADDITIONAL FIGURES FOR WORK PRESENTED 
B.1  Amino Acid Sequence for Engineered 3D5 antibodies 
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B.3  Vectors Maps Used for Periplasm Expression 




Typical lac promoter and expresses 1-5mg/L culture 
VL – inserted between Nco1 and Not1 sites       (1440 – 2124 – His8) 
VH – inserted between Nhe1 and Hind111 sites  [Flag tag at Heavy Chain end]  (2268 – 2980 – 
Flag) 
 
NcoI   (C’CATG,G)     37oC with NEB 1/2/3/4   1442 
NotI  (GC’GGCC,GC)  37oC with NEB 3   1802 
NheI  (G’CTAG,C)  37oC with NEB 1/2/4   2262 
HindIII  (A’AGCT,T)  37oC with NEB 2   2627  
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Reading Primers:   5’ pFabs_1309 (VLfor):    GTG AGC GGA TAA CAA TTT CAC ACA 
GG 
 
   LENGTH: 26  
   GC CONTENT: 46.2 %     MELT TEMP: 58.2 ºC   
   MW: 8028.3 g/mole     EXT COEF: 263600 L/(mole·cm)  
   nmole/OD260: 3.79     µg/OD260: 30.46 
 
  5’ pFabs_2184 (VHfor):  GAG AAG GAG ATA TAC ATA TGA AGT CGC TAC 
TCC C 
 
   LENGTH: 34  
   GC CONTENT: 44.1 %    MELT TEMP: 59.8 ºC   
   MW: 10483.9 g/mole    EXT COEF: 346800 L/(mole·cm)  
   nmole/OD260: 2.88    µg/OD260: 30.23 
 





B.4  Crystallization Conditions for the Antibodies Used in Crystallization Trials in 
this Work 
 







14B7 (WT) scFv 0.1 Hepes (pH 7.5) 
20% PEG 4000 
10% IPA 
~14mg/mL 
(1:1 or 1:2) 
24 hours Maynard 
14B7 (M18) scFv 0.1M HEPES (pH 7.5) 




6 months Harvey 
3D5 (mut1+mut2) 
scFv 
0.1M MES (pH 6.4)  
0.2M MgAc 
20% PEG 8000 
0.02% Sodium Azide (NaN3) 
~3.8mg/mL 
(5:1) 
2 weeks Kauffman 
Anti-EE scFv and 
scAb 
0.1M Tris (pH 8.5) 
1.0M Lithium Sulfate 




4 months In House 
3D5/EE_48 0.1M Mes (pH 6.4) 
 0.1 MgAc 




(1:1 or 1:2) 
4 weeks In House 
3D5/His_683 Still in Progress    
 
 
B.5.  Crystallization of αEE scAb monomers (Images) 
(a) and αEE scFv monomers (b) crystallized with conditions: 0.1M Tris (pH 8.5), 1.0M 






B.6  Primers Utilized in 3D5 Library 
(3D5 parent actual sequence in pM024 and pak100 frozen stock!!) 
 





  P  G  K  G  L  E  W  I  G  D  I  N  P  N  N  G  G  T  S  Y  N  Q  K  F  K  G   
                                                           TAA   TAA      TAG  
GTCCAGGAAAGGGTCTGGAGTGGATCGGAGACATTAACCCGAATAATGGCGGCACGAGCTATAACCAAAAGTTCAAGGGC 
CAGGTCCTTTCCCAGACCTCACCTAGCCTCTGTAATTGGGCTTATTACCGCCGTGCTCGATATTGGTTTTCAAGTTCCCG 
                                       GCTTATTACCGCCGTGCTCGATTTTGATTTTCAAGATCCCG  
 




TCCCGGTGTG                                                                   GCA    
 
 Y  Y  C  E  S  Q  S  G  A  Y  W  G  Q  G  T  T  V  T  C  S  A  S  G  A  E  F  A 





  A  A  A  P  S  V  F  I  F  P  P  S  D  E  Q  L  K  S  G  T  A  S  V  V  C  L   
CGGCCGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTG 
 
Note the change in the nucleotide sequence at H:G106 (in the mo54 stock nucleotide was a T) 
5’ 3STP_3D5_CDR3for (31bp)  
 
5'-  TCAAGGAACCACAGTCACCGTCTCGGCCTCG -3' 
 
GC  Content: 61.3 %    Extinction Coeff: 288000 L/(mole·cm) 
Melt Temp: 68.4 ºC     nmole/OD260: 3.47  
MW: 9426.1 g/mole    µg/OD260: 32.73 
 
3’3STP_3D5_CDR3rev (49bp) 
5'-  GGT TCC TTG ACC CCA TTA AGC TCA GCT TTA ACT TTC ACA GTA GTA TAC G  -3' 
 
GC Content: 42.9 %    Extinction Coeff: 462200 L/(mole·cm)  
Melt Temp: 65.4 ºC    nmole/OD260: 2.16  





5'-  AGG GCC ACA CTC ACC GTG GAT AAG TCC AGC AGC  -3' 
 
GC Content: 60.6 %    Extinction Coeff: 318900 L/(mole·cm)  
Melt Temp: 69.5 ºC     nmole/OD260: 3.14  
MW: 10117.6 g/mole    µg/OD260: 31.73 
 
3’3STP_3D5_CDR2rev (51bp) 
5'-  G TGT GGC CCT GCC CTA GAA CTT TTA GTT TTA GCT CGT GCC GCC ATT ATT CG  -3' 
 
GC Content 51.0 %    Extinction Coeff: 509100 L/(mole·cm)  
Melt Temp: 69.6 ºC    nmole/OD260: 1.96  
MW: 15784.3 g/mole    µg/OD260: 31.00 
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G  G  G  S  G  G  G  G  S  S  G  G  G  S  Q  V  Q  L  Q  Q  S  G  P  E  D  V  K   
GGTGGTGGTTCTGGCGGCGGCGGCTCCAGTGGTGGTGGATCCCAGGTGCAGCTGCAGCAGTCTGGCCCTGAGGATGTGAA 
 
 P  G  A  S  V  K  I  S  C  K  A  S  G  Y  T  F  T  D  Y  Y  M  N  W  V  K  Q  S 
GCCCGGCGCGAGCGTGAAAATCAGTTGTAAAGCCTCTGGATATACATTCACCGATTATTATATGAACTGGGTTAAACAGA 
 
  P  G  K  G  L  E  W  I  G  D  I  N  P  N  N  G  G  T  S  Y  N  Q  K  F  K  G   
           GGTCTGGAGTGGATCGGANNSATTHRKHYTNNSRRTNNSNNSNNSNNSTATAACNVSRNKDNBAAGNNS 
GTCCAGGAAAGGGTCTGGAGTGGATCGGAGACATTAACCCGAATAATGGCGGCACGAGCTATAACCAAAAGTTCAAGGGC 
CAGGTCCTTTCCCAGACCTCACCTAGCCTCTGTAATTGGGCTTATTACCGCCGTGCTCGATATTGGTTTTCAAGTTCCCG 
           CCAGACCTCACCTAGCCTNNSTAADYMDRANNSYYANNSNNSNNSNNSATATTGNBSYNMHNVTTCNNS 
 
R  A  T  L  T  V  D  K  S  S  S  T  A  Y  M  E  L  R  S  L  T  S  E  D  S  S  V 
AGGGCCACACTCACCGTG                                                           CGT 
AGGGCCACACTCACCGTGGATAAGTCCAGCAGCACGGCATACATGGAGCTCAGGAGTCTGACCAGCGAAGATAGTTCCGT 
TCCCGGTGTGAGTGGCACCTATTCAGGTCGTCGTGCCGTATGTACCTCGAGTCCTCAGACTGGTCGCTTCTATCAAGGCA 
TCCCGGTGTGAGTGGCAC                                                           GCA 
 
 Y  Y  C  E  S  Q           S  G        A        Y  W  G  Q  G  T  T  V  T  C  S   
ATACTACTGTGCANVTNNSNNSNNSNNSAGCNNSNNSNNSGCTATGGATTACTGGGGTCAAGG   
ATACTACTGTGAAAGTCAA         AGCGGT      GCT      TACTGGGGTCAAGGAACCACAGTCACCGTCT 
TATGATGACACTTTCAGTT         TCGCCA      CGA      ATGACCCCAGTTCCTTGGTGTCAGTGGCAGA 
TATGATGACACGTNBANNSNNSNNSNNSTCGNNSNNSNNSCGATACCTAATGACCCCAGTTCC 
 
A  S  G  A  E  F  A 
CGGCCTCGGGGGCCGAATTCG 
 
Note the change in the nucleotide sequence at H:G106 (in the mo54 stock nucleotide was a T) 




LENGTH: 87  
GC CONTENT: 54.4 %  
MELT TEMP RANGE:  MIN  MEAN  MAX  
67.1 ºC  72.5 ºC  77.7 ºC  
  
MW: 26668.3 g/mole  
Extinc Coeff: 814460 L/(mole·cm)  
nmole/OD260: 1.23  
µg/OD260: 32.74 
Heavy CDR3 Library (reverse reading frame 5’  3’) - IDEAL 
CCTTGACCCCAGTAATCCATAGCSNNSNNSNNGCTSNNSNNSNNSNNABNTGCACAGTAGTATACG 
 
LENGTH: 66  
GC CONTENT: 54.8 %  
MELT TEMP RANGE:  MIN  MEAN  MAX  
66.3 ºC  71.8 ºC  76.4 ºC  
MW: 20237.7 g/mole  
Extinc Coeff: 626013 L/(mole·cm)  
nmole/OD260: 1.60  
µg/OD260: 32.33 
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B.6.3 Rationale for Library Diversity of 3D5 Heavy Chain 2 and 3 
Cobaugh, C.W., et al., Synthetic antibody libraries focused towards peptide ligands. J 






Degenerate Codon Codes: 
R –  A  G 
Y –   C  T 
M –  A  C 
K –    G T 
S –   C G 
W –  A   T 
H –  A C  T 
B –   C G T 
V –  A C  G 
D –  A  G T 
N –  A  C G  T 
 
Kabat # aEE 3D5 CODON Residue Encoded Reason
50 H D NNS all Randomization
51 I I ATT I Common between aEE and 3D5
52 Y N HRK NSRHYW/KQC Coverage based on Cobaugh (74%) (include a stop codon TAG)
52a P HYT FSLPT/I Coverage based on Cobaugh (91%) - one primer made without this
53 W N NNS all Randomization
54 D N RRT GSDN Coverage based on Cobaugh (89%)
55 D G NNS all Randomization
56 D G NNS all Randomization
57 K T NNS all Randomization
58 R S NNS all Randomization
59 Y Y TAT Y Common between aEE and 3D5
60 N N AAC N Common between aEE and 3D5
61 P Q NVS STCPNQKRHDE/TAYWG Hydrophillic - Polar Uncharged (only TAG stop codon) by JCPai
62 S K RNK RGTNEVAS/IMKD Hydrophillic using codon (w/ majority) from Cobaugh
63 L F DNB FYWGALVMIC/STNKRDE Hydrophobic bias (only TAG stop codon) by JCPai
64 K K AAG K Common between aEE and 3D5
65 S G NNS all Randomization
Heavy CDR2 Library Diversity
Kabat # aEE 3D5 CODON Residue Encoded Reason
93 A E GCA A Standard for anti-peptide library (Cobaugh) 
94 R S NVT CDGHNPRSTY charged hydrophillic from sidhu and weiss
95 R Q NNS all Randomization
96 G NNS all Randomization
97 G NNS all Randomization
98 S NNS all Randomization
99 S S AGC S Common between aEE and 3D5
100 H G NNS all Randomization (No Common Characteristics!)
100a Y NNS all Randomization
100b Y TAT Y Standard for anti-peptide library (Cobaugh) 
100c A A GCT A Common between aEE and 3D5
100d M ATG M Standard for anti-peptide library (Cobaugh) 
101 D GAT(GAC in aEE) D Standard for anti-peptide library (Cobaugh) 
102 Y Y TAC Y Common between aEE and 3D5
Heavy CDR3 Library Diversity
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B.7  Preliminary Graftwork for anti-peptide scFv variants  (3D5g and 14B7g) 
B.7.1.  Aligned WAM predicted models  
 
(a) 14B7graft scFv versions 1 and 2 (14B7g-1, 14B7g-2) with αEE scFv, RMSD: 1.60Å 
(b) enlarged region of CDR3 flexible loops (c) 3D5graft scFv versions 1 and 2 (3D5g-1, 






Light Blue: 14B7graft - 1 




Light Green: 3D5graft - 1 






Light Blue: 14B7graft - 1 




Light Green: 3D5graft - 1 






B.7.2  Qualitative Analysis for expression of αEE and engineered grafts 
 
Figure A.8.2.  (a) Purification on a size exclusion column (FPLC-SEC) using superdex 
(S200) column;   (b) Circular Dichroism (CD) measurements of αEE and engineered 
grafts.  Table of CD Measurements of grafts with the calculated secondary structure 
compositions using Chen & Yang reference data set. 14B7graft-1 was not placed on these 
figures because of it‟s extremely low-yield.    
 
B.7.3  Thermal Stability Measurements using from Real-Time PCR   






Graft scAb Monomeric Separation (250mL Culture) using 

















aEE 3D5graft1 3D5graft2 14B7graft1 14B7graft2
% α 21.4 25.3 14 26.8 16.7
% β 37.1 22.2 22.2 35.2 32.3
% Turn 12.3 18.6 22.1 9.6 16.3
% Random 29.3 33.9 41.7 28.4 34.7








































3D5graft48 w H2O 50.95 0.308
3D5graft51 48.03 1.201
Averaged Tm OVERALL from Real-time PCR
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B.8  Additional Data for 14B7 Intermolecular Contact Analysis 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































B.8.3   Representative Diffraction Images from some of the 14B7 variants 
Diffracted at the home x-ray source at the University of Texas at Austin.  For each 
variant, the single diffraction image is shown in addition to an image overlaid with the 
predicted space group symmetry (yellow & green).  A) L:D28A B) L:Y32A C) H:R99A 




   
   
   
P4 Space Group 
a = 84.31 
b = 84.31 
c = 199.86 
α = β = γ = 90 
P4 Space Group* 
a = 79.79 
b = 79.79 
c = 68.25 





*Initial Indexing gave 
P1, however appears 
more like two crystals 
are diffracted resulting 
in twin intensity peaks. 
P4 Space Group 
a = 80.11 
b = 80.11 
c = 68.21 





Extremely Poor and 
resulted in being unable 
to calculate an initial 
Index. 
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B.8.4  Detailed look at 14B7 (D28A) scFv Crystallization Kinetics 
Although it was expected that the light chain D28A mutation would improve the 
crystal contact, it was surprising how drastic the improvement was for crystallization (2 
hour crystallization).  To better understand how a free energy contribution of < 0 
kcal/mol drastically improves crystallization further analysis is required for the D28A 
mutant.  Its distinctive cross shaped crystal formation deviated slightly from the wildtype 
crystal form, as a result of rapid nucleation on unclean crystal edges.  Timed growth rate 
studies for the D28A variant showed that higher concentrations of scFv produced a 
biphasic crystallization growth with the transition occurring at 6 hours regardless of the 
amount of scFv used (Fig. B.1).  Crystals diffracted to 2.6Å even with its improved 
crystallization while retaining a primitive tetragonal index.   A full diffraction data set for 
the D28A crystals is in progress to determine the impact that this substitution has on the 
interprotein interaction.   
 
Figure B.1.  Timed Crystal Growth Rate Analysis of D28A  
Crystallization conditions were performed using various protein concentrations and with 





















Crystallization Growth Rate Analysis D28A with various







B.9  Overall protein analysis of crystallization contacts with 3D5 protein family 
An anti-peptide antibody fragment family well characterized utilizing 
crystallization techniques (PDB IDs including 1KTR, 1MAJ, 2CJU, 1DLF, 2UUD, 
1DSF, 1WZ1, 1N4X, 2G60) was used as the model group to study common 
characteristics of protein-protein interactions in crystal lattices.  Additionally two scFvs 
engineered in house derived from the 3D5 scFv were also included in this analysis.  
Careful analysis of the crystal lattice contacts formed in each of these crystals was 
examined using Protein Interfaces, Surfaces and Assemblies (PISA) (Fig. B.2).  The 
antibodies categorized in this family carry a highly conserved variable light chain with at 
least ~85% homology to the VL chain from the murine V1 germline with variation 
occurring in the heavy chain.  Although the sequence homology of these fragment 
antibodies are similar, the diversity in their crystallization conditions and lattices space 
groups shows their propensity for crystallization (Table B.1, Table B.2).  The survey of 
the antibodies submitted into the Protein Data Bank (PDB) in addition to two additional 
variants engineered in lab displays this family‟s capability of crystallizing into at least 
four different space group families (P, C, I, F) and over a wide range of pHs (5.25 – 8.4).  
A survey of the crystal contacts indicates that the largest (“major”) contact involves an 
approximate area of 444.4 Å
2
 ± 83.5.   
Table B.1 Homology of variants in the 3D5 murine family  









Anti-histidine 3D5 scFv 1KTR P3221 100.0 100.0 467.1 [99] 
Anti-2-Phenyl-5-Oxazolone NQ16-113.8 scFv 2CJU I212121 71.0 95.6 489.2 [102] 
Anti-2-Phenyl-5-Oxazolone NNQ10-1.12 scFv 2UUD C2 69.2 95.6 452.2 [102] 
Anti-dansyl monoclonal Fv 1DLF P212121 66.1 90.3 407.4 [103] 
Anti-dansyl monoclonal Fv 2DLF P212121 66.1 90.3 413.8 [103] 
Anti-dansyl monoclonal Fv with Ligand 1WZ1 P43212 65.2 88.5 325.9 [206] 
Anti-cancer Antibody B1 scFv 1DSF P6122 65.6 85.0 542.6 [207] 
scFv – inhibits HIV-1 &HIV-2 proteases  1N4X P212121 68.3 91.2 334.4 [208] 
Anti-histidine 3D5/His_683 In lab In progress 92.3 95.6 N/A Ch. 3 
Anti-gluglu peptide tag 3D5/EE_48 3NN8 F23 82.2 95.6 567.3 Ch. 3 











Crystallization Conditions Crystal 
Appearance 
Ref. 
Anti-histidine 3D5 scFv P3221 1:5 3.8 0.1M MES (pH 6.4), 0.2M MgAc, 
20% PEG8000, 0.02% NaAzide – 4oC 




I212121 1:1.2 8.0 0.1M Tris-HCL (pH 8.4), 0.2M 
Ammonium sulfate, 37% PEG 8000, 





C2 1:1.2 9.0 0.1M Tris-HCl (pH 7.6), 0.2M 
Ammonium sulfate, 30% (w/v) 




P212121 6:3 5.0 0.025M sodium cacdylate (pH 5.25, 
1.6M Ammonium sulfate) – 20oC 
3 months [103] 
Anti-dansyl monoclonal 
Fv 
P212121 6:3 5.0 1.6M Ammonium sulfate and 25mM 
sodium cacdylate (pH 6.75) – 20oC 
3 months [103] 
Anti-dansyl monoclonal 
Fv with Ligand 
P43212 1.35:1.35 7.0 0.03M Sodium Cacodylate (pH 6.5), 




Anti-cancer Antibody B1 
scFv 
P6122 3:3 16.0 1.6M Ammonium sulfate, 0.1M 
HEPES at pH 7.0 – Room Temp, 20oC 
1 – 7 days [207] 
scFv – inhibits HIV-1 
&HIV-2 proteases  
P212121 1.1 5.0 0.1M sodium citrate (pH 3.5), 17.5% 







1:1 – 1:3 3.8 See table 5.X 4 days Ch. 3 
Anti-gluglu peptide tag 
3D5/EE_48 
F23 1:1-2 3.8 0.1M Mes (pH 6.4), 0.1 MgAc, 20-
24% PEG 8000 – 4oC 
4 weeks Ch. 3 
 
 
A survey of the residues involved in lattice contact of these similar antibodies 
showed that a consistent region across the group is involved in one of the crystal lattice 
contacts even with the unique crystallization condition and space groups.  Comparison of 
amino acids involved in each of the crystal contacts that form the lattice framework for 
each antibody as been highlighted (Figure 5.1) to determine if there were any consistent 
driving forces that guide crystallization.  Amino acids involved with the largest (“major”) 
crystal contact were colored orange followed by yellow for the second largest contact and 
green for the third.  While some antibodies displayed larger crystal lattice contacts the 
“conserved contact” was still one of the four major interactions, suggesting that this 
reoccurring contact is critical to crystallize propensity.  The consistent crystal contact 
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across many of the antibodies (including 3D5, 3D5/EE_48, anti-dansyl Fv and inhibiting 
scFv for HIV proteases) involves residues in the light chain region (before LCDR1 and 
between LCDR2 and LCDR3) and contains relatively few amino acids in the heavy 
CDRs.  The residues that are located on the CDRs are shown to be varied among the 
different members of the family, indicating that these amino acids are not critical for 
driving the interaction for this crystal contact.  Instead these residues appear to contribute 
as a result of their location association to other critical residues involved in the 
intermolecular interactions.    
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Figure B.2  Contact survey of antibodies with VL derived from the VK1germline.   
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Glossary 
10XFlag: MDYKAFDNL, improved M2 specific 10x stronger 
ccc-DNA: covalently closed circular DNA 
CCP: co-crystallization Protein 
CD: circular dichroism 
CDR: complimentary determining regions 
cfu: colony forming units  
dU-ssDNA – dUTP-containing single-stranded DNA 
EE: EYMPME epitope (peptide) 
ELISA: enzyme-linked immunosorbent assay 
Fab: fragment antibody 
Flag:  original tag, DYKDDDK, see also 10XFlag 
FPLC: fast protein liquid chromatography 
HBS: hepes-buffered saline 
HCDR: heavy chain CDR (HCDR1, HCDR loop 1, HCDR2, HCDR loop 2; 
HCDR3, HCDR loop3) 
His6: hexa-histidine 
LCDR: light chain CDR (LCDR1, LCDR loop 1, LCDR2, LCDR loop 2; 
LCDR3, LCDR loop3) 
MBP: maltose binding protein 
PCR: polymerase chain reaction 
PDB: Protein Data Bank 
POI: protein of interest 
QCM – quick change mutagenesis 
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REM: random extensive mutagenesis 
scFv:  single chain antibody fragment (variable) 
SEC: size exlusion chromatography 
SER: surface entropy reduction 
SDM: site directed mutagenesis 
SPR: surface plasmon resonance 
ssDNA: single stranded DNA 
TCR: T-Cell receptor 
TMB: tetramethylbenzidine 
VH: variable heavy chain 
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